WO2007121323A2 - Endoprosthesis having a fiber meshwork disposed thereon - Google Patents

Endoprosthesis having a fiber meshwork disposed thereon Download PDF

Info

Publication number
WO2007121323A2
WO2007121323A2 PCT/US2007/066568 US2007066568W WO2007121323A2 WO 2007121323 A2 WO2007121323 A2 WO 2007121323A2 US 2007066568 W US2007066568 W US 2007066568W WO 2007121323 A2 WO2007121323 A2 WO 2007121323A2
Authority
WO
WIPO (PCT)
Prior art keywords
medical device
fiber
layer
fiber meshwork
meshwork
Prior art date
Application number
PCT/US2007/066568
Other languages
French (fr)
Other versions
WO2007121323A3 (en
Inventor
Jan Weber
James Q. Feng
Liliana Atanasoska
Original Assignee
Boston Scientific Scimed, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Scientific Scimed, Inc. filed Critical Boston Scientific Scimed, Inc.
Priority to EP07760597A priority Critical patent/EP2010099A2/en
Publication of WO2007121323A2 publication Critical patent/WO2007121323A2/en
Publication of WO2007121323A3 publication Critical patent/WO2007121323A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/072Encapsulated stents, e.g. wire or whole stent embedded in lining
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/075Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/003Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time

Definitions

  • This invention relates to medical devices, such as endoprostheses, and methods of making such devices.
  • the body includes various passageways including blood vessels such as arteries, and other body lumens. These passageways sometimes become occluded or weakened. For example, they can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis.
  • An endoprosthesis is an artificial implant that is typically placed in a passageway or lumen in the body. Many endoprostheses are tubular members, examples of which include stents, stent-grafts, and covered stents.
  • endoprostheses can be delivered inside the body by a catheter.
  • the catheter supports a reduced- size or compacted form of the endoprosthesis as it is transported to a desired site in the body, for example the site of weakening or occlusion in a body lumen.
  • a desired site for example the site of weakening or occlusion in a body lumen.
  • the endoprosthesis Upon reaching the desired site the endoprosthesis is installed so that it can contact the walls of the lumen.
  • One method of installation involves expanding the endoprosthesis.
  • the expansion mechanism used to install the endoprosthesis may include forcing it to expand radially.
  • the expansion can be achieved with a catheter that carries a balloon in conjunction with a balloon-expandable endoprosthesis reduced in size relative to its final form in the body.
  • the balloon is inflated to deform and/or expand the endoprosthesis in order to fix it at a predetermined position in contact with the lumen wall.
  • the balloon can then be deflated, and the catheter withdrawn.
  • the endoprosthesis is formed of an elastic material that can be reversibly compacted and expanded (e.g., elastically or through a reversible phase transition of its constituent material).
  • the endoprosthesis Before and during introduction into the body until it reaches the desired implantation site, the endoprosthesis is restrained in a compacted condition. Upon reaching the desired site, the restraint is removed, for example by retracting a restraining device such as an outer sheath, enabling the endoprosthesis to self-expand by its own internal elastic restoring force.
  • endoprostheses are sometimes made of relatively strong materials, such as stainless steel or Nitinol (a nickel-titanium alloy), formed into struts or wires.
  • the material from which an endoprosthesis is made can impact not only the way in which it is installed, but its lifetime and efficacy within the body.
  • a medical device comprising: an underlying structure having a fiber meshwork disposed thereon, wherein the underlying structure is biodisintegrable.
  • the medical device can further comprise a layer-by-layer coating situated on the fiber meshwork.
  • a medical device for implantation into an organism comprising: an underlying structure; and a fiber meshwork disposed upon the structure, wherein the fiber meshwork is configured to ensure steady biodisintegration of the underlying structure over a period of time inside the organism.
  • a medical device comprising a fiber meshwork formed of a material that is deposited by FFESS on to an underlying structure.
  • a method of achieving steady disintegration of a medical device in an organism comprising: forming the device by depositing a fiber meshwork on to an underlying structure; and implanting the device into the organism; wherein the disintegration of the underlying structure occurs over a first period of time inside the organism.
  • a method of making a medical device comprising depositing a fiber meshwork by FFESS on to an underlying structure.
  • FIGs. IA and IB are respectively perspective and cross-sectional views of an exemplary endoprosthesis.
  • FIG. 2 A shows how a biodisintegrable stent corrodes before a fiber meshwork disappears, giving a drug release beyond the lifetime of the mechanical support; and FIG. 2B shows how particles from a disintegrating mechanical support are captured by a fiber meshwork.
  • FIG. 3 is a schematic diagram comparing conventional electro-spraying and FFESS technology.
  • FIG. 4 shows various options for a meshwork composed of two different drug filled polymers with different fiber thicknesses and their respective drug release profiles with time.
  • FIGs. 5A and 5B show various polymer layers suitable for use with a fiber meshwork, and their respective structural formulae.
  • FIG. 6 shows various configurations of layer-by-layer coatings that contain drugs, and are deposited on the mechanical support or on the fiber meshwork.
  • the device structure itself may also disintegrate in a non-uniform manner so that large particles loosen, break off and float into the bloodstream, causing boli and secondary blockages.
  • the devices herein address such issues by incorporating material that is strong enough to last longer than the underlying structure so as to prevent both its uncontrolled breakdown and non-uniform drug release, yet which is flexible enough to permit regulated access of bodily fluids to the underlying structure.
  • a biocompatible material is a material that can be introduced into living tissue or a living system, and is non-toxic or non-injurious to the tissue or system, and does not cause an immunological reaction or rejection.
  • a “biodisintegrable material” is a biocompatible material that undergoes at least one of dissolution, degradation, absorption, erosion, corrosion, resorption, chemical transformation, or other disintegration processes over the period that the device formed at least in part from the biodisintegrable material is designed to reside in an organism.
  • Chemical transformation can include oxidation or other chemical reactions of the stent body material.
  • a biodisintegrable material is a material that exhibits substantial mass or density reduction by one or more of dissolution, degradation, absorption, erosion, corrosion, resorption, decomposition, degeneration, chemical transformation and/or other disintegration processes after it is introduced into an organism.
  • the disintegration occurs to a desirable extent in a timeframe that can provide a clinical benefit. Mass reduction of a biodisintegrable device can also occur, but in some cases does not occur, by fragmentation of the material.
  • the disintegration can be the result of the chemical and biological interaction of the material with the physiological environment into which it is implanted and/or can be initiated by applying a suitable triggering influence, such as a chemical reactant or source of energy to the stent.
  • a biodisintegrable material for use with the present invention exhibits substantial mass reduction after a period of time for which a function of the material, such as support of a lumen wall or delivery of a therapeutic agent in the immediate vicinity of the device, is no longer needed or desirable.
  • a substantial reduction is meant that the biodisintegrable material exhibits a mass reduction through biodisintegration of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 50%, at least about 75%, or at least about 90%, after a period of implantation.
  • the period of implantation over which the mass reduction through biodisintegration takes place can be chosen to be one day or more, 14 days or more, 30 days or more, 60 days or more, 90 days or more, 180 days or more, 300 days or more, 600 days or more, or about 1,000 days or less.
  • the level of biodisintegrability can be tailored to achieve a given level of mass reduction over a certain desired duration. For example, a medical device may be required to have reached a 75% reduction in mass in 30 days. In another embodiment, it may be required to have attained a 30% reduction in mass in 180 days.
  • a period of days such as 300 days, as used herein, entails a level of imprecision such that periods of 3-5 days either shorter or longer than the period in question are also acceptable equivalent timescales for measuring levels of biodisintegrability.
  • an exterior layer or coating may be non- biodisintegrable, while an interior layer or body is biodisintegrable.
  • a degradable material is a material that can dissociate, depolymerize, or otherwise reduce in molecular weight from its starting molecular weight, such that a resulting compound is soluble in an aqueous medium such as water or, if insoluble, can be suspended in a body fluid and transported away from an implantation site without obstructing the flow of the body fluid.
  • a biodegradable material is one that will degrade into biocompatible compounds as part of a biological process.
  • a biodegradable material exhibits substantial mass reduction after a period of time for which a function of the material, such as support of a lumen wall or delivery of a therapeutic agent in the immediate vicinity of the device, is no longer needed or desirable.
  • a substantial reduction is meant that the biodegradable material exhibits a mass reduction through bio degradation of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 50%, at least about 75%, or at least about 90%, after a period of implantation.
  • the period of implantation over which the mass reduction through biodegradation takes place can be chosen to be one day or more, 14 days or more, 30 days or more, 60 days or more, 90 days or more, 180 days or more, 300 days or more, 600 days or more, or about 1,000 days or less.
  • the level of biodegradability can be tailored to achieve a given level of mass reduction over a certain desired duration. For example, a material may be required to have reached a 25% reduction in mass in 600 days. In another embodiment, it may be required to have attained a 30% reduction in mass in 300 days.
  • a period of days such as 180 days, as used herein, entails a level of imprecision such that periods of 3-5 days either shorter or longer than the period in question are also acceptable equivalent timescales for measuring levels of biodegradability.
  • a resorbable material is a material that is soluble, biodisintegrable as defined herein, or is an aggregate of soluble and/or disintegrable material(s) with insoluble material(s) such that, with the resorption of the soluble and/or disintegrable materials, the residual insoluble materials are of sufficiently fine size that they can be suspended in a body fluid and transported away from the implantation site without obstructing the flow of the body fluid. Ultimately, the particles are eliminated from the body either by excretion in fluids such as perspiration, urine or feces, or are themselves dissolved, degraded, corroded or otherwise metabolized into soluble components that are then excreted from the body.
  • a bioresorbable material is a resorbable material that is biocompatible.
  • body fluid refers to fluids in the body of an organism — especially a mammal — including, but not limited to, blood, urine, saliva, lymph, plasma, gastric, biliary, or intestinal fluids, seminal fluids, and mucosal fluids or humors.
  • therapeutic agent pharmaceutically active agent
  • pharmaceutically active material pharmaceutically active ingredient
  • drug pharmaceutically active ingredient
  • other related terms include, but are not limited to, small organic molecules, peptides, oligopeptides, proteins, nucleic acids, oligonucleotides, genetic therapeutic agents, non-genetic therapeutic agents, vectors for delivery of genetic therapeutic agents, cells, and therapeutic agents identified as candidates for vascular treatment regimens, for example, as agents targeting restenosis.
  • small organic molecule an organic molecule having 50 or fewer carbon atoms, and fewer than 100 non-hydrogen atoms in total.
  • an "antimicrobial agent” is any agent that is harmful to microbes, especially pathogenic bacteria.
  • treatment refers to the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination of a disease or condition.
  • biostable materials e.g., polyelectrolytes
  • a “biostable material” is a material that does not undergo substantial dissolution, degradation, absorption, erosion, decomposition, corrosion, chemical transformation, resorption and/or other disintegration processes over the period that the material is designed to reside in an organism.
  • FIGs. IA and IB Two views of an exemplary device 1 are shown in FIGs. IA and IB, in which an underlying structure 10 is covered at least in part by a fiber meshwork 20 comprising one or more fibers (not individually depicted in FIGs. IA or IB) that may optionally contain or be coated with material containing at least one therapeutic agent such as a pharmaceutically active ingredient.
  • Exemplary device 1 is generally tubular in shape and as depicted may be, e.g., a stent. As shown in the exploded view of FIG.
  • the underlying structure 10 may optionally be coated by a multi-layer structure 30, in one or more layers of which is optionally contained a therapeutic agent.
  • the fiber or fibers of which the fiber meshwork 20 is composed may also optionally be coated with a multi-layer structure 40 as shown in FIG. IB.
  • Multi-layer structure 40 may also optionally contain at least one therapeutic agent in one or more of its constituent layers.
  • the underlying structure 10 is bio-disintegrable and is made from a different material than is the fiber meshwork 20.
  • the underlying structure can include (e.g. , be formed of) a biodisintegrable metal or a biodisintegrable polymer, as described in BoIz, U.S. Patent No. 6,287,332; Heublein, U.S. Patent Application Publication No. 2002/0004060 Al; U.S. Patent No. 5,587,507; and U.S. Patent No. 6,475,477.
  • the fiber meshwork can wrap around the underlying structure without totally encapsulating it, thereby permitting fluid access to it.
  • the fiber meshwork can be of a sufficient strength to retain its shape for a longer time than that of the underlying structure itself. If the mechanical support is bio-disintegrable, it is thereby allowed to degrade in a controlled manner, while the fiber meshwork retains its structure.
  • Fiber meshwork 20 can be formed from a material impregnated with a therapeutic agent that releases such an agent slowly over time.
  • the fiber meshwork 20 is overcoated with a multilayer structure.
  • the multilayer structure can be a layer-by-layer (LBL) coating wherein one or more layers contain a therapeutic agent.
  • LBL layer-by-layer
  • the fiber meshwork is thus able to ensure both a controlled release of a therapeutic agent absorbed within it or coated over it, as well as a controlled degradation of the underlying structure.
  • a still further advantage of deploying a fiber meshwork impregnated with a drug or coated with layers containing a drug is that, when used in conjunction with an endoprosthesis whose underlying structure itself has a lattice or mesh structure, or similar, it can provide a more uniform release profile of the drug in the region of the stent than, e.g., a coating directly deposited on such a lattice or mesh structure. The latter may tend to release higher concentration of drug along the struts of the endoprosthesis than in the gaps in between such struts.
  • the underlying structure 10 is also covered with a multilayer structure such as a LBL coating.
  • the fiber meshwork acts as an enclosing envelope to regulate release of a therapeutic agent from loosely packed particulate materials situated within it.
  • the fiber meshwork can be created with electro-spun nano-fibers or micro-fibers, and by flow-limited field-injection electrostatic spraying (FFESS), as further described herein.
  • FFESS flow-limited field-injection electrostatic spraying
  • the fiber meshwork can be amorphous, i.e., does not possess a regular structure.
  • the fiber meshwork contains one or more fibers.
  • Each individual fiber can be considered to consist of a number of contiguous segments.
  • Each fiber wraps around the underlying structure in such a manner that one of its segments crosses either another segment of the same fiber or another fiber at least once.
  • the fiber meshwork is composed of a number of fiber segments that cross one another, when viewed from a given direction.
  • the fiber meshwork comprises a single fiber. However, equally satisfactory fiber meshworks may be utilized that comprise more than one fiber.
  • the fiber meshwork can utilize 10 or fewer fibers, such as 2, 3, 5, or 7 fibers.
  • From 10 to about 100 fibers can also be used, for example, 20, 50, or 80 fibers are effective. In such embodiments, not all of the fibers need to be made of the same material. Each of such fibers may be as long as several millimeters, or may be as long as about 1 centimeter, or as long as about 5 centimeters, or as long as about 10 centimeters, and may even be as long as about 20 centimeters. Where more than one fiber is present, it is not necessary that every fiber have the same or a similar length. Thus it is possible that several fibers are used, all having lengths of between 5 and 7mm. It is also possible that several fibers are used, having lengths of 5 mm, 2 cm, 5 cm, and 10 cm.
  • a fiber meshwork can also be constructed based on a very large number of short lengths of fibers. Such fibers may be as short as about 10 micron, or may be from about 10 to about 100 ⁇ , but the overall meshwork may consist of many thousands, and may even consist of many hundreds of thousands of such fibers.
  • the fiber meshwork itself envelop the entirety of the exterior surface of the underlying support.
  • the fiber meshwork when suitably rigid, can be manufactured to extend beyond the dimensions of the underlying structure, thereby permitting delivery of a therapeutic agent contained therein to regions of the body lumen outside of those supported by the underlying structure.
  • the nature of the fiber meshwork can be such that there are minute gaps between the various segments of fiber so that body fluids can contact the underlying structure.
  • the fiber meshwork thus has an effective porosity that results from its structure in a manner different from that of other materials, for example a polymer matrix.
  • the benefits of the fiber meshwork arise from a combination of its porosity and durability.
  • porosity defined as the proportion of the non-solid volume to the total volume of material, the fiber meshwork is able to attain a porosity higher than that of a polymer matrix of comparable volume.
  • the porosity of the fiber meshwork is in the range 0.1 - 0.6, and in other embodiments it is in the range 0.2 - 0.4.
  • the fiber meshwork is harder and less flexible, thereby retaining more of its structure as an underlying structure degrades.
  • the fiber meshwork can retain a therapeutic agent and allow for its release over time.
  • the nature of the fiber meshwork is such that it has a large surface area and thus is capable of releasing uniformly a therapeutic agent absorbed within it or in a layer coated on top of it.
  • the fiber meshwork may comprise a polymeric material such as a polymer, or a blend of polymers.
  • a "polymer” is any macromolecule composed of two or more monomers, and includes dimers, trimers, tetramers, etc.
  • a "monomer” is a polymerizable molecule.
  • the polymeric materials comprise polymer molecules having a median number of monomers that numbers in the tens (10 to 99), in the hundreds (100 to 999), in the thousands (1,000 to 9,999), or in the tens of thousands (10,000 to 99,999) as well as a mixture of polymers having different median numbers of monomers.
  • the polymeric materials can comprise polymer molecules having a median number of monomers that is 100,000 or more.
  • Such polymers may be crosslinked or uncrosslinked, linear or branched, natural or synthetic, thermoplastic or thermosetting, and may be biostable, biodegradable, bioabsorbable, biodisintegrable, or dissolvable.
  • the polymers used to form the fiber meshwork are biodegradable.
  • the polymers can substantially degrade over a period of time that is different from the period of time over which the underlying structure substantially biodisintegrates.
  • the polymers of the fiber meshwork biodegrade over a longer period of time than the period of time for which the underlying structure biodisintegrates.
  • the polymers are biostable.
  • Polymers for use in the fiber meshwork can include any polymer that is biocompatible, and in particular a polymer that is compatible with the specific implantation environment in instances where local conditions are unusually hostile to non-native materials.
  • An exemplary polymer is poly(D,L-lactide-co-glycolide) (TLG').
  • Other polymers are further described herein.
  • Still other exemplary polymers include, but are not limited to: poly(lactic acid); poly(glycolic acid); poly(caprolactone); poly(hydroxybutyrate); poly(orthoester); poly(alkane anhydride); gelatin collagen; oxidized cellulose; and poly(phosphazene).
  • the fiber meshwork may also be constructed from other materials that are biodegradable, including metals. Accordingly, in certain embodiments the fiber meshwork is made from magnesium fibers. In other embodiments, the fiber meshwork is made from fibers of iron, or zinc. Additionally, fibers of metal alloys are contemplated.
  • the fiber meshwork is coated onto the underlying support so that it forms from about 10% to about 50% by weight of the entire device.
  • the fiber meshwork forms about 20% to about 30% by weight of the entire device weight.
  • the polymers from which the fiber meshwork is formed lead to self-supporting fibers so that, as shown schematically in FIG. 2A, at such time as the underlying structure 10 has substantially biodisintegrated, the fiber meshwork 20 retains its original shape or a close approximation thereof. By so doing, the fiber meshwork does not collapse and obstruct free passage of bodily fluids through the lumen in which it is situated. Instead, the fiber meshwork retains a support structure that helps to maintain the structure of the lumen itself where previously the underlying structure of the endoprosthesis had provided support.
  • the fiber meshwork becomes embedded, either partially or completely, in layers of cells as may be found on the internal surface of a body passageway.
  • the fiber meshwork is reinforced, even after the underlying structure has degraded, and has a reduced propensity to collapse.
  • the fiber meshwork is able to continue release of a therapeutic agent contained within it, as further described herein.
  • close approximation thereof it is understood that the fiber meshwork will naturally distort overtime but it is intended that it does so to only a small extent.
  • the structure of the fiber meshwork produced with a method such as FFESS is such that fluid access to the surface of the mechanical support is permitted.
  • the fiber meshwork itself can be chosen to be biostable or very slowly degrading, to act as an enclosing envelope for the more rapidly disintegrating device structure, thereby addressing the problem of uneven device degradation, as shown in FIG. 2B for the example of a stent.
  • FIG. 2B for the example of a stent.
  • Biostable materials for forming the fiber meshwork include, for example, styrene-isobutylene-styrene ('SIBS'), silicone elastomers; poly(ethylene-co-vinyl acetate); and Polyacrylates.
  • the underlying structure comprises a first ring and a second ring, wherein the first ring and the second ring are connected to one another by the fiber meshwork.
  • the first ring is made of a first material and the second ring is made of a second material.
  • the first material and the second material are different from a material of which the fiber meshwork is comprised.
  • the first and second ring are arranged coaxially to one another. It is to be expected, however, that due to flexibility of the fiber meshwork, the first and second ring may not be always situated exactly coaxially with respect to one another, and may also not always be disposed so that their respective planes are parallel to one another. For example, the centers of the respective rings may be offset with respect to one another and/or the planes of the rings may be disposed at an angle other than 180° with respect to one another. Such variations are to be expected within both manufacture and operation of the embodiment.
  • the overall device has a flexibility imparted by the fiber meshwork and thus can, e.g., bend if necessary in a curved or flexible section of a body lumen.
  • a therapeutic agent such as may be absorbed within the fibers of the fiber meshwork, is desired.
  • the fiber meshwork may also itself degrade in a controllable manner and therefore be used to fine-tune the disintegration of the underlying structure.
  • the biodisintegrable material of the underlying structure can become more exposed to water in the bodily fluids that surround it. This increased exposure to water can cause the underlying structure to begin to disintegrate, or to disintegrate more rapidly. Eventually, the underlying structure may disintegrate entirely.
  • the fiber meshwork can be comprised of polymers to which a surface charge can readily be attached, or which are naturally charged such that a multi-layer structure can be disposed thereon, using a layer-by-layer method that builds up layers of alternating charges, as further described herein.
  • the fiber meshwork may be deposited by a number of methods of creating and depositing extremely thin fibers, known to one of ordinary skill in the art. Such methods are typically related to electrospraying. In essence, in electrospraying, an electric field is used to drive charged particles to a grounded substrate. A charged solution exits from a spray nozzle in a conical configuration, referred to as the Taylor cone. If the Taylor cone doesn't break up, the solution forms fibers; otherwise the material becomes individual spray droplets. The two principal parameters that control behavior of the Taylor cone are the viscosity and voltage at the nozzle. Exemplary methods of creating ultra-thin fibers for use in creating a fiber meshwork involve electro-spinning.
  • Fibers that are micrometers in diameter can be created by melt spinning or gel spinning, i.e., they are formed out of a gel or a molten melt.
  • a particularly exemplary method of depositing the fiber meshwork is to use a process referred to as flow-limited field-injection electrostatic spraying (FFESS).
  • FFESS is a form of electrospraying which offers a very high degree of control over shape and flow regimes, and which allows spinning a fiber-meshwork on top of a medical device, such as an endoprosthesis, with a glass spray nozzle. The nozzle generates a charge at the liquid meniscus that enables successful electrospray .
  • FIG. 3 A schematic comparison of apparatuses used respectively for conventional electro-spraying and FFESS is shown in FIG. 3 in which a structure to be sprayed is denoted 201.
  • FFESS sprays a polymer/solvent solution 230 from a smooth glass capillary 200 whereas CES uses a metal hypodermic needle 210, and second that FFESS uses a sharpened tungsten needle 220 inside capillary 200, whereas CES has no analogous structure.
  • the overall effect of the FFESS apparatus is to improve jet stability and uniformity of the polymer sprayed by FFESS relative to that from CES.
  • FFESS method for electro-spinning creates a fiber meshwork in which the one or more fibers have a highly controlled fiber diameter.
  • the diameter of the fibers formed during the spinning process can be controlled.
  • electrostatic Spinning and Properties of Ultrafme Fibers see, e.g., “Electrostatic Spinning and Properties of Ultrafme Fibers", Rutledge, et al, National Textile Center Annual Report, M01-D22, (November 2001), incorporated herein by reference. See also further description on the internet at vvwvv .c)ie. . vt.edu/Wilke ⁇ It is also consistent with the fiber meshwork that the diameter of the fibers can be changed during deposition.
  • a further advantage of FFESS is thus that, because of the high degree of control of the fiber diameter, if the weight of the fiber meshwork as well as the density of the polymer material for a given fiber diameter are known, the total surface area of the meshwork can be precisely calculated.
  • the surface area of a fiber of diameter d, and of length / is ⁇ dl, ignoring contributions from the ends of the fibers.
  • FFESS is further described in "Controlling surface nano-structure using flow-limited field-injection electrostatic spraying (FFESS) of poly(d,l-lactide-co-glycolide)", Berkland, Pack, and Kim, Biomaterials, 25: 5649-5658, (2004) and U.S. Patent Application Publication No. 2004/0022939, both of which are incorporated herein by reference in their entirety.
  • the median diameter of the fiber or fibers in the fiber meshwork can be less than about 1 micron, for example, less than about 500 nm. In some embodiments, the fibers have a median diameter from about 5 nanometers to about 500 nanometers. For example, the fibers can have a median diameter of about 50 nm, about 100 nm, about 150 nm, about 200 nm, about 250 nm, about 300 nm, about 350 nm, about 400 nm, or about 450 nm.
  • a reference to a median diameter of, for example, about 300 nm would encompass other median diameters within +/- 25 nm of 300 nm. It is to be understood that where a fiber is not perfectly circular in cross-section, the diameter of a particular fiber can refer to an average length of any two orthogonal lines that both pass through the geometric center of the fiber cross-section and have end points on the perimeter of the fiber, or to the length of any one such line. It is also to be understood that although the diameter of a fiber can vary along its length, the diameter is the mean diameter of the fiber.
  • morphologies could be utilized to the extent that they embody the properties desired of a polymer structure for placing on the surface of an underlying structure 10. As further discussed herein, such properties include at least an ability to substantially retain shape after the underlying structure has biodisintegrated, a porosity sufficient to permit access of body fluids to the underlying structure, and a sufficient surface area to give rise to sustained release of a therapeutic agent absorbed within the polymer structure or from layers coated upon it.
  • Other morphologies of polymer such as particles, beads, porous sheets, webs, nets and smooth surfaces may be created with FFESS, as further illustrated in Berkland, et al, Biomaterials, 25: 5649-5658, (2004) and U.S. Pat. App. Pub. No. 2004/0022939.
  • a web or net-like structure for the fiber meshwork is advantageous because it reduces the chance that short individual fibers can become disconnected from the underlying structure.
  • the fiber is deposited as a mixture of fibers and beads.
  • a fiber composed of a biodegradable material in which is embedded a therapeutic agent will release the agent at a rate that depends upon the diameter of the fiber. It can be advantageous to mix in amongst such fibers beads of material which, being thicker than the fibers, will release the therapeutic agent over a more prolonged period of time.
  • One of ordinary skill in the art is capable of manipulating the electrospinning process to ensure production of beads at one time, fibers at one time, or a mixture of beads and fibers. See, e.g., Shenoy, S.
  • a first option is to place the therapeutic agent inside the fiber material as it is being sprayed by a process such as FFESS.
  • FFESS a process such as FFESS.
  • the drug may be dissolved in the polymer solution before it is sprayed.
  • This approach is also advantageous because it is possible to spray different therapeutic agents from different fibers using different nozzles to achieve simultaneous delivery of a mixture of drug components, as shown in FIG. 4. For example, at the top of FIG.
  • FIG. 4 are shown three embodiments of a stent having disposed thereon, from left to right, a fiber meshwork made from a single fiber, two fiber meshworks made from fibers of the same thickness, and two fiber meshworks made from fibers of different thicknesses wherein the thicker fibers are only disposed at the ends of the stent.
  • the lower portion of FIG. 4 shows two embodiments of a stent, having fiber meshworks composed of fibers of different thicknesses disposed thereon and, below each, drug release profiles showing concentration of released drug (vertical axis) as a function of time (horizontal axis).
  • concentration of released drug vertical axis
  • the same drug is loaded into fibers of different thicknesses
  • different drugs are loaded into fibers of different thicknesses.
  • the level of control of fiber diameter achievable with FFESS is also useful because, as further described herein, release of a therapeutic agent absorbed in such fibers is directly related to the diameter of the fibers.
  • the porous structure of the fiber meshwork disposed on the underlying structure allows all of the fibers to release their drug content directly to the surrounding milieu at the same time.
  • a specific release profile can be achieved.
  • use of FFESS permits creation of a differential release profile across the medical device. For example, by spraying a thinner fiber- structure at the end sections of the device, one can obtain a higher drug release at the ends by virtue of a higher surface area to volume ratio there.
  • a second option for introducing a therapeutic agent into the fiber meshwork is to embed Magnetite nano-particles into the fibers.
  • Such nano-particles are ferro-magnetic and would themselves permit binding of magnetic drug delivery particles to the fiber matrix by methods within the capability of one of ordinary skill in the art.
  • magnetic drug delivery particles see, e.g., "Functionalisation of magnetic nanoparticles for applications in biomedicine", Berry, C. C, et ah, J. Phys. D: Appl. Phys., 36 R198-R206, (2003), incorporated herein by reference in its entirety.
  • a dispersion of a desired nanoparticle in a polymer-solvent solution would be spun into fibers, such as with FFESS, such that the fibers themselves have the nanoparticles incorporated therein.
  • the fiber meshwork may also contain a nanocomposite instead of or in addition to a purely polymeric material.
  • Nanocomposite refers to a composition comprising a polymeric material and relatively small amounts (generally less than about 10% by weight) of nanometer-sized (average size smaller than 1 micrometer) mineral, clay, or nanosized ceramic particles dispersed therein.
  • nanocomposites are referred to as "nanoclay” or “nanoceramic”.
  • nanocomposites are disclosed in International Publication No. WO 93/1014118, and U.S. Pat. Nos. 5,385,776, and 6,251,980 all of which are incorporated herein by reference in their entirety. These particles may themselves contain therapeutic agents that are released as the polymer of the meshwork degrades.
  • liposomes which are embedded in the fiber meshwork. Methods of embedding liposomes into thin films have been described elsewhere, and are generally known to one of ordinary skill in the art (see, e.g., Vermette et al., "Immobilized liposome layers for drug delivery applications: inhibition of angiogenesis", J. Controlled Release, 80:179-195 (2002)).
  • Liposomes are lipid-bilayer bound vesicles, typically less than 1 micron in diameter, for example, in the range 50 - 400 nm in diameter, that can be used as drug-delivery vehicles. Typically such liposomes are electrically charged: both cationic and anionic liposomes are known in the art as drug delivery vehicles.
  • Therapeutic agents can be encapsulated into liposomes prior to implantation in an organism, and slowly leech out as the liposome degrades.
  • Charged liposomes can bind to a fiber meshwork as described herein by, for example, coating the fiber meshwork with a layer-by-layer composition (of alternating cationic and anionic layers) such that the outermost (last-deposited) layer has an opposite charge to that of the liposome.
  • a layer-by-layer composition of alternating cationic and anionic layers
  • the liposomes become bound to the fiber meshwork.
  • fibers of the fiber meshwork can comprise magnetic nanoparticles.
  • Liposomes having magnetite particles can bound to such a fiber meshwork.
  • polyelectrolyte multilayer capsules may be used as transporters of drugs that may be embedded in a fiber meshwork.
  • Drug-filled polyelectrolyte capsules can be prepared by any one of several methods known to one of ordinary skill in the art, (see, e.g., Antipov, A. A., and Sukhorukov, G. B., "Polyelectrolyte multilayer capsules as vehicles with tunable permeability", Adv. Colloid and Interface Sci. , 111, 49-61 , (2004)).
  • a therapeutic agent is introduced into a medical device via a layer-by-layer (LBL) coating process which overcoats the fiber-meshwork with one or more alternating single molecular layers of cationic and anionic materials, as further described herein.
  • LBL layer-by-layer
  • Many bioactive molecules, such as proteins, enzymes, DNA, are charged, and can be readily included in these types of coatings.
  • a number of LBL coatings, as shown in FIGs. 5 and 6, and as further described herein, can be used.
  • the LBL coating process can permit coating of highly complex 3D structures without webbing, and is able to penetrate inside complex structures. Webbing is an effect that occurs when a very viscous solution is applied to coat very fine wires.
  • the coating will form a kind of webbing between one fiber and another, which can be undesirable. Since layer by layer technology uses low viscous water-based solutions, it can penetrate into all manner of geometries without the risk for webbing.
  • An example is described in, e.g., Artyukhin, et al., Langmuir, 20, 1442-1448, (2004), and H. Kong, et al., "Polyelectrolyte-functionalized multiwalled carbon nanotubes: preparation, characterization and layer-by- layer self-assembly", Polymer 46:2472-2485, (2005), both of which are incorporated by reference herein in their entirety, and which demonstrate overcoating of multiwall carbon nano-tubes with several layers of different molecules.
  • a functionalized multi-wall carbon nanotube (MWNT) 300 such as MWNT-COOH, MWNT-PAA (where PAA is polyacrylic acid), or MWNT-PSS (where PSS is poly(sodium 4-styrenesulfonate)) can accept a number of layers of different charge, disposed thereon.
  • MWNT multi-wall carbon nanotube
  • HPSA hyperbranched polysulfone amine
  • PDMAEMA poly(2-(N,N-dimethylaminoethyl) methacrylate), both of which are positively charged, can be disposed on a MWNT functionalized with negatively charged groups such as carboxylates.
  • PSS negatively charged
  • PDMAEMA HPSA
  • HPSA positively charged
  • PDMAEMA HPSA
  • HPSA positively charged
  • PDMAEMA PDMAEMA
  • HPSA fiber meshwork
  • FIG. 5B The formulae of PSS, HPSA, and PDMAEMA are shown in FIG. 5B.
  • the fiber meshwork is able to elute a drug contained within it, or absorbed in a layer upon it, over a longer period of time than the lifetime of the mechanical support.
  • the f ⁇ ber-meshwork sprayed by a method such as FFESS can be overcoated with several layers, one or more of which contains a therapeutic agent, using layer-by- layer (LBL) technology.
  • LBL layer-by- layer
  • the layer-by-layer coating process produces a multi-layered structure such as 40, in FIG. IB, on the fiber meshwork.
  • Advantages of such an arrangement include a controlled release profile of the therapeutic agent.
  • a profile may be designed to include a first phase, characterized by a massive release of the agent from the top LBL coating by virtue of its large surface area, followed by a secondary release of the agent out of deeper layers of the LBL coating, or from the fiber meshwork itself as also discussed herein.
  • LBL coatings are also very effective in preventing degradation of the fiber meshwork, because they follow complex surfaces precisely, such as those of the fiber meshwork, and they are composed out of charged molecules which impede free motion of water molecules through the coating.
  • the use of an LBL coating on the underlying structure 10 allows control of the disintegration (e.g., corrosion) of the underlying structure over a desired timeframe. This may be important if it is wished to maintain the mechanical integrity of the device for such a defined timeframe.
  • FIG. 6 shows an underlying structure 10 having a fiber meshwork 20 disposed thereon.
  • the fibers of fiber meshwork can also have a layer-by-layer coating 40 disposed thereon, as shown in the various cutouts.
  • the underlying structure 10 can also have a layer-by-layer structure 30 disposed thereon.
  • the bottom of FIG. 6 shows a schematic of a device having multiple fiber meshworks 600 disposed on an underlying structure (denoted "support").
  • Each of the fiber meshworks 602-612 alternates in charge to facilitate deposition.
  • Peptide molecules are denoted "P" and are attached to fibers of one of the fiber meshworks 612. It is to be understood that molecules other than peptides can be similarly attached to one or more of the fiber meshworks.
  • At least one of the charged layers includes a polyelectrolyte.
  • Polyelectrolytes are polymers having charged groups or groups that dissociate to form ions (also called polyions). The number of these groups in a polyelectrolyte can be so large that the polymer is soluble in polar solvents (including water) when in ionic form.
  • One or more charged layers can include one type of polyelectrolyte or different types of polyelectrolytes.
  • polyelectrolytes can be classified as polyacids and polybases.
  • polyacids When dissociated, polyacids form polyanions, after protons have been released.
  • Polyacids include inorganic and organic molecules, as well as biopolymers.
  • Examples of polyacids are polyphosphoric acids, polyvinylsulfuric acids, polyvinylsulfonic acids, polyvinylphosphonic acids, and polyacrylic acids.
  • Examples of the corresponding salts, which are called polysalts are polyphosphates, polyvinylsulfates, polyvinylsulfonates, polyvinylphosphonates and polyacrylates, respectively.
  • anionic polyelectrolytes examples include poly(styrenesulfonate) polyanions (e.g., poly(sodium styrene sulfonate) (PSS)), polyacrylic acid polyanions, sodium alginate polyanions, eudragit polyanions, gelatin polyanions, hyaluronic acid polyanions, carrageenan polyanions, chondroitin sulfate polyanions, and carboxymethylcellulose polyanions.
  • poly(styrenesulfonate) polyanions e.g., poly(sodium styrene sulfonate) (PSS)
  • PSS poly(sodium styrene sulfonate)
  • polyacrylic acid polyanions sodium alginate polyanions
  • eudragit polyanions e.g., poly(sodium styrene sulfonate) (PSS)
  • PSS poly(
  • Polybases contain groups that are capable of accepting protons, e.g., by reaction with an acid, to form a salt. By accepting protons, polybases form cationic polyelectrolytes (polycations).
  • polybases having dissociable groups within their backbone and/or side groups are polyallylamine, polyethylimine, polyvinylamine and polyvinylpyridine.
  • polyelectrolyte cations include protamine sulfate polycations, poly(allylamine) polycations (e.g., poly(allylamine hydrochloride) (PAH)), polydiallyldimethylammonium polycations, polyethyleneimine polycations, chitosan polycations, gelatin polycations, spermidine polycations and albumin polycations
  • polyelectrolytes have both anionic and cationic groups, but nonetheless have a net positive or negative charge.
  • An example of such a polyelectrolyte is gelatin.
  • Some polyelectrolytes have combinations of both anionic and cationic groups such as to maintain electrical neutrality. Whether a polyelectrolyte having both anionic and cationic groups has a net positive or negative charge can depend, for example, on the pH of the environment surrounding the polyelectrolyte.
  • the polyelectrolytes for use with layer-by-layer coatings can include those based on biopolymers. Examples include alginic acid, gum arabicum, nucleic acids, pectins, proteins, chemically modified biopolymers such as carboxymethyl cellulose, and lignin sulfonates.
  • the polyelectrolytes for use with layer-by-layer coatings can also include those based on synthetic polymers, such as polymethacrylic acid, polyvinylsulfonic acid, polyvinylphosphonic acid and polyethylenimine.
  • Polyelectrolytes may be linear or branched, either or both of which can be used. Using branched polyelectrolytes can lead to less compact polyelectrolyte multilayers having a higher degree of wall porosity.
  • polyelectrolyte molecules can be crosslinked within and/or between the individual layers, to enhance stability, e.g. , by crosslinking amino groups on one polymer molecule with aldehyde moieties on another.
  • polyelectrolytes can be amphiphilic.
  • Amphiphilic substances can include any substance having hydrophilic and hydrophobic groups.
  • Amphiphilic polyelectrolytes e.g., amphiphilic block or random copolymers having partial polyelectrolyte character, can be used in some embodiments to affect permeability towards polar small molecules.
  • a layer including an amphiphilic polyelectrolyte may be more permeable to polar molecules than a layer including a polyelectrolyte that is not amphiphilic.
  • Amphiphilic polyelectrolytes can be used as ionic amphiphilic substances in some embodiments.
  • a polyelectrolyte comprising charged groups (which are hydrophilic) as well as hydrophobic groups, such as polyethylenimine (PEI) or poly(styrene sulfonate) (PSS), can be employed.
  • PEI polyethylenimine
  • PSS poly(styrene sulfonate)
  • Cationic and anionic surfactants may also be used as amphiphilic substances in some embodiments of the layer by layer coatings used with the present invention.
  • Cationic surfactants include quaternary ammonium salts (R 4 N + X " ), where R is an organic radical and where X " is a counter-anion, e.g., a halide.
  • examples of cationic surfactants include di- dodecyldimethylammonium bromide (DDDAB); alkyltrimethylammonium bromides such as hexadecyltrimethylammonium bromide (HDTAB), dodecyltrimethylammonium bromide (DTMAB), myristyltrimethylammonium bromide (MTMAB), or palmityltrimethyl- ammonium bromide; tertiary amines (RsNH + X " ), such as cholesteryl-3 ⁇ -N-(dimethyl- aminoethyl)-carbamate; and N-alkylpyridinium salts; or mixtures thereof.
  • DDDAB di- dodecyldimethylammonium bromide
  • HDTAB hexadecyltrimethylammonium bromide
  • DTMAB dodecyltrimethylammonium bromide
  • MTMAB myristyltrimethylammonium bro
  • Anionic surfactants include alkyl or olefin sulfates of general formula R-OSOsTVl + where M + is a metal counter-ion. Examples include a dodecyl sulfate such as sodium dodecyl sulfate (SDS), and a lauryl sulfate such as sodium lauryl sulfate (SLS). Anionic surfactants further include an alkyl or olefin sulfonate of general formula R-SOsTVl + , for example, sodium-n- dodecylbenzene sulfonate.
  • anionic surfactants include fatty acids (of formula R-COO M + , where R is an organic radical and M + is a counter-cation), for example, a dodecanoic acid sodium salt, or other acids including phosphoric acids, cholic acids, fluoro- organic acids such as lithium-3-[2-(perfluoroalkyl)ethylthio]propionate, or mixtures thereof.
  • fatty acids of formula R-COO M + , where R is an organic radical and M + is a counter-cation
  • R is an organic radical and M + is a counter-cation
  • the polyelectrolyte layers can restrict or prevent water molecules and/or certain ions from accessing the biodisintegrable materials of the underlying device structure.
  • polyelectrolytes can, in addition to the fiber meshwork, prevent the biodisintegrable materials from disintegrating prematurely (e.g., during delivery and/or deployment of the medical device to a target site).
  • such layers include one or more therapeutic agents.
  • one or more layers contain a radiopaque material, and/or one or more layers capable of enhancing the mechanical properties of the device structure.
  • the layers of the multi-layer structure disposed on the underlying structure include biodegradable polyelectrolytes that degrade at a slower rate than the rate of disintegration of the biodisintegrable material of the underlying structure. As the underlying structure disintegrates, it may break into multiple pieces. Because the layers of polyelectrolytes degrade at a slower rate than the biodisintegrable material of the underlying structure, at least some of the layers may limit or prevent movement of these multiple pieces to other places in the body, causing the pieces to disintegrate and be resorbed instead at the implantation site within the body.
  • a layer formed of a biodegradable polyelectrolyte can degrade over a period of at least about one second (e.g., at least about 10 seconds, at least about 30 seconds, at least about one minute, at least about 10 minutes, at least about one hour, at least about five hours, at least about 10 hours, at least about one day, at least about two days, at least about four days, at least about six days), and/or at most about one week (e.g., at most about six days, at most about four days, at most about two days, at most about one day, at most about 10 hours, at most about five hours, at most about one hour, at most about 10 minutes, at most about one minute, at most about 30 seconds, at most about 10 seconds).
  • at least about one second e.g., at least about 10 seconds, at least about 30 seconds, at least about one minute, at least about 10 minutes, at least about 10 minutes, at least about one hour, at least about five hours, at most about 10 hours, at most about 30 seconds, at most about 10
  • biodegradable polyelectrolytes can be used so that a therapeutic agent can be released into the subject at a rate that is dependent upon the rate of degradation of the polyelectrolyte layers. For example, by using polyelectrolytes that are biodegradable near the outer surface of the medical device, this rate can be initially highest.
  • Biodegradable polyelectrolytes can also be used in embodiments in which the underlying structure, and/or a fiber meshwork disposed thereon, is itself biodisintegrable. As the biodegradable polyelectrolytes in layers of the coating disintegrate, they may provide less protection for the underlying device structure. As a result, the structure can begin to disintegrate or can disintegrate at a faster rate.
  • biodegradable polyelectrolytes include heparin, polyglycolic acid (PGA), polylactic acid (PLA), polyamides, poly-2-hydroxy-butyrate (PHB), polycaprolactone (PCL), poly(lactic-co-glycolic)acid (PLGA), protamine sulfate, polyallylamine, polydiallyldimethylammonium species (e.g., poly(diallyldimethylammonium chloride) (PDADMA, available from Aldrich)), polyethyleneimine, chitosan, eudragit, gelatin, spermidine, albumin, polyacrylic acid, sodium alginate, poly(styrene sulfonate) (PSS, Scientific Polymer Products), hyaluronic acid, carrageenan, chondroitin sulfate, carboxymethylcellulose, polypeptides, proteins, DNA, and poly(/V-octyl-4-vinyl pyridin
  • Biodegradable polyelectrolytes are described, for example, in T. R. Farhat and J. B. Schlenoff, "Corrosion Control Using Polyelectrolyte Multilayers", Electrochemical and Solid State Letters, 5(4) B 13-Bl 5 (2002), incorporated by reference herein.
  • the layers are made from biostable polyelectrolyte materials, or the entire multi-layer structure is constructed so as to be biostable.
  • various layers are cross-linked to each other so that the multi-layered structure is biostable, the underlying structure may disintegrate over a given period of time, while the multi-layer structure remains in the body of the subject.
  • an endoprosthesis can include two or more polyelectrolyte layers that are cross-linked to each other.
  • the cross-linked polyelectrolyte layers may be used, for example, to confine a biodisintegrable material in the underlying structure.
  • a medical device can include a structure (e.g., a multi- layered structure) having a combination of cross-linked polyelectrolytes and biodegradable polyelectrolytes, to provide further tailoring of the disintegration of the device.
  • a biodegradable polyelectrolyte in one layer can be cross- linked (e.g., using heat and/or UV radiation) to another biodegradable polyelectrolyte in another layer.
  • cross-linking between polyelectrolytes in different layers can cause the polyelectrolytes to degrade at a slower rate than they would otherwise.
  • a layer including a cross-linked polyelectrolyte can degrade over a period of at least about one week (e.g., at least about two weeks, at least about three weeks, at least about four weeks, at least about six weeks, at least about eight weeks, at least about 10 weeks, at least about 12 weeks, at least about 14 weeks, at least about 16 weeks, at least about 18 weeks, at least about 20 weeks, at least about 22 weeks), and/or at most about 24 weeks (e.g.
  • a polyelectrolyte layer including diazonium cations may be covalently cross-linked to a polyelectrolyte layer including sulfonate groups or acrylic acid groups, using UV radiation or heat.
  • a polyelectrolyte layer including a diazo resin may be cross-linked to a polyelectrolyte layer including polyoxometalates.
  • ammonium groups in one polyelectrolyte layer may be covalently bonded to carboxylate groups in another polyelectrolyte layer.
  • polyelectrolyte layers including poly(allylamine hydrochloride) (PAH) can be covalently bonded to polyelectrolyte layers including poly(acrylic acid) (PAA).
  • Cross- linking of polyelectrolyte layers is described, for example, in Zhang et ⁇ l, "Improving multilayer films endurance by photoinduced interaction between Dawson-type polyoxometalate and diazo resin", Materials Chemistry and Physics, 90 (2005), 47-52, and in Zhang et al, “Ways for fabricating stable layer-by-layer self-assemblies: combined ionic self-assembly and post chemical reaction", Colloids and Surfaces A: Physicochemical and Engineering Aspects, 198-200, 439-442, (2002), both of which are incorporated herein by reference in their entirety.
  • one or more of the top polyelectrolyte layers on a medical device can be cross-linked. This can, for example, limit or prevent degradation or dissolution of the multi-layer structure on the medical device in the body.
  • multiple layers of polyallylamine hydrochloride (PAH) and polyacrylic acid (PAA) can be deposited on a plurality of other polyelectrolyte layers.
  • PAH polyallylamine hydrochloride
  • PAA polyacrylic acid
  • the entire multi-layered structure can then be heated at 130 0 C for about an hour under a nitrogen atmosphere to crosslink the ammonium groups of the PAH and the carboxylic groups of the PAA to form amide bonds.
  • a nylon- like top film that is impermeable to liquids can be created. In certain embodiments, this liquid- impermeable top film can later be removed (e.g., using excimer ablation).
  • one or more regions of a polyelectrolyte layer may be cross-linked to one or more regions of another polyelectrolyte layer (e.g., by selectively irradiating certain regions of the polyelectrolyte layers), while the polyelectrolyte layers may not be cross-linked to each other in other regions.
  • the multiple layers may have one or more (e.g., two, three, four, five, 10, 15, 20, 25, 50, 100, 500, or 1,000) holes in them in order to facilitate biodisintegration of the device on which the structure is placed.
  • the one or more holes can be added to a layer using a laser.
  • the holes can, for example, provide water and/or ions with limited access to the underlying structure, thereby helping to cause the underlying structure to disintegrate.
  • the multi-layer structure comprises one or more non- polyelectrolyte layers.
  • the non-polyelectrolyte layers can be biodisintegrable or biostable.
  • non-polyelectrolyte biodisintegrable materials include polylactides such as polylactic acid (PLA), polyglycolides such as polyglycolic acid, poly(lactide-co-glycolides), polyanhydrides, and polyorthoesters.
  • PLA polylactic acid
  • polyglycolides such as polyglycolic acid
  • poly(lactide-co-glycolides) polyanhydrides
  • polyorthoesters polyorthoesters.
  • an endoprosthesis according to the present invention can further include one or more non-polyelectrolyte layers, which can be added to it using, for example, a spraying technique.
  • the non-polyelectrolyte layer(s) may be added on top of and/or underneath the multi-layered structure.
  • an endoprosthesis can include more than one multi-layered structure, and/or can include one or more non-polyelectrolyte layers located between the multi-layered structures.
  • the non-polyelectrolyte layer(s) may be thicker than one or more of the layers in the multi-layered structure(s).
  • a non-polyelectrolyte layer may exhibit better adhesion to the surface of a tubular structure of an endoprosthesis than a polyelectrolyte layer.
  • a multi-layered structure may include at least two positively charged layers that are formed of different materials (e.g. , different polyelectrolytes) and/or at least two negatively charged layers that are formed of different materials (e.g., different polyelectrolytes).
  • one portion of the underlying structure may be coated with a multi-layered structure, while another portion of the underlying structure may not have any coatings on it, or may be coated with just one layer.
  • charged layers of a multi-layer structure containing various polyelectrolytes can be interleaved with other layers that contain magnetic clusters.
  • inorganic materials such as polyoxometalates in a multi-layered structure using a layer-by-layer method are described, for example, in Caruso et al, Langmuir (1998), 14, 3462-3465, and also in pending U.S. Patent Application Serial No. 10/985,242, both of which are incorporated herein by reference in their entirety.
  • a multi-layered structure in conjunction with a fiber meshwork can also be applied to the underlying structures of numerous medical devices. For example, they can be applied to grafts, filterwires, valves, filters (e.g., vena cava filters), aneurysm coils, distal protection devices, guidewires, and other implantable devices.
  • a multi-layered structure can be applied to a catheter (e.g., a renal or vascular catheter such as a balloon catheter).
  • a multi-layered structure can be applied to a balloon.
  • a multi-layered structure such as multi-layered structure can be applied to a coil (e.g., an aneurysm coil). Coils are described, for example, in Twyford, Jr. et al., ⁇ .S. Patent No. 5,304,195.
  • the multi-layered structure can include nanoparticles.
  • the nanoparticles can, for example, enhance the mechanical properties (e.g., strength) of the multi-layered structure.
  • the nanoparticles can have at least one dimension (e.g., the thickness for a nanoplate, the diameter for a nanosphere, a nanocylinder and a nanotube) that is less than 1,000 nanometers (e.g., less than 100 nanometers).
  • Nanoplates can have at least one dimension that is less than 1 ,000 nanometers; nano fibers can have at least two orthogonal dimensions (e.g., the diameter for a cylindrical nano fiber) that are less than 1,000 nanometers; and other nanoparticles can have three orthogonal dimensions (e.g., the diameter for nanospheres) that may be less than 1,000 nanometers.
  • charged layers containing various polyelectrolytes can be interspersed with other layers to form a multi-layer structure using a method in which the layers electrostatically self-assemble.
  • a first layer comprising a first material having a first surface charge is deposited on an underlying structure or substrate, followed by a second layer comprising a second material having a second surface charge that is opposite in sign to the surface charge of the first layer.
  • the charge on the outer layer is reversed upon deposition of each sequential layer.
  • Additional layers, for example of first and second materials can then be alternatingly deposited on the substrate to build a multi-layered structure to a predetermined or targeted thickness.
  • This method allows a multi-layer structure to be formed on an underlying structure directly and/or, for example, on a flexible sleeve (e.g., a polymer sleeve) carried by the underlying structure, as well as on a fiber meshwork of the present invention.
  • the layer-by- layer structure thus formed is capable of controlling the disintegration of the underlying structure, while allowing the device to remain flexible and adaptable to the vessel in which the device is implanted.
  • Layer-by-layer self-assembly is described, for example, in Liu et al, Journal of Cluster Science, Vol. 14, No. 3, 405-419, (2003); and Caruso et al, Langmuir, 14, 3462-3465, (1998).
  • the substrate can be the underlying structure, or the fiber meshwork.
  • the layer can be coated with a layer of an oppositely charged material.
  • the device can be washed to remove excess material.
  • a multi-layer structure can be formed by repeated treatment with alternating, oppositely charged, materials, e.g., a positive polyelectrolyte and a negative polyoxometalate, as described in pending U.S. Patent Application Serial No. 11/127,968, incorporated by reference herein.
  • the respective layers self-assemble by electrostatic layer- by-layer deposition, thus forming a multi-layered structure over the underlying structure or the fiber meshwork of the device.
  • the multi-layer structure is formed by exposing a selected charged substrate (e.g. , the underlying structure of a stent, or a fiber meshwork) to solutions or suspensions that contain species of alternating net charge, such as solutions or suspensions that optionally contain charged magnetic clusters, charged therapeutic agents and/or nanoparticles.
  • a selected charged substrate e.g. , the underlying structure of a stent, or a fiber meshwork
  • solutions or suspensions that contain species of alternating net charge, such as solutions or suspensions that optionally contain charged magnetic clusters, charged therapeutic agents and/or nanoparticles.
  • concentration of the charged species within these solutions and suspensions which can be dependent on the types of species being deposited, can range, for example, from about 0.01 mg/ml to about 30 mg/ml.
  • the pH of these suspensions and solutions can be such that polyelectrolytes, optional magnetic clusters, and therapeutic agents and/or nanoparticles to be included within the layers maintain their charge. Buffer systems can be used to maintain
  • the solutions and suspensions containing the charged species can be applied to the charged substrate surface using a variety of methods. Examples of such methods include spraying methods, dipping methods, roll and brush coating methods, ink jet methods, spin coating methods, web coating methods, microstamping methods, and methods involving coating via mechanical suspension such as air suspension, as well as combinations of these methods.
  • Layers can be applied over an underlying structure by immersing the entire structure into a solution or suspension containing the charged species, or by immersing half of the structure into the solution or suspension, flipping the structure through 180°, and immersing the other half of the substrate into the solution or suspension to complete the coating.
  • the substrate is rinsed after application of each charged species layer, for example, using a washing solution with a pH that maintains the charge of the outer layer.
  • the substrate is itself charged.
  • a fiber meshwork can therefore be composed of charged polymer molecules or, at least, carries a surface charge to facilitate deposition of a first layer of a layer-by-layer structure upon it.
  • polymers include PEI, polyamides, polyacrylic acid, carboxymethyl cellulose, chitosan, PEI, polyamides, and polystyrene. The last of these, polystyrene, can be dissolved in an organic solvent such as THF after the layer-by-layer coating is assembled, thereby giving rise to a hollow fiber that can be filled with one or more therapeutic agents.
  • the extent of surface charge on the surface of a given material can be deduced by measuring the Zeta-potential of the material, using methods known to one of ordinary skill in the art.
  • multiple layers of alternating charge can thereby be applied to the fiber meshwork, or to an underlying structure.
  • the number of layers varies according to application. In some embodiments, at least 10 layers (e.g., at least 20 layers, at least 30 layers, at least 50 layers, at least 100 layers, at least 200 layers) and/or at most 300 layers (e.g., at most 200 layers, at most 100 layers, at most 50 layers, at most 30 layers, at most 20 layers) can be applied over the substrate.
  • the total thickness of a multi-layered structure built up by a layer-by-layer process can be a function of the materials (e.g., polyelectrolytes) used, and can range, for example, from 5 nanometers to 1,500 nanometers.
  • the total thickness of the multi-layered structure can be at least five nanometers (e.g., at least 10 nanometers; at least 50 nanometers; at least 100 nanometers; at least 500 nanometers; at least 1,000 nanometers; at least 1,500 nanometers; at least 2,000 nanometers; at least 5,000 nanometers; at least 10,000 nanometers; at least 20,000 nanometers; at least 30,000 nanometers) and/or at most 40,000 nanometers (e.g., at most 30,000 nanometers; at most 20,000 nanometers; at most 10,000 nanometers; at most 5,000 nanometers; at most 2,000 nanometers; at most 1,500 nanometers; at most 1,000 nanometers, at most 500 nanometers, at most 100 nanometers, at most 50 nanometers, at most 10 nanometers).
  • nanometers e.g., at least 10 nanometers; at least 50 nanometers; at least 100 nanometers; at least 500 nanometers; at least 1,000 nanometers; at least 1,500 nano
  • the number of layers and/or the total thickness of a multi-layered structure deposited on a fiber meshwork, or an underlying structure can be determined empirically and can be a function of, for example, the compositions of the layers and the type of medical device. For example, for a given medical device, the number of layers, their sequences and compositions, and/or the total thickness of multi-layered structure can be varied and the effectiveness of the multi-layered structure can be tested. After an effective combination is determined, the same combination can be repeatedly applied to other such devices.
  • the multi-layered structure can be formed on a substrate, removed from the substrate, and subsequently applied (e.g., with an adhesive) to an underlying structure or a fiber meshwork of a medical device according to the present invention.
  • the substrate can be removed by destroying it, for example, by melting, sublimation, combustion, or dissolution, or a combination thereof, to free the multi-layered structure.
  • a removable substrate made of dental waxes (such as those available from MDL Dental Products, Inc., Seattle, WA, USA) or polyvinyl alcohol can be used. These materials can respectively melt at moderately elevated temperatures (e.g., 60 0 C) and dissolve in hot water.
  • Layers of a multi-layer structure may have the same thickness as one another or different thicknesses.
  • the thickness of a layer may depend on the molecular weight of the materials, such as polyelectrolyte(s), included in the layer, and/or the presence of other materials (e.g., nanoparticles) in the layer.
  • a layer comprising a relatively low molecular weight polyelectrolyte such as low molecular weight heparin (e.g. , heparin having a molecular weight of from about 1,000 Daltons to about 10,000 Daltons) may be relatively thin.
  • the thickness of a layer may depend on the conditions (e.g., salt concentration and/or pH) during the deposition of the layer.
  • an individual layer and/or an individual layer may have a thickness of at least about 0.2 nanometer (e.g., at least about 0.5 nanometer, at least about 1.0 nanometer, at least about 5.0 nanometers, at least about 10 nanometers, at least about 50 nanometers, at least about 100 nanometers, at least about 300 nanometers), and/or at most about 500 nanometers (e.g., at most about 300 nanometers, at most about 100 nanometers, at most about 50 nanometers, at most about 10 nanometers, at most about five nanometers at most about one nanometer, or at most about 0.5 nanometer).
  • different regions of the medical device are coated with multi-layer structures having different numbers of layers.
  • the biodisintegrable material in a region of the underlying structure that is coated with a relatively large number of layers may begin to disintegrate after, and/or more slowly than, the biodisintegrable material in a region that includes a relatively small number of polyelectrolyte layers.
  • the polyelectrolyte layers on an underlying structure may be used to provide different disintegration rates of biodisintegrable material in different regions of the medical device.
  • an endoprosthesis can include an arrangement of polyelectrolyte layers that causes one or both of the ends of the endoprosthesis to start disintegrating before the middle of the endoprosthesis. This may limit the likelihood of the medical device breaking apart into two or more pieces during disintegration. Further examples of such devices are found in pending U.S. Patent Application Serial No. 11/127,968.
  • one portion of a medical device includes a multi-layered structure with at least 10 layers (e.g., at least 20 layers, at least 30 layers, or at least 40 layers), and another portion of a medical device includes a multi-layered structure with at least 20 layers (e.g., at least 30 layers, at least 40 layers, or at least 50 layers).
  • one portion of a medical device may include a multi-layered structure with 10 layers and another portion of the medical device may include a multi-layered structure with 40 layers.
  • a multi-layered structure on one portion of a medical device can include from five to 50 layers (e.g., from 10 to 30 layers) more than a multi-layered structure on another portion of the medical device.
  • one or more portions of a medical device may not be coated with any layers at all.
  • devices having portions with different numbers of layers on them can be formed by dipping one end (e.g., 2/3) of a device in one material, turning the device around, and dipping the other end (e.g., 2/3) of the device in another material, and repeating the process multiple times. The result is that the middle of the device (e.g., the middle 1/3 of it) receives more layers than either end of the device.
  • devices having portions with different numbers of layers on them can be formed by other techniques, such as ink jet techniques, microstamping, spraying, roll coating, or brush coating.
  • the underlying structure or fiber meshwork can be pretreated prior to forming a multi-layer structure on it.
  • an underlying structure can be cleaned to remove surface contaminants, such as oil, that can affect the homogeneity of the multi-layered structure.
  • the underlying structure or fiber meshwork can be cleaned, for example, in a solvent such as acetone, or in a mixture such as H 2 (VHCl, HCI/HNO3, H 2 SO 4 ZK 2 Cr 2 Oy, H2O2/NH3, and/or NaOH/NaOCl.
  • the structure can also be pretreated with a solution including 10 ⁇ -2 z M SDS/0.12 N HCl for 15 minutes at 100 0 C.
  • An embodiment of a method of making a device using a layer-by-layer technique includes pretreating an underlying structure for layer-by-layer deposition. Next, a charged layer, e.g., containing a polyelectrolyte, is applied to the underlying structure. A layer of opposite charge is then applied to the previously applied charged layer. The previous two steps can then be repeated to build a multi-layered structure of a desired thickness.
  • multi-layered structure can further include one or more layers that contain a therapeutic agent, one or more layers that contain a radio-opaque material, and/or one or more layers capable of enhancing the mechanical properties of the underlying structure. These additional layers can be applied between layers of different charges in any combination.
  • the material can be provided with a positive charge by covalently attaching functional groups having a positive charge (e.g., amine, imine or other basic groups) or functional groups having a negative charge (e.g., carboxylic, phosphonic, phosphoric, sulfuric, sulfonic, or other acid groups) to it.
  • functional groups having a positive charge e.g., amine, imine or other basic groups
  • functional groups having a negative charge e.g., carboxylic, phosphonic, phosphoric, sulfuric, sulfonic, or other acid groups
  • a surface charge can be provided by exposing the device to a charged amphiphilic substance.
  • the amphiphilic substance includes at least one electrically charged group to provide the device surface with a net electrical charge. Therefore, the amphiphilic substances that are used herein can also be referred to as ionic amphiphilic substances.
  • a surface charge can be provided on a material by adsorbing cations (e.g., protamine sulfate, polyallylamine, polydiallyldimethylammonium species, polyethyleneimine, chitosan, gelatin, spermidine, and/or albumin) or by adsorbing anions (e.g., polyacrylic acid, sodium alginate, polystyrene sulfonate, eudragit, gelatin (an amphiphilic polymer that fits in both categories depending how it is being prepared), hyaluronic acid, carrageenan, chondroitin sulfate, and/or carboxymethylcellulose) to the surface of the material as a first charged layer or to impart a surface charge.
  • adsorbing cations e.g., protamine sulfate, polyallylamine, polydiallyldimethylammonium species, polyethyleneimine, chitosan, gelatin, spermidine
  • poly(ethylene imine) (PEI, Aldrich, MW ⁇ 25 kD) can be dissolved in water in a concentration of about 0.5 g/L to apply a first coating.
  • more than one surface charge layer can be applied to provide complete coverage of the material.
  • Application of surface charge layers is described in, e.g., "Multilayer on Solid Planar Substrates", Multi-layer Thin Films, Sequential Assembly of Nanocomposite Materials, Wiley-VCH ISBN 3-527-30440-1, Chapter 14; and "Surface-chemistry Technology for Microfluidics” Hau, Winky L. W. et al., J. Micromech. Microeng., 13, 272-278, (2003).
  • the species for establishing a surface charge can be applied to the material by a variety of methods. Examples of such methods include spraying methods, dipping methods, roll and brush coating methods, methods involving coating via mechanical suspension such as air suspension, ink jet methods, spin coating methods, web coating methods and combinations of these processes. Dipping and spraying methods (without masking) can be employed, for example, to apply the species to an entire device. Roll coating, brush coating and ink jet printing can be employed, for example, to apply the species only to selected portions of the device (e.g., in the form of a pattern).
  • the polymer from which the fiber meshwork is made is charged.
  • an oppositely-charged layer can be easily deposited thereon.
  • the multi-layered structure includes one or more layers that contain a therapeutic agent.
  • one or more therapeutic agents can be disposed on or within the multi-layered structure giving the medical device a drug releasing function upon implantation. Therapeutic agents may be used singly or in combination.
  • Examples of therapeutic agents can be found at cols. 4 - 6 of U.S. Patent No. 6,899,731 to Li et al, and at cols. 5 - 8 of U.S. Patent No. 6,923,996 to Epstein et al, the disclosures of which are incorporated by reference in their entirety. It is to be understood that the therapeutic agents that can be used are not limited to those found herein.
  • antimicrobial agents have broad-spectrum activity and include triclosan, chlorhexidine, silver sulfadiazine, silver ions, benzalkonium chloride, and zinc pyrithione, as well as broad-spectrum antibiotics such as quinolones, fluoroquinolones, aminoglycosides and sulfonamides.
  • Antiseptics such as iodine, methenamine, nitrofurantoin, validixic acid and other acidifying agents, including acids extracted from cranberry juice may also be used.
  • the therapeutic agent can be charged, either because it is itself a charged molecule or because it becomes charged upon, for example, a change in ambient pH or upon association with a charged species.
  • charged therapeutic agents include small molecule and polymeric therapeutic agents containing ionically dissociable groups.
  • the therapeutic agent does not possess one or more charged groups, it can nevertheless be provided with a charge, for example, through non-covalent association with a charged species.
  • non-covalent associations include hydrogen bonding, electrostatic, van der Waals, and hydrophobic/lipophilic interactions.
  • a therapeutic agent can be associated with an ionic amphiphilic substance.
  • one or more layers consisting of the charged therapeutic agent are deposited during the course of assembling the multi-layer structure.
  • an entire layer may be composed of a therapeutic agent.
  • the therapeutic agent can itself be a polyelectrolyte (e.g., where the therapeutic agent is a polypeptide or a polynucleotide) and is thereby used to create one or more polyelectrolyte layers within the multi-layer structure.
  • the charged therapeutic agent is not a polyelectrolyte (e.g., it may be a charged small molecule drug), but one or more layers of the charged therapeutic agent can be substituted for one or more layers of the same charge (i.e., positive or negative) during the layer-by-layer assembly process.
  • a wide range of therapeutic agent loadings can be used.
  • the amount of such loading can be readily determined by those of ordinary skill in the art, and will ultimately depend upon the condition to be treated, the nature of the therapeutic agent itself, the avenue by which the therapeutic-agent-loaded layer-by-layer structure or fiber meshwork is administered to the intended subject, and so forth.
  • the loaded fiber meshwork, or multi- layered structure may comprise, for example, from about 1 wt. % to about 70 wt. % therapeutic agent.
  • the amount of the therapeutic agent may be limited by the propensity of such agent to cause an undesirable localized or systemic toxic reaction and by the impairment of mechanical properties necessary for proper functioning of the device.
  • the therapeutic agent can be provided within charged nanocapsules, which are formed, for example, using methods such as those described in U.S. Patent Application Publication No. 2005-0129727, entitled “Localized Drug Delivery Using Drug-Loaded Nanocapsules".
  • one or more layers of charged nanocapsules can be deposited during the course of the layer-by-layer assembly process.
  • the multi-layer structure is loaded with a therapeutic agent subsequent to its formation.
  • the porosity, and thus the permeability, of the multi-layer structure can be modified by adjusting the pH exposed to the structure, as described, for example, in Antipov, A. A., et al., "Polyelectrolyte multilayer capsule permeability control," Colloids and Surfaces A: Physicochemical and Engineering Aspects, 198-200, 535-541, (2002).
  • a porous layer can absorb a therapeutic agent after the layer is in place.
  • the underlying structure of the medical device of the present invention is, in some embodiments, formed of a biocompatible material, such as the materials described herein.
  • a biocompatible material such as the materials described herein.
  • Specific examples of biocompatible materials from which the underlying structure can be formed are described in U.S. patent application serial no. 10/440,063, filed May 15, 2003; and U.S. Patent Application Publication Nos. 2003-0018380, 2002-0144757, and 2003- 0077200.
  • Still further examples of biocompatible materials are described, for example, in Weber et al. , U.S. Patent Application Publication No. 2004/0230290 Al , published on November 18, 2004; Craig et al, U.S. Patent Application Publication No.
  • the biocompatible material can be suitable for use in, for example, a balloon- expandable stent, a self-expandable stent, or a combination of both (see e.g., U.S. Patent No. 5,366,504).
  • a self-expandable stent can be formed of a continuous solid mass of a relatively elastic biocompatible material, such as a superelastic or pseudo-elastic metal alloy, for example, a Nitinol (e.g., 55% nickel, 45% titanium).
  • a self-expanding stent has a mechanical memory such that it can return to a preformed shape after it has been compressed or deformed.
  • the stent is initially configured in its final desired shape and is then contracted by deforming or constraining it using any of several methods known in the art. It remains in a contracted state until it is delivered to the target site where it is allowed to expand to its initial state.
  • materials that can be used for a balloon-expandable stent include noble metals, radiopaque materials, stainless steel, and alloys comprising stainless steel and one or more radiopaque materials.
  • the underlying structure can be formed of a biodisintegrable material, such as a biodisintegrable metal, a biodisintegrable metal alloy, or a biodisintegrable non-metal.
  • Biodisintegrable materials are described, for example, in U.S. Patent No. 6,287,332 to BoIz; U.S. Patent Application Publication No. US 2002/0004060 Al to Heublein; U.S. Patent Nos. 5,587,507 and 6,475,477 to Kohn et al.
  • Examples of biodisintegrable metals for use with the underlying structure include alkali metals, alkaline earth metals (e.g., magnesium), iron, zinc, and aluminum.
  • biodisintegrable metal alloys examples include alkali metal alloys, alkaline earth metal alloys (e.g. , magnesium alloys), iron alloys (e.g. , alloys including iron and up to seven percent carbon), zinc alloys, and aluminum alloys.
  • a biodisintegrable material from which the underlying structure is formed can include at least one metallic component and at least one non-metallic component, or at least two different metallic components.
  • a biodisintegrable material can include at least one of the following: manganese, cobalt, nickel, chromium, copper, cadmium, lead, tin, thorium, zirconium, silver, gold, palladium, platinum, rhenium, silicon, calcium, lithium, aluminum, zinc, iron, carbon, and sulfur.
  • a biodisintegrable material can include at least two of the following metals in proportions by weight of greater than about 1%: magnesium, titanium, zirconium, niobium, tantalum, zinc, or silicon, and lithium, sodium, potassium, calcium, iron, or manganese.
  • the biodisintegrable material can include a first component selected from the group consisting of: magnesium, titanium, zirconium, niobium, tantalum, zinc, silicon, and another, different, component selected from the group consisting of: lithium, sodium, potassium, calcium, iron, manganese.
  • biodisintegrable non-metals examples include biodisintegrable polymers, such as polyiminocarbonates, polycarbonates, polyarylates, polylactides, or polyglycolic esters.
  • a biodisintegrable metal or metal alloy containing metals such as magnesium, iron, or zinc can be sintered.
  • the biodisintegrable material can be a polymer, such as, without limitation, those described at cols. 8 - 9 of U.S. Patent No. 6,918,869 to Shaw et al.
  • the biodisintegrable material can be a ceramic such as an alumina-based ceramic, or a glass-based ceramic such as Macor®.
  • the properties of the underlying structure depend upon the material from which it is formed. Magnesium, for example, has a relatively low mass attenuation factor, and the CT visibility of the region (e.g., a body lumen) in which a magnesium structure is located can be relatively high.
  • a medical device for use as described herein can be manufactured, or can be obtained commercially.
  • Methods of making medical devices such as stents are described in, for example, U.S. Patent No. 5,780,807, and U.S. Patent Application Publication No. 2004-0000046-A1, both of which are incorporated herein by reference.
  • Stents are also available, for example, from Boston Scientific Corporation, Natick, MA, USA, and Maple Grove, MN, USA.
  • Metallic materials from which the underlying structure is made may be made into filaments and then woven so that the underlying structure forms a regular network of metal mesh.
  • Polymer filaments may also be used together with the metallic filaments to form a network. If the network is made of metal, the intersection between different filaments may formed by welding, twisting, bending, gluing, tying (with suture), heat sealing, or by any other manner known in the art.
  • a stent may include a tubular structure that is formed entirely of a biodisintegrable material
  • the tubular structure of a stent can include one or more biostable materials in addition to including one or more biodisintegrable materials.
  • One or more polymers may be used (as described herein) to control the disintegration of one or more of the biodisintegrable regions of the stent.
  • the polymers may be in the form of layers over the biodisintegrable and/or biostable regions of the stent or a fiber meshwork similarly disposed.
  • biostable materials include stainless steel, tantalum, nickel-chrome, cobalt-chromium alloys such as Elgiloy® and Phynox®, Nitinol (e.g., 55% nickel, 45% titanium), and other alloys based on titanium, including nickel titanium alloys, thermo-memory alloy materials.
  • Stents including biostable and biodisintegrable regions are described, for example, in U.S. Patent Application Serial No. 11/004,009, filed on December 3, 2004, and entitled "Medical Devices and Methods of Making the Same".
  • Devices such as stents, may be formed from many known constructions such as cross-hatched or mesh filaments or interlocking loops.
  • exemplary medical devices are implantable or insertable medical devices, including catheters (for example, urinary catheters or vascular catheters such as balloon catheters), guide wires, balloons, filters (e.g., vena cava filters), stents of any desired shape and size (including coronary vascular stents, aortic stents, cerebral stents, urology stents such as urethral stents and ureteral stents, biliary stents, tracheal stents, gastrointestinal stents, peripheral vascular stents, neurology stents and esophageal stents), grafts such as stent grafts and vascular grafts, cerebral aneurysm filler coils (including GDC- Guglilmi detachable coils-and metal coils), filters, my
  • embodiments herein can be suitably used with any underlying structure (which can be, for example, metallic, polymeric or ceramic, though typically metallic) which is coated with a fiber meshwork in accordance with methods herein and which is designed for use in a patient, either for procedural use or as an implant.
  • any underlying structure which can be, for example, metallic, polymeric or ceramic, though typically metallic
  • a fiber meshwork in accordance with methods herein and which is designed for use in a patient, either for procedural use or as an implant.
  • the medical devices may further include drug delivery medical devices for systemic treatment, or for treatment of any mammalian tissue or organ.
  • Subjects can be mammalian subjects, such as human subjects.
  • tissues and organs for treatment include the heart, coronary or peripheral vascular system, lungs, trachea, esophagus, brain, liver, kidney, bladder, urethra and ureters, eye, intestines, stomach, colon, pancreas, ovary, prostate, gastrointestinal tract, biliary tract, urinary tract, skeletal muscle, smooth muscle, breast, cartilage, and bone.
  • the medical device is used to temporarily treat a subject without permanently remaining in the body of the subject.
  • the medical device can be used for a certain period of time (e.g., to support a lumen of a subject), and then can disintegrate after that period of time.
  • the underlying structure of the medical device can be generally tubular in shape and can be a part of a stent.
  • Simple tubular structures having a single tube, or with complex structures, such as branched tubular structures, can be used.
  • stents can have a diameter of between, for example, 1 mm and 46 mm.
  • a coronary stent can have an expanded diameter of from about 2 mm to about 6 mm.
  • a peripheral stent can have an expanded diameter of from about 4 mm to about 24 mm.
  • a gastrointestinal and/or urology stent can have an expanded diameter of from about 6 mm to about 30 mm.
  • a neurology stent can have an expanded diameter of from about 1 mm to about 12 mm.
  • An abdominal aortic aneurysm (AAA) stent and a thoracic aortic aneurysm (TAA) stent can have a diameter from about 20 mm to about 46 mm.
  • Stents can also be a part of a stent-graft or a covered stent.
  • stents can include and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene.
  • PTFE polytetrafluoroethylene
  • expanded PTFE polyethylene
  • urethane polypropylene
  • Stents can also be biodisintegrable, such as a biodisintegrable abdominal aortic aneurysm (AAA) stent, or a biodisintegrable vessel graft.
  • AAA abdominal aortic aneurysm
  • Example 1 Collagen-based fiber meshwork on a stent
  • Collagen type I (Sigma- Aldrich (St. Louis, MO)) dissolves in 1,1,1,2,2,2- hexafluoro-2-propanol (HFIP).
  • HFIP 1,1,1,2,2,2- hexafluoro-2-propanol
  • a solution was prepared making a 8% by weight solution of Collagen in HFIP.
  • a stent (BSC, stainless steel, express stent, 16 mm length, 3.0 mm diameter), was crimped on a Teflon mandrel having diameter 3.0 mm, with a fine 10 micron gold wire (California Fine Wire, 338 So. Fourth Street, Grover Beach, CA 93433-0199) placed in between the stent and the mandrel such that there was electrical contact between the stent and the gold wire. The gold wire was grounded.
  • a nozzle with Syringe was placed at a distance of 7 cm from the stent surface and connected to a syringe pump (type SPlOIi, World Precision Instruments, Liegnitzer Str.15, D- 10999 Berlin, Germany), and a high voltage supply (Type CS2091, High Voltage Power Solutions, Inc. (HVPSI), Dallas, TX 75370).
  • the mandrel was rotated at 5 Hz during the spraying process and moved along the axis in a cyclic movement at 12 Hz with an amplitude of 2 mm.
  • the spraying was done at the following settings (18 kV, 0.02 ml/min, 10 seconds on cycle).
  • Example 2 Polyetherimide-based fiber meshwork on a stent
  • PEI Polyetherimide
  • BiopolTM polyhydroxybutyrate-valerate
  • Monsanto Company 800 North Lindbergh, St. Louis, MO 63167. Both components were mixed in chloroform making solutions having 23 wt.% PEI and 21 wt.% PHBV. These solutions were mixed to a ratio of 75/25 (PEI/PHBV)
  • a stent (Boston SciMed Corporation, stainless steel, express stent, 16 mm length, 3.0 mm diameter), was crimped on a Teflon mandrel diameter 3.0 mm with a fine 10 micron gold wire (California Fine Wire, 338 So. Fourth Street, Grover Beach, CA 93433-0199) placed in between the stent and the mandrel, such that there was electrical contact between the stent and the gold wire. The gold wire was grounded.
  • a nozzle with syringe was placed at a distance of 15 cm from the stent surface and connected to a syringe pump (type SPlOIi, World Precision Instruments, Liegnitzer Str.15, D- 10999 Berlin, Germany), and a high voltage supply (Type CS2091, High Voltage Power Solutions, Inc. (HVPSI), High Voltage Power Solutions, Inc., Dallas, TX 75370).
  • the mandrel was rotated at 5 Hz during the spraying process and moved along the axis in a cyclic movement at 12 Hz with an amplitude of 2 mm.
  • the spraying was carried out at the following settings: 15 kV, 0.05 ml/min, 15 seconds on cycle.
  • the stent sprayed in this way was thermally treated for 90 minutes at 210 0 C in a nitrogen environment to decompose the PHBV component and leave behind a fiber meshwork made of porous PEI fibers.
  • Heparin in sodium salt form from Bioiberica (Barcelona, Spain) is negatively charged and binds readily to the positively charged PEI surface when the stent with fiber meshwork is dipped for 10 minutes in an aqueous(2 mg/ml) heparin solution followed drying with a stream of nitrogen.
  • the PEI fiber meshwork created in this way can also be used to deliver drug- filled liposome capsules (e.g., as described in Vermette et ah, "Immobilized liposome layers for drug delivery applications: inhibition of angiogenesis", J. Controlled Release, 80:179- 195 (2002), incorporated herein by reference in its entirety) or other polyelectrolyte capsules filled with various drugs. Leaving the stent with the electro-spun network on the Teflon mandrel while attaching the capsules will assure that they only attach to the outside and that, in use, they are therefore all trapped in between the stent and the wall of the vessel or body lumen.
  • drug- filled liposome capsules e.g., as described in Vermette et ah, "Immobilized liposome layers for drug delivery applications: inhibition of angiogenesis", J. Controlled Release, 80:179- 195 (2002), incorporated herein by reference in its entirety
  • Example 3 Collagen-based fiber meshwork modified with polyelectrolyte layers
  • the collagen fibers as discussed in Example 1 can also be coated with additional polyelectrolyte layers, but using only non-polymeric biological material such as collagen and alternating hyaluronic acid or heparin elements (see e.g., Zhang, et al, "Natural polyelectrolyte films based on layer-by- layer deposition of collagen and hyaluronic acid", Biomaterials, 26:3353-3361, (2005)). To those layers again, capsules are bound using polyelectrolyte constructions. [0172] All non-patent literature publications, patent applications, patent application publications, and patents, referred to in the instant application are incorporated herein by reference in their entirety.

Abstract

The present invention comprises a medical device (1) having an underlying structure (10) on which is disposed a fiber meshwork (20) composed of one or more fibers of substantially uniform diameter. The fiber meshwork may optionally have a multi-layer structure disposed upon it. Either or both of the fiber meshwork or the multi-layer structure may have one or more therapeutic agents absorbed within it. The fiber meshwork is permeable to body fluids and thereby permits body fluids to contact the underlying structure to facilitate its controlled disintegration. The fiber meshwork degrades more slowly than the underlying structure thereby permitting release of the therapeutic agent over a timescale longer than that of the lifetime of the underlying structure, while also ensuring that the support function of the underlying structure is not abrogated by the disintegration of the underlying structure.

Description

ENDOPROSTHESIS HAVING A FIBER MESHWORK DISPOSED THEREON
FIELD OF THE INVENTION
[0001] This invention relates to medical devices, such as endoprostheses, and methods of making such devices.
BACKGROUND
[0002] The body includes various passageways including blood vessels such as arteries, and other body lumens. These passageways sometimes become occluded or weakened. For example, they can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is an artificial implant that is typically placed in a passageway or lumen in the body. Many endoprostheses are tubular members, examples of which include stents, stent-grafts, and covered stents.
[0003] Many endoprostheses can be delivered inside the body by a catheter. Typically the catheter supports a reduced- size or compacted form of the endoprosthesis as it is transported to a desired site in the body, for example the site of weakening or occlusion in a body lumen. Upon reaching the desired site the endoprosthesis is installed so that it can contact the walls of the lumen.
[0004] One method of installation involves expanding the endoprosthesis. The expansion mechanism used to install the endoprosthesis may include forcing it to expand radially. For example, the expansion can be achieved with a catheter that carries a balloon in conjunction with a balloon-expandable endoprosthesis reduced in size relative to its final form in the body. The balloon is inflated to deform and/or expand the endoprosthesis in order to fix it at a predetermined position in contact with the lumen wall. The balloon can then be deflated, and the catheter withdrawn.
[0005] In another delivery technique, the endoprosthesis is formed of an elastic material that can be reversibly compacted and expanded (e.g., elastically or through a reversible phase transition of its constituent material). Before and during introduction into the body until it reaches the desired implantation site, the endoprosthesis is restrained in a compacted condition. Upon reaching the desired site, the restraint is removed, for example by retracting a restraining device such as an outer sheath, enabling the endoprosthesis to self-expand by its own internal elastic restoring force.
[0006] To support or keep a passageway open, endoprostheses are sometimes made of relatively strong materials, such as stainless steel or Nitinol (a nickel-titanium alloy), formed into struts or wires. The material from which an endoprosthesis is made can impact not only the way in which it is installed, but its lifetime and efficacy within the body.
SUMMARY
[0007] A medical device, comprising: an underlying structure having a fiber meshwork disposed thereon, wherein the underlying structure is biodisintegrable. The medical device can further comprise a layer-by-layer coating situated on the fiber meshwork.
[0008] A medical device for implantation into an organism, comprising: an underlying structure; and a fiber meshwork disposed upon the structure, wherein the fiber meshwork is configured to ensure steady biodisintegration of the underlying structure over a period of time inside the organism.
[0009] A medical device comprising a fiber meshwork formed of a material that is deposited by FFESS on to an underlying structure.
[0010] A method of effecting controlled release of a pharmaceutically active agent from a medical device, wherein the medical device is implanted in an organism, comprising: depositing a fiber meshwork containing a therapeutic agent on an underlying structure, wherein the fiber meshwork degrades over a period of time inside the organism and simultaneously releases the therapeutic agent.
[0011] A method of achieving steady disintegration of a medical device in an organism, comprising: forming the device by depositing a fiber meshwork on to an underlying structure; and implanting the device into the organism; wherein the disintegration of the underlying structure occurs over a first period of time inside the organism.
[0012] A method of making a medical device comprising depositing a fiber meshwork by FFESS on to an underlying structure. [0013] A method of using a medical device that comprises an underlying structure having a fiber meshwork disposed thereon, wherein the underlying structure is Biodisintegrable, the method comprising implanting the medical device in a body passageway of an organism.
[0014] The various details of one or more embodiments of the invention are set forth in the accompanying drawings and the description hereinbelow. Other aspects, features, and advantages of the invention will be apparent from the description and drawings, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] FIGs. IA and IB are respectively perspective and cross-sectional views of an exemplary endoprosthesis.
[0016] FIG. 2 A shows how a biodisintegrable stent corrodes before a fiber meshwork disappears, giving a drug release beyond the lifetime of the mechanical support; and FIG. 2B shows how particles from a disintegrating mechanical support are captured by a fiber meshwork.
[0017] FIG. 3 is a schematic diagram comparing conventional electro-spraying and FFESS technology.
[0018] FIG. 4 shows various options for a meshwork composed of two different drug filled polymers with different fiber thicknesses and their respective drug release profiles with time.
[0019] FIGs. 5A and 5B show various polymer layers suitable for use with a fiber meshwork, and their respective structural formulae.
[0020] FIG. 6 shows various configurations of layer-by-layer coatings that contain drugs, and are deposited on the mechanical support or on the fiber meshwork.
[0021] Like reference symbols in the various drawings indicate like elements.
DETAILED DESCRIPTION
[0022] Although endoprostheses have been highly effective at removing restrictions in body passageways, a number of problems have emerged that arise from their long-term placement. Restenosis is one; another is that, over time, microbes and other material can build up on a structure such as a stent and cause their own obstruction to free passage of body fluids through the lumen. Restenosis has been addressed by coating a stent with a polymer containing a drug that inhibits growth of smooth muscle cells (see, e.g., "The Billion Dollar Stent," Technology Review, 108(10), 41, (October 2005)). Accumulations of unwanted material have been deterred by loading the device structure with an anti-microbial agent, but with limited success. Accordingly, there has been a move towards making endoprostheses out of bio-absorbable materials, such as magnesium or iron alloys and biodegradable polymers, that ensure that the device structure naturally degrades over time. Such materials may, however, disintegrate too quickly thus requiring them to be made out of thicker elements than would be preferred. On the other hand, the presence of a coating on the device, such as is typically used to achieve local delivery of a therapeutic agent at the implantation site, can hinder degradation of the underlying device structure. For example, with coating patterns that are based on a closed polymer matrix, the coating impedes fluid access to the device surface, thereby significantly delaying — or even preventing inception of — the desired degradation process. In many instances, it would be preferable to have the underlying structure disappear (or at least start to disappear) before the coating has disappeared. This would also ensure a much longer delivery regime of a therapeutic agent absorbed in the coating than the timeframe over which the device structure disappears.
[0023] On the other hand, polymer coatings that disappear in a very short timeframe, thereby offering the exposure of the underlying device structure required to bring about its degradation, have several attendant drawbacks. First, the rapid decay of the coating leads to a massive initial drug release. The consequent inability to control the process of polymer disintegration, also entails the risk of a highly variable drug release profile during the process. Slight variations in various environmental parameters such as temperature, fluid flow-rate, and local concentrations of critical agents, can cause a huge difference in the degradation course of different regions of exposed surface area. Finally, if the polymer coating disintegrates too rapidly, the device structure itself may also disintegrate in a non-uniform manner so that large particles loosen, break off and float into the bloodstream, causing boli and secondary blockages. [0024] Accordingly, the devices herein address such issues by incorporating material that is strong enough to last longer than the underlying structure so as to prevent both its uncontrolled breakdown and non-uniform drug release, yet which is flexible enough to permit regulated access of bodily fluids to the underlying structure.
Definitions
[0025] A biocompatible material is a material that can be introduced into living tissue or a living system, and is non-toxic or non-injurious to the tissue or system, and does not cause an immunological reaction or rejection.
[0026] As used herein, a "biodisintegrable material" is a biocompatible material that undergoes at least one of dissolution, degradation, absorption, erosion, corrosion, resorption, chemical transformation, or other disintegration processes over the period that the device formed at least in part from the biodisintegrable material is designed to reside in an organism. Chemical transformation can include oxidation or other chemical reactions of the stent body material.
[0027] Specifically, a biodisintegrable material is a material that exhibits substantial mass or density reduction by one or more of dissolution, degradation, absorption, erosion, corrosion, resorption, decomposition, degeneration, chemical transformation and/or other disintegration processes after it is introduced into an organism. The disintegration occurs to a desirable extent in a timeframe that can provide a clinical benefit. Mass reduction of a biodisintegrable device can also occur, but in some cases does not occur, by fragmentation of the material. The disintegration can be the result of the chemical and biological interaction of the material with the physiological environment into which it is implanted and/or can be initiated by applying a suitable triggering influence, such as a chemical reactant or source of energy to the stent.
[0028] In some embodiments, a biodisintegrable material for use with the present invention exhibits substantial mass reduction after a period of time for which a function of the material, such as support of a lumen wall or delivery of a therapeutic agent in the immediate vicinity of the device, is no longer needed or desirable. By "a substantial reduction" is meant that the biodisintegrable material exhibits a mass reduction through biodisintegration of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 50%, at least about 75%, or at least about 90%, after a period of implantation. The period of implantation over which the mass reduction through biodisintegration takes place can be chosen to be one day or more, 14 days or more, 30 days or more, 60 days or more, 90 days or more, 180 days or more, 300 days or more, 600 days or more, or about 1,000 days or less. Thus, it would be understood that the level of biodisintegrability can be tailored to achieve a given level of mass reduction over a certain desired duration. For example, a medical device may be required to have reached a 75% reduction in mass in 30 days. In another embodiment, it may be required to have attained a 30% reduction in mass in 180 days. It would also be understood by one of ordinary skill in the art that a period of days, such as 300 days, as used herein, entails a level of imprecision such that periods of 3-5 days either shorter or longer than the period in question are also acceptable equivalent timescales for measuring levels of biodisintegrability.
[0029] In certain embodiments of the present invention, only portions of the device exhibit biodisintegrability. For example, an exterior layer or coating may be non- biodisintegrable, while an interior layer or body is biodisintegrable.
[0030] A degradable material is a material that can dissociate, depolymerize, or otherwise reduce in molecular weight from its starting molecular weight, such that a resulting compound is soluble in an aqueous medium such as water or, if insoluble, can be suspended in a body fluid and transported away from an implantation site without obstructing the flow of the body fluid. A biodegradable material is one that will degrade into biocompatible compounds as part of a biological process.
[0031] In some embodiments, a biodegradable material exhibits substantial mass reduction after a period of time for which a function of the material, such as support of a lumen wall or delivery of a therapeutic agent in the immediate vicinity of the device, is no longer needed or desirable. By "a substantial reduction" is meant that the biodegradable material exhibits a mass reduction through bio degradation of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 50%, at least about 75%, or at least about 90%, after a period of implantation. The period of implantation over which the mass reduction through biodegradation takes place can be chosen to be one day or more, 14 days or more, 30 days or more, 60 days or more, 90 days or more, 180 days or more, 300 days or more, 600 days or more, or about 1,000 days or less. Thus, it would be understood that the level of biodegradability can be tailored to achieve a given level of mass reduction over a certain desired duration. For example, a material may be required to have reached a 25% reduction in mass in 600 days. In another embodiment, it may be required to have attained a 30% reduction in mass in 300 days. It would also be understood by one of ordinary skill in the art that a period of days, such as 180 days, as used herein, entails a level of imprecision such that periods of 3-5 days either shorter or longer than the period in question are also acceptable equivalent timescales for measuring levels of biodegradability.
[0032] A resorbable material is a material that is soluble, biodisintegrable as defined herein, or is an aggregate of soluble and/or disintegrable material(s) with insoluble material(s) such that, with the resorption of the soluble and/or disintegrable materials, the residual insoluble materials are of sufficiently fine size that they can be suspended in a body fluid and transported away from the implantation site without obstructing the flow of the body fluid. Ultimately, the particles are eliminated from the body either by excretion in fluids such as perspiration, urine or feces, or are themselves dissolved, degraded, corroded or otherwise metabolized into soluble components that are then excreted from the body. A bioresorbable material is a resorbable material that is biocompatible.
[0033] The term "body fluid" as used herein refers to fluids in the body of an organism — especially a mammal — including, but not limited to, blood, urine, saliva, lymph, plasma, gastric, biliary, or intestinal fluids, seminal fluids, and mucosal fluids or humors.
[0034] The terms "therapeutic agent", "pharmaceutically active agent", "pharmaceutically active material", "pharmaceutically active ingredient", "drug" and other related terms may be used interchangeably herein and include, but are not limited to, small organic molecules, peptides, oligopeptides, proteins, nucleic acids, oligonucleotides, genetic therapeutic agents, non-genetic therapeutic agents, vectors for delivery of genetic therapeutic agents, cells, and therapeutic agents identified as candidates for vascular treatment regimens, for example, as agents targeting restenosis.
[0035] By small organic molecule is meant an organic molecule having 50 or fewer carbon atoms, and fewer than 100 non-hydrogen atoms in total.
[0036] As used herein, an "antimicrobial agent" is any agent that is harmful to microbes, especially pathogenic bacteria. [0037] As used herein, "treatment" refers to the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination of a disease or condition.
[0038] In certain embodiments, as further described herein, biostable materials, e.g., polyelectrolytes, may be utilized. As used herein, a "biostable material" is a material that does not undergo substantial dissolution, degradation, absorption, erosion, decomposition, corrosion, chemical transformation, resorption and/or other disintegration processes over the period that the material is designed to reside in an organism.
Overview
[0039] Medical devices having a fiber meshwork disposed upon an underlying structure such as a mechanical support, and methods of making the devices are disclosed. Two views of an exemplary device 1 are shown in FIGs. IA and IB, in which an underlying structure 10 is covered at least in part by a fiber meshwork 20 comprising one or more fibers (not individually depicted in FIGs. IA or IB) that may optionally contain or be coated with material containing at least one therapeutic agent such as a pharmaceutically active ingredient. Exemplary device 1 is generally tubular in shape and as depicted may be, e.g., a stent. As shown in the exploded view of FIG. IB, the underlying structure 10 may optionally be coated by a multi-layer structure 30, in one or more layers of which is optionally contained a therapeutic agent. The fiber or fibers of which the fiber meshwork 20 is composed may also optionally be coated with a multi-layer structure 40 as shown in FIG. IB. Multi-layer structure 40 may also optionally contain at least one therapeutic agent in one or more of its constituent layers.
[0040] In some embodiments, the underlying structure 10 is bio-disintegrable and is made from a different material than is the fiber meshwork 20. For example, the underlying structure can include (e.g. , be formed of) a biodisintegrable metal or a biodisintegrable polymer, as described in BoIz, U.S. Patent No. 6,287,332; Heublein, U.S. Patent Application Publication No. 2002/0004060 Al; U.S. Patent No. 5,587,507; and U.S. Patent No. 6,475,477. The fiber meshwork can wrap around the underlying structure without totally encapsulating it, thereby permitting fluid access to it. The fiber meshwork can be of a sufficient strength to retain its shape for a longer time than that of the underlying structure itself. If the mechanical support is bio-disintegrable, it is thereby allowed to degrade in a controlled manner, while the fiber meshwork retains its structure.
[0041] Fiber meshwork 20 can be formed from a material impregnated with a therapeutic agent that releases such an agent slowly over time. Alternatively, the fiber meshwork 20 is overcoated with a multilayer structure. The multilayer structure can be a layer-by-layer (LBL) coating wherein one or more layers contain a therapeutic agent. The fiber meshwork is thus able to ensure both a controlled release of a therapeutic agent absorbed within it or coated over it, as well as a controlled degradation of the underlying structure. A still further advantage of deploying a fiber meshwork impregnated with a drug or coated with layers containing a drug is that, when used in conjunction with an endoprosthesis whose underlying structure itself has a lattice or mesh structure, or similar, it can provide a more uniform release profile of the drug in the region of the stent than, e.g., a coating directly deposited on such a lattice or mesh structure. The latter may tend to release higher concentration of drug along the struts of the endoprosthesis than in the gaps in between such struts.
[0042] In alternative embodiments, the underlying structure 10 is also covered with a multilayer structure such as a LBL coating.
[0043] In an alternative embodiment, the fiber meshwork acts as an enclosing envelope to regulate release of a therapeutic agent from loosely packed particulate materials situated within it.
[0044] The fiber meshwork can be created with electro-spun nano-fibers or micro-fibers, and by flow-limited field-injection electrostatic spraying (FFESS), as further described herein.
Fiber meshwork
[0045] The fiber meshwork can be amorphous, i.e., does not possess a regular structure. Thus, the fiber meshwork contains one or more fibers. Each individual fiber can be considered to consist of a number of contiguous segments. Each fiber wraps around the underlying structure in such a manner that one of its segments crosses either another segment of the same fiber or another fiber at least once. In this way, the fiber meshwork is composed of a number of fiber segments that cross one another, when viewed from a given direction. [0046] In some embodiments, the fiber meshwork comprises a single fiber. However, equally satisfactory fiber meshworks may be utilized that comprise more than one fiber. The fiber meshwork can utilize 10 or fewer fibers, such as 2, 3, 5, or 7 fibers. From 10 to about 100 fibers can also be used, for example, 20, 50, or 80 fibers are effective. In such embodiments, not all of the fibers need to be made of the same material. Each of such fibers may be as long as several millimeters, or may be as long as about 1 centimeter, or as long as about 5 centimeters, or as long as about 10 centimeters, and may even be as long as about 20 centimeters. Where more than one fiber is present, it is not necessary that every fiber have the same or a similar length. Thus it is possible that several fibers are used, all having lengths of between 5 and 7mm. It is also possible that several fibers are used, having lengths of 5 mm, 2 cm, 5 cm, and 10 cm.
[0047] A fiber meshwork can also be constructed based on a very large number of short lengths of fibers. Such fibers may be as short as about 10 micron, or may be from about 10 to about 100 μ, but the overall meshwork may consist of many thousands, and may even consist of many hundreds of thousands of such fibers.
[0048] It is not required that the fiber meshwork itself envelop the entirety of the exterior surface of the underlying support. Alternatively, the fiber meshwork, when suitably rigid, can be manufactured to extend beyond the dimensions of the underlying structure, thereby permitting delivery of a therapeutic agent contained therein to regions of the body lumen outside of those supported by the underlying structure.
[0049] The nature of the fiber meshwork can be such that there are minute gaps between the various segments of fiber so that body fluids can contact the underlying structure. The fiber meshwork thus has an effective porosity that results from its structure in a manner different from that of other materials, for example a polymer matrix. Advantageously, the benefits of the fiber meshwork arise from a combination of its porosity and durability. Regarding porosity, defined as the proportion of the non-solid volume to the total volume of material, the fiber meshwork is able to attain a porosity higher than that of a polymer matrix of comparable volume. In some embodiments, the porosity of the fiber meshwork is in the range 0.1 - 0.6, and in other embodiments it is in the range 0.2 - 0.4. By contrast with a polymer matrix, however, the fiber meshwork is harder and less flexible, thereby retaining more of its structure as an underlying structure degrades. [0050] The fiber meshwork can retain a therapeutic agent and allow for its release over time. The nature of the fiber meshwork is such that it has a large surface area and thus is capable of releasing uniformly a therapeutic agent absorbed within it or in a layer coated on top of it.
[0051] The fiber meshwork may comprise a polymeric material such as a polymer, or a blend of polymers. A "polymer" is any macromolecule composed of two or more monomers, and includes dimers, trimers, tetramers, etc. A "monomer" is a polymerizable molecule. Typically, the polymeric materials comprise polymer molecules having a median number of monomers that numbers in the tens (10 to 99), in the hundreds (100 to 999), in the thousands (1,000 to 9,999), or in the tens of thousands (10,000 to 99,999) as well as a mixture of polymers having different median numbers of monomers. The polymeric materials can comprise polymer molecules having a median number of monomers that is 100,000 or more.
[0052] Such polymers may be crosslinked or uncrosslinked, linear or branched, natural or synthetic, thermoplastic or thermosetting, and may be biostable, biodegradable, bioabsorbable, biodisintegrable, or dissolvable.
[0053] In some embodiments, the polymers used to form the fiber meshwork are biodegradable. For example, the polymers can substantially degrade over a period of time that is different from the period of time over which the underlying structure substantially biodisintegrates. In such embodiments, the polymers of the fiber meshwork biodegrade over a longer period of time than the period of time for which the underlying structure biodisintegrates. In other embodiments, the polymers are biostable.
[0054] Polymers for use in the fiber meshwork can include any polymer that is biocompatible, and in particular a polymer that is compatible with the specific implantation environment in instances where local conditions are unusually hostile to non-native materials. An exemplary polymer is poly(D,L-lactide-co-glycolide) (TLG'). Other polymers are further described herein. Still other exemplary polymers include, but are not limited to: poly(lactic acid); poly(glycolic acid); poly(caprolactone); poly(hydroxybutyrate); poly(orthoester); poly(alkane anhydride); gelatin collagen; oxidized cellulose; and poly(phosphazene).
[0055] The fiber meshwork may also be constructed from other materials that are biodegradable, including metals. Accordingly, in certain embodiments the fiber meshwork is made from magnesium fibers. In other embodiments, the fiber meshwork is made from fibers of iron, or zinc. Additionally, fibers of metal alloys are contemplated.
[0056] Typically the fiber meshwork is coated onto the underlying support so that it forms from about 10% to about 50% by weight of the entire device. For example, the fiber meshwork forms about 20% to about 30% by weight of the entire device weight.
[0057] In certain embodiments, the polymers from which the fiber meshwork is formed lead to self-supporting fibers so that, as shown schematically in FIG. 2A, at such time as the underlying structure 10 has substantially biodisintegrated, the fiber meshwork 20 retains its original shape or a close approximation thereof. By so doing, the fiber meshwork does not collapse and obstruct free passage of bodily fluids through the lumen in which it is situated. Instead, the fiber meshwork retains a support structure that helps to maintain the structure of the lumen itself where previously the underlying structure of the endoprosthesis had provided support. It is also envisaged that, in certain environments, the fiber meshwork becomes embedded, either partially or completely, in layers of cells as may be found on the internal surface of a body passageway. In such an eventuality, the fiber meshwork is reinforced, even after the underlying structure has degraded, and has a reduced propensity to collapse. Furthermore, by retaining its original shape or a close approximation thereof, the fiber meshwork is able to continue release of a therapeutic agent contained within it, as further described herein. By the term "close approximation thereof as used herein, it is understood that the fiber meshwork will naturally distort overtime but it is intended that it does so to only a small extent.
[0058] The structure of the fiber meshwork produced with a method such as FFESS is such that fluid access to the surface of the mechanical support is permitted. The fiber meshwork itself can be chosen to be biostable or very slowly degrading, to act as an enclosing envelope for the more rapidly disintegrating device structure, thereby addressing the problem of uneven device degradation, as shown in FIG. 2B for the example of a stent. Furthermore, as also shown in FIG. 2B, were an underlying structure 10 to disintegrate unevenly, to give large particles such as 12, 14, those particles may be captured by the fiber meshwork 20 before floating off into the body fluid. Biostable materials for forming the fiber meshwork include, for example, styrene-isobutylene-styrene ('SIBS'), silicone elastomers; poly(ethylene-co-vinyl acetate); and Polyacrylates. [0059] In another embodiment, the underlying structure comprises a first ring and a second ring, wherein the first ring and the second ring are connected to one another by the fiber meshwork. In another variant of such an embodiment, the first ring is made of a first material and the second ring is made of a second material. In still another variant, the first material and the second material are different from a material of which the fiber meshwork is comprised. In an exemplary embodiment, the first and second ring are arranged coaxially to one another. It is to be expected, however, that due to flexibility of the fiber meshwork, the first and second ring may not be always situated exactly coaxially with respect to one another, and may also not always be disposed so that their respective planes are parallel to one another. For example, the centers of the respective rings may be offset with respect to one another and/or the planes of the rings may be disposed at an angle other than 180° with respect to one another. Such variations are to be expected within both manufacture and operation of the embodiment.
[0060] In such embodiments in which the underlying structure comprises two rings separated from one another, and connected to one another, by the fiber meshwork, the overall device has a flexibility imparted by the fiber meshwork and thus can, e.g., bend if necessary in a curved or flexible section of a body lumen. Such an embodiment has still further application in body lumens where the support function may be unnecessary, but delivery of a therapeutic agent, such as may be absorbed within the fibers of the fiber meshwork, is desired.
[0061] The fiber meshwork may also itself degrade in a controllable manner and therefore be used to fine-tune the disintegration of the underlying structure. As the fiber meshwork itself degrades, the biodisintegrable material of the underlying structure can become more exposed to water in the bodily fluids that surround it. This increased exposure to water can cause the underlying structure to begin to disintegrate, or to disintegrate more rapidly. Eventually, the underlying structure may disintegrate entirely.
[0062] Furthermore, the fiber meshwork can be comprised of polymers to which a surface charge can readily be attached, or which are naturally charged such that a multi-layer structure can be disposed thereon, using a layer-by-layer method that builds up layers of alternating charges, as further described herein. FFESS
[0063] The fiber meshwork may be deposited by a number of methods of creating and depositing extremely thin fibers, known to one of ordinary skill in the art. Such methods are typically related to electrospraying. In essence, in electrospraying, an electric field is used to drive charged particles to a grounded substrate. A charged solution exits from a spray nozzle in a conical configuration, referred to as the Taylor cone. If the Taylor cone doesn't break up, the solution forms fibers; otherwise the material becomes individual spray droplets. The two principal parameters that control behavior of the Taylor cone are the viscosity and voltage at the nozzle. Exemplary methods of creating ultra-thin fibers for use in creating a fiber meshwork involve electro-spinning. Electro-spinning methods are described in Shin, Hohman, Brenner, and Rutledge, "Experimental Characterization of electrospinning: the electrically forced jet and instabilities", Polymer 42, 9955-9967, (2001), incorporated herein by reference in its entirety. Fibers that are micrometers in diameter can be created by melt spinning or gel spinning, i.e., they are formed out of a gel or a molten melt.
[0064] A particularly exemplary method of depositing the fiber meshwork, is to use a process referred to as flow-limited field-injection electrostatic spraying (FFESS). FFESS is a form of electrospraying which offers a very high degree of control over shape and flow regimes, and which allows spinning a fiber-meshwork on top of a medical device, such as an endoprosthesis, with a glass spray nozzle. The nozzle generates a charge at the liquid meniscus that enables successful electrospray . A schematic comparison of apparatuses used respectively for conventional electro-spraying and FFESS is shown in FIG. 3 in which a structure to be sprayed is denoted 201. The two principal differences are first that FFESS sprays a polymer/solvent solution 230 from a smooth glass capillary 200 whereas CES uses a metal hypodermic needle 210, and second that FFESS uses a sharpened tungsten needle 220 inside capillary 200, whereas CES has no analogous structure. The overall effect of the FFESS apparatus is to improve jet stability and uniformity of the polymer sprayed by FFESS relative to that from CES.
[0065] Using the FFESS method for electro-spinning creates a fiber meshwork in which the one or more fibers have a highly controlled fiber diameter. In particular, as would be understood by one of ordinary skill in the art, by controlling the voltage, flow-rate, concentration of polymer in the spray fluid, the viscosity of the spray fluid, and the distance of the nozzle from the surface of the underlying structure 10, the diameter of the fibers formed during the spinning process can be controlled. For exemplary descriptions of the various factors, see, e.g., "Electrostatic Spinning and Properties of Ultrafme Fibers", Rutledge, et al, National Textile Center Annual Report, M01-D22, (November 2001), incorporated herein by reference. See also further description on the internet at vvwvv .c)ie..vt.edu/Wilke^ It is also consistent with the fiber meshwork that the diameter of the fibers can be changed during deposition.
[0066] A further advantage of FFESS is thus that, because of the high degree of control of the fiber diameter, if the weight of the fiber meshwork as well as the density of the polymer material for a given fiber diameter are known, the total surface area of the meshwork can be precisely calculated. Thus, the surface area of a fiber of diameter d, and of length /, assuming a uniform perfectly cylindrical constant cross-section along its length, is πdl, ignoring contributions from the ends of the fibers. FFESS is further described in "Controlling surface nano-structure using flow-limited field-injection electrostatic spraying (FFESS) of poly(d,l-lactide-co-glycolide)", Berkland, Pack, and Kim, Biomaterials, 25: 5649-5658, (2004) and U.S. Patent Application Publication No. 2004/0022939, both of which are incorporated herein by reference in their entirety.
[0067] The median diameter of the fiber or fibers in the fiber meshwork can be less than about 1 micron, for example, less than about 500 nm. In some embodiments, the fibers have a median diameter from about 5 nanometers to about 500 nanometers. For example, the fibers can have a median diameter of about 50 nm, about 100 nm, about 150 nm, about 200 nm, about 250 nm, about 300 nm, about 350 nm, about 400 nm, or about 450 nm. By use of the qualifier "about", it would be understood by one of ordinary skill in the art that a reference to a median diameter of, for example, about 300 nm, would encompass other median diameters within +/- 25 nm of 300 nm. It is to be understood that where a fiber is not perfectly circular in cross-section, the diameter of a particular fiber can refer to an average length of any two orthogonal lines that both pass through the geometric center of the fiber cross-section and have end points on the perimeter of the fiber, or to the length of any one such line. It is also to be understood that although the diameter of a fiber can vary along its length, the diameter is the mean diameter of the fiber. [0068] Other morphologies could be utilized to the extent that they embody the properties desired of a polymer structure for placing on the surface of an underlying structure 10. As further discussed herein, such properties include at least an ability to substantially retain shape after the underlying structure has biodisintegrated, a porosity sufficient to permit access of body fluids to the underlying structure, and a sufficient surface area to give rise to sustained release of a therapeutic agent absorbed within the polymer structure or from layers coated upon it. Other morphologies of polymer such as particles, beads, porous sheets, webs, nets and smooth surfaces may be created with FFESS, as further illustrated in Berkland, et al, Biomaterials, 25: 5649-5658, (2004) and U.S. Pat. App. Pub. No. 2004/0022939. A web or net-like structure for the fiber meshwork is advantageous because it reduces the chance that short individual fibers can become disconnected from the underlying structure.
[0069] It is also consistent with the fiber meshwork used herein that the fiber is deposited as a mixture of fibers and beads. As further described herein, a fiber composed of a biodegradable material in which is embedded a therapeutic agent will release the agent at a rate that depends upon the diameter of the fiber. It can be advantageous to mix in amongst such fibers beads of material which, being thicker than the fibers, will release the therapeutic agent over a more prolonged period of time. One of ordinary skill in the art is capable of manipulating the electrospinning process to ensure production of beads at one time, fibers at one time, or a mixture of beads and fibers. See, e.g., Shenoy, S. L., et al., "Role of chain entanglements on fiber formation during electrospinning of polymer solutions: good solvent, non-specific polymer-polymer interaction limit", Polymer, 46:3372-3384, (2005), in particular Fig. 1 therein, and Tan, et al., "Systematic parameter study for ultra- fine fiber fabrication via electrospinning process", Polymer, 46:6128-6134, (2005), both of which are incorporated herein by reference.
[0070] There are various options, familiar to one of ordinary skill in the art, for introducing a therapeutic agent into the fiber meshwork. A first option is to place the therapeutic agent inside the fiber material as it is being sprayed by a process such as FFESS. Thus the drug may be dissolved in the polymer solution before it is sprayed. This approach is also advantageous because it is possible to spray different therapeutic agents from different fibers using different nozzles to achieve simultaneous delivery of a mixture of drug components, as shown in FIG. 4. For example, at the top of FIG. 4 are shown three embodiments of a stent having disposed thereon, from left to right, a fiber meshwork made from a single fiber, two fiber meshworks made from fibers of the same thickness, and two fiber meshworks made from fibers of different thicknesses wherein the thicker fibers are only disposed at the ends of the stent. The lower portion of FIG. 4 shows two embodiments of a stent, having fiber meshworks composed of fibers of different thicknesses disposed thereon and, below each, drug release profiles showing concentration of released drug (vertical axis) as a function of time (horizontal axis). On the left hand side, the same drug is loaded into fibers of different thicknesses, and on the right hand side, different drugs are loaded into fibers of different thicknesses.
[0071] The level of control of fiber diameter achievable with FFESS is also useful because, as further described herein, release of a therapeutic agent absorbed in such fibers is directly related to the diameter of the fibers. The porous structure of the fiber meshwork disposed on the underlying structure allows all of the fibers to release their drug content directly to the surrounding milieu at the same time. Furthermore, by ensuring a specific fiber diameter, a specific release profile can be achieved. In other embodiments, use of FFESS permits creation of a differential release profile across the medical device. For example, by spraying a thinner fiber- structure at the end sections of the device, one can obtain a higher drug release at the ends by virtue of a higher surface area to volume ratio there.
[0072] A second option for introducing a therapeutic agent into the fiber meshwork is to embed Magnetite nano-particles into the fibers. Such nano-particles are ferro-magnetic and would themselves permit binding of magnetic drug delivery particles to the fiber matrix by methods within the capability of one of ordinary skill in the art. For examples of magnetic drug delivery particles, see, e.g., "Functionalisation of magnetic nanoparticles for applications in biomedicine", Berry, C. C, et ah, J. Phys. D: Appl. Phys., 36 R198-R206, (2003), incorporated herein by reference in its entirety. In one such embodiment, as a prerequisite to facilitating such a delivery mechanism, one would start with a dispersion of a desired nanoparticle in a polymer-solvent solution; the solution would be spun into fibers, such as with FFESS, such that the fibers themselves have the nanoparticles incorporated therein.
[0073] The fiber meshwork may also contain a nanocomposite instead of or in addition to a purely polymeric material. "Nanocomposite" refers to a composition comprising a polymeric material and relatively small amounts (generally less than about 10% by weight) of nanometer-sized (average size smaller than 1 micrometer) mineral, clay, or nanosized ceramic particles dispersed therein. Sometimes nanocomposites are referred to as "nanoclay" or "nanoceramic". For example, nanocomposites are disclosed in International Publication No. WO 93/1014118, and U.S. Pat. Nos. 5,385,776, and 6,251,980 all of which are incorporated herein by reference in their entirety. These particles may themselves contain therapeutic agents that are released as the polymer of the meshwork degrades.
[0074] Another approach is to use liposomes, which are embedded in the fiber meshwork. Methods of embedding liposomes into thin films have been described elsewhere, and are generally known to one of ordinary skill in the art (see, e.g., Vermette et al., "Immobilized liposome layers for drug delivery applications: inhibition of angiogenesis", J. Controlled Release, 80:179-195 (2002)). Liposomes are lipid-bilayer bound vesicles, typically less than 1 micron in diameter, for example, in the range 50 - 400 nm in diameter, that can be used as drug-delivery vehicles. Typically such liposomes are electrically charged: both cationic and anionic liposomes are known in the art as drug delivery vehicles. Therapeutic agents can be encapsulated into liposomes prior to implantation in an organism, and slowly leech out as the liposome degrades. An advantage of attaching capsules to the PEI fiber meshwork instead of attaching them to the stent surface {e.g. , by means of coating the stent with self-assembled poly-electrolyte multi-layers), is that if the capsules are large enough compared to the porosity of the fibrous network, then the capsules can be trapped in between the stent and the vessel wall.
[0075] Charged liposomes can bind to a fiber meshwork as described herein by, for example, coating the fiber meshwork with a layer-by-layer composition (of alternating cationic and anionic layers) such that the outermost (last-deposited) layer has an opposite charge to that of the liposome. Thus after coating, if fibers having an anionic outer layer (for example) are dipped into a solution of cationic liposome particles, the liposomes become bound to the fiber meshwork. It is also consistent with the medical device described herein that liposomes can be bound by magnetic attraction to a fiber meshwork. For example, as described hereinabove, fibers of the fiber meshwork can comprise magnetic nanoparticles. Liposomes having magnetite particles (see, e.g., Matsuoka, F., et al, "Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma", BioMagnetic Research and Technology, Vol. 2, p. 3 et seq., (2004), incorporated herein by reference) can bound to such a fiber meshwork.
[0076] In still other embodiments, as an alternative to liposomes, polyelectrolyte multilayer capsules may be used as transporters of drugs that may be embedded in a fiber meshwork. Drug-filled polyelectrolyte capsules can be prepared by any one of several methods known to one of ordinary skill in the art, (see, e.g., Antipov, A. A., and Sukhorukov, G. B., "Polyelectrolyte multilayer capsules as vehicles with tunable permeability", Adv. Colloid and Interface Sci. , 111, 49-61 , (2004)).
[0077] The use of drug-containing capsules such as liposomes and polyelectrolyte multilayer capsules addresses one of the drawbacks of devices in the art such as drug-eluting stents. Such devices offer only a non-homogeneous drug delivery profile because the drug is supplied by the framework of the device, such as the struts of a stent. This mechanism leaves large areas in between the struts free of the drug. Although there is some movement of the drug from the area immediately adjacent to the struts to the open cell area, there is always a difference in concentration between such regions. Trapping drug filled capsules in between a fiber meshwork and the wall of the body lumen gives a much more homogeneous release profile. This is particularly important in applications such as abluminal drug release.
[0078] In an alternative embodiment, a therapeutic agent is introduced into a medical device via a layer-by-layer (LBL) coating process which overcoats the fiber-meshwork with one or more alternating single molecular layers of cationic and anionic materials, as further described herein. Many bioactive molecules, such as proteins, enzymes, DNA, are charged, and can be readily included in these types of coatings. A number of LBL coatings, as shown in FIGs. 5 and 6, and as further described herein, can be used. The LBL coating process can permit coating of highly complex 3D structures without webbing, and is able to penetrate inside complex structures. Webbing is an effect that occurs when a very viscous solution is applied to coat very fine wires. The coating will form a kind of webbing between one fiber and another, which can be undesirable. Since layer by layer technology uses low viscous water-based solutions, it can penetrate into all manner of geometries without the risk for webbing. An example is described in, e.g., Artyukhin, et al., Langmuir, 20, 1442-1448, (2004), and H. Kong, et al., "Polyelectrolyte-functionalized multiwalled carbon nanotubes: preparation, characterization and layer-by- layer self-assembly", Polymer 46:2472-2485, (2005), both of which are incorporated by reference herein in their entirety, and which demonstrate overcoating of multiwall carbon nano-tubes with several layers of different molecules. This process is carried out in a batch process without the fibers sticking together, as shown in FIG. 5. A functionalized multi-wall carbon nanotube (MWNT) 300 such as MWNT-COOH, MWNT-PAA (where PAA is polyacrylic acid), or MWNT-PSS (where PSS is poly(sodium 4-styrenesulfonate)) can accept a number of layers of different charge, disposed thereon. For example, HPSA (hyperbranched polysulfone amine) and PDMAEMA (poly(2-(N,N-dimethylaminoethyl) methacrylate), both of which are positively charged, can be disposed on a MWNT functionalized with negatively charged groups such as carboxylates. Thereafter, alternating layers of PSS (negatively charged) and PDMAEMA or HPSA can be further built up. Each of HPSA, PSS or PDMAEMA can be disposed as a fiber meshwork. The formulae of PSS, HPSA, and PDMAEMA are shown in FIG. 5B.
[0079] In any of the embodiments herein, the fiber meshwork is able to elute a drug contained within it, or absorbed in a layer upon it, over a longer period of time than the lifetime of the mechanical support.
Layer-By-Layer technology
[0080] The fϊber-meshwork sprayed by a method such as FFESS can be overcoated with several layers, one or more of which contains a therapeutic agent, using layer-by- layer (LBL) technology. The layer-by-layer coating process produces a multi-layered structure such as 40, in FIG. IB, on the fiber meshwork. Advantages of such an arrangement include a controlled release profile of the therapeutic agent. For example, if desired, a profile may be designed to include a first phase, characterized by a massive release of the agent from the top LBL coating by virtue of its large surface area, followed by a secondary release of the agent out of deeper layers of the LBL coating, or from the fiber meshwork itself as also discussed herein. Adjustment of concentrations of the therapeutic agent at various layers, taking into account their respective thicknesses, solubilities, and surface areas, can ensure a specific desired release profile. LBL coatings are also very effective in preventing degradation of the fiber meshwork, because they follow complex surfaces precisely, such as those of the fiber meshwork, and they are composed out of charged molecules which impede free motion of water molecules through the coating. [0081] In some embodiments, the use of an LBL coating on the underlying structure 10, either instead of or as well as one on the fiber meshwork, allows control of the disintegration (e.g., corrosion) of the underlying structure over a desired timeframe. This may be important if it is wished to maintain the mechanical integrity of the device for such a defined timeframe. FIG. 6 shows an underlying structure 10 having a fiber meshwork 20 disposed thereon. The fibers of fiber meshwork can also have a layer-by-layer coating 40 disposed thereon, as shown in the various cutouts. The underlying structure 10 can also have a layer-by-layer structure 30 disposed thereon. The bottom of FIG. 6 shows a schematic of a device having multiple fiber meshworks 600 disposed on an underlying structure (denoted "support"). Each of the fiber meshworks 602-612 alternates in charge to facilitate deposition. Peptide molecules are denoted "P" and are attached to fibers of one of the fiber meshworks 612. It is to be understood that molecules other than peptides can be similarly attached to one or more of the fiber meshworks.
Layer by layer coatings
[0082] In some embodiments, at least one of the charged layers includes a polyelectrolyte. Polyelectrolytes are polymers having charged groups or groups that dissociate to form ions (also called polyions). The number of these groups in a polyelectrolyte can be so large that the polymer is soluble in polar solvents (including water) when in ionic form. One or more charged layers can include one type of polyelectrolyte or different types of polyelectrolytes.
[0083] Depending on the type of dissociable groups, polyelectrolytes can be classified as polyacids and polybases.
[0084] When dissociated, polyacids form polyanions, after protons have been released. Polyacids include inorganic and organic molecules, as well as biopolymers. Examples of polyacids are polyphosphoric acids, polyvinylsulfuric acids, polyvinylsulfonic acids, polyvinylphosphonic acids, and polyacrylic acids. Examples of the corresponding salts, which are called polysalts, are polyphosphates, polyvinylsulfates, polyvinylsulfonates, polyvinylphosphonates and polyacrylates, respectively.
[0085] Examples of anionic polyelectrolytes (polyanions) include poly(styrenesulfonate) polyanions (e.g., poly(sodium styrene sulfonate) (PSS)), polyacrylic acid polyanions, sodium alginate polyanions, eudragit polyanions, gelatin polyanions, hyaluronic acid polyanions, carrageenan polyanions, chondroitin sulfate polyanions, and carboxymethylcellulose polyanions.
[0086] Polybases contain groups that are capable of accepting protons, e.g., by reaction with an acid, to form a salt. By accepting protons, polybases form cationic polyelectrolytes (polycations).
[0087] Examples of polybases having dissociable groups within their backbone and/or side groups are polyallylamine, polyethylimine, polyvinylamine and polyvinylpyridine.
[0088] Still other examples of polyelectrolyte cations (polycations) include protamine sulfate polycations, poly(allylamine) polycations (e.g., poly(allylamine hydrochloride) (PAH)), polydiallyldimethylammonium polycations, polyethyleneimine polycations, chitosan polycations, gelatin polycations, spermidine polycations and albumin polycations
[0089] Some polyelectrolytes have both anionic and cationic groups, but nonetheless have a net positive or negative charge. An example of such a polyelectrolyte is gelatin. Some polyelectrolytes have combinations of both anionic and cationic groups such as to maintain electrical neutrality. Whether a polyelectrolyte having both anionic and cationic groups has a net positive or negative charge can depend, for example, on the pH of the environment surrounding the polyelectrolyte.
[0090] The polyelectrolytes for use with layer-by-layer coatings can include those based on biopolymers. Examples include alginic acid, gum arabicum, nucleic acids, pectins, proteins, chemically modified biopolymers such as carboxymethyl cellulose, and lignin sulfonates.
[0091] The polyelectrolytes for use with layer-by-layer coatings can also include those based on synthetic polymers, such as polymethacrylic acid, polyvinylsulfonic acid, polyvinylphosphonic acid and polyethylenimine.
[0092] Polyelectrolytes may be linear or branched, either or both of which can be used. Using branched polyelectrolytes can lead to less compact polyelectrolyte multilayers having a higher degree of wall porosity. In some embodiments, polyelectrolyte molecules can be crosslinked within and/or between the individual layers, to enhance stability, e.g. , by crosslinking amino groups on one polymer molecule with aldehyde moieties on another.
[0093] Furthermore, in certain embodiments, polyelectrolytes can be amphiphilic. Amphiphilic substances can include any substance having hydrophilic and hydrophobic groups. Amphiphilic polyelectrolytes, e.g., amphiphilic block or random copolymers having partial polyelectrolyte character, can be used in some embodiments to affect permeability towards polar small molecules. In some embodiments, a layer including an amphiphilic polyelectrolyte may be more permeable to polar molecules than a layer including a polyelectrolyte that is not amphiphilic.
[0094] Amphiphilic polyelectrolytes can be used as ionic amphiphilic substances in some embodiments. For example, a polyelectrolyte comprising charged groups (which are hydrophilic) as well as hydrophobic groups, such as polyethylenimine (PEI) or poly(styrene sulfonate) (PSS), can be employed.
[0095] Cationic and anionic surfactants may also be used as amphiphilic substances in some embodiments of the layer by layer coatings used with the present invention. Cationic surfactants include quaternary ammonium salts (R4N+X"), where R is an organic radical and where X" is a counter-anion, e.g., a halide. Thus, examples of cationic surfactants include di- dodecyldimethylammonium bromide (DDDAB); alkyltrimethylammonium bromides such as hexadecyltrimethylammonium bromide (HDTAB), dodecyltrimethylammonium bromide (DTMAB), myristyltrimethylammonium bromide (MTMAB), or palmityltrimethyl- ammonium bromide; tertiary amines (RsNH+X"), such as cholesteryl-3β-N-(dimethyl- aminoethyl)-carbamate; and N-alkylpyridinium salts; or mixtures thereof. Anionic surfactants include alkyl or olefin sulfates of general formula R-OSOsTVl+ where M+ is a metal counter-ion. Examples include a dodecyl sulfate such as sodium dodecyl sulfate (SDS), and a lauryl sulfate such as sodium lauryl sulfate (SLS). Anionic surfactants further include an alkyl or olefin sulfonate of general formula R-SOsTVl+, for example, sodium-n- dodecylbenzene sulfonate. Still further examples of anionic surfactants include fatty acids (of formula R-COO M+, where R is an organic radical and M+ is a counter-cation), for example, a dodecanoic acid sodium salt, or other acids including phosphoric acids, cholic acids, fluoro- organic acids such as lithium-3-[2-(perfluoroalkyl)ethylthio]propionate, or mixtures thereof. [0096] Exemplary polyelectrolytes for use with the multi-layer structures have molecular weights ranging from a few hundred Daltons (low-molecular weight polyelectrolytes) up to several million Daltons, as commonly found with macromolecular polyelectrolytes (e.g. , polyelectrolytes of synthetic or biological origin).
[0097] When disposed on the underlying device structure, the polyelectrolyte layers can restrict or prevent water molecules and/or certain ions from accessing the biodisintegrable materials of the underlying device structure. In certain embodiments, polyelectrolytes can, in addition to the fiber meshwork, prevent the biodisintegrable materials from disintegrating prematurely (e.g., during delivery and/or deployment of the medical device to a target site). In still other embodiments, such layers include one or more therapeutic agents. In still other embodiments, one or more layers contain a radiopaque material, and/or one or more layers capable of enhancing the mechanical properties of the device structure.
[0098] In some embodiments, the layers of the multi-layer structure disposed on the underlying structure include biodegradable polyelectrolytes that degrade at a slower rate than the rate of disintegration of the biodisintegrable material of the underlying structure. As the underlying structure disintegrates, it may break into multiple pieces. Because the layers of polyelectrolytes degrade at a slower rate than the biodisintegrable material of the underlying structure, at least some of the layers may limit or prevent movement of these multiple pieces to other places in the body, causing the pieces to disintegrate and be resorbed instead at the implantation site within the body.
[0099] In some embodiments, a layer formed of a biodegradable polyelectrolyte can degrade over a period of at least about one second (e.g., at least about 10 seconds, at least about 30 seconds, at least about one minute, at least about 10 minutes, at least about one hour, at least about five hours, at least about 10 hours, at least about one day, at least about two days, at least about four days, at least about six days), and/or at most about one week (e.g., at most about six days, at most about four days, at most about two days, at most about one day, at most about 10 hours, at most about five hours, at most about one hour, at most about 10 minutes, at most about one minute, at most about 30 seconds, at most about 10 seconds). [0100] In some embodiments, biodegradable polyelectrolytes can be used so that a therapeutic agent can be released into the subject at a rate that is dependent upon the rate of degradation of the polyelectrolyte layers. For example, by using polyelectrolytes that are biodegradable near the outer surface of the medical device, this rate can be initially highest. Biodegradable polyelectrolytes can also be used in embodiments in which the underlying structure, and/or a fiber meshwork disposed thereon, is itself biodisintegrable. As the biodegradable polyelectrolytes in layers of the coating disintegrate, they may provide less protection for the underlying device structure. As a result, the structure can begin to disintegrate or can disintegrate at a faster rate.
[0101] Examples of biodegradable polyelectrolytes include heparin, polyglycolic acid (PGA), polylactic acid (PLA), polyamides, poly-2-hydroxy-butyrate (PHB), polycaprolactone (PCL), poly(lactic-co-glycolic)acid (PLGA), protamine sulfate, polyallylamine, polydiallyldimethylammonium species (e.g., poly(diallyldimethylammonium chloride) (PDADMA, available from Aldrich)), polyethyleneimine, chitosan, eudragit, gelatin, spermidine, albumin, polyacrylic acid, sodium alginate, poly(styrene sulfonate) (PSS, Scientific Polymer Products), hyaluronic acid, carrageenan, chondroitin sulfate, carboxymethylcellulose, polypeptides, proteins, DNA, and poly(/V-octyl-4-vinyl pyridinium iodide) (PNOVP). Biodegradable polyelectrolytes are described, for example, in T. R. Farhat and J. B. Schlenoff, "Corrosion Control Using Polyelectrolyte Multilayers", Electrochemical and Solid State Letters, 5(4) B 13-Bl 5 (2002), incorporated by reference herein.
[0102] In other embodiments, the layers are made from biostable polyelectrolyte materials, or the entire multi-layer structure is constructed so as to be biostable. Thus if, for example, various layers are cross-linked to each other so that the multi-layered structure is biostable, the underlying structure may disintegrate over a given period of time, while the multi-layer structure remains in the body of the subject. Accordingly, in certain embodiments, an endoprosthesis can include two or more polyelectrolyte layers that are cross-linked to each other. The cross-linked polyelectrolyte layers may be used, for example, to confine a biodisintegrable material in the underlying structure. In certain embodiments, this confinement of the biodisintegrable material may limit the likelihood that one or more pieces of the biodisintegrable material will break away from the endoprosthesis during use and move to a location other than the target site. [0103] In some embodiments, a medical device can include a structure (e.g., a multi- layered structure) having a combination of cross-linked polyelectrolytes and biodegradable polyelectrolytes, to provide further tailoring of the disintegration of the device.
[0104] In certain embodiments, a biodegradable polyelectrolyte in one layer can be cross- linked (e.g., using heat and/or UV radiation) to another biodegradable polyelectrolyte in another layer. In some embodiments, cross-linking between polyelectrolytes in different layers can cause the polyelectrolytes to degrade at a slower rate than they would otherwise. In certain embodiments, a layer including a cross-linked polyelectrolyte can degrade over a period of at least about one week (e.g., at least about two weeks, at least about three weeks, at least about four weeks, at least about six weeks, at least about eight weeks, at least about 10 weeks, at least about 12 weeks, at least about 14 weeks, at least about 16 weeks, at least about 18 weeks, at least about 20 weeks, at least about 22 weeks), and/or at most about 24 weeks (e.g. , at most about 22 weeks, at most about 20 weeks, at most about 18 weeks, at most about 16 weeks, at most about 14 weeks, at most about 12 weeks, at most about 10 weeks, at most about eight weeks, at most about six weeks, at most about four weeks, at most about three weeks, at most about two weeks).
[0105] As an example of cross-linking layers, a polyelectrolyte layer including diazonium cations may be covalently cross-linked to a polyelectrolyte layer including sulfonate groups or acrylic acid groups, using UV radiation or heat. As another example, a polyelectrolyte layer including a diazo resin may be cross-linked to a polyelectrolyte layer including polyoxometalates. As an additional example, ammonium groups in one polyelectrolyte layer may be covalently bonded to carboxylate groups in another polyelectrolyte layer. In certain embodiments, polyelectrolyte layers including poly(allylamine hydrochloride) (PAH) can be covalently bonded to polyelectrolyte layers including poly(acrylic acid) (PAA). Cross- linking of polyelectrolyte layers is described, for example, in Zhang et αl, "Improving multilayer films endurance by photoinduced interaction between Dawson-type polyoxometalate and diazo resin", Materials Chemistry and Physics, 90 (2005), 47-52, and in Zhang et al, "Ways for fabricating stable layer-by-layer self-assemblies: combined ionic self-assembly and post chemical reaction", Colloids and Surfaces A: Physicochemical and Engineering Aspects, 198-200, 439-442, (2002), both of which are incorporated herein by reference in their entirety. [0106] In some embodiments, one or more of the top polyelectrolyte layers on a medical device can be cross-linked. This can, for example, limit or prevent degradation or dissolution of the multi-layer structure on the medical device in the body. For example, multiple layers of polyallylamine hydrochloride (PAH) and polyacrylic acid (PAA) can be deposited on a plurality of other polyelectrolyte layers. The entire multi-layered structure can then be heated at 130 0C for about an hour under a nitrogen atmosphere to crosslink the ammonium groups of the PAH and the carboxylic groups of the PAA to form amide bonds. A nylon- like top film that is impermeable to liquids can be created. In certain embodiments, this liquid- impermeable top film can later be removed (e.g., using excimer ablation).
[0107] In some embodiments, one or more regions of a polyelectrolyte layer may be cross-linked to one or more regions of another polyelectrolyte layer (e.g., by selectively irradiating certain regions of the polyelectrolyte layers), while the polyelectrolyte layers may not be cross-linked to each other in other regions.
[0108] In certain embodiments in which a multi-layered structure is biostable, the multiple layers may have one or more (e.g., two, three, four, five, 10, 15, 20, 25, 50, 100, 500, or 1,000) holes in them in order to facilitate biodisintegration of the device on which the structure is placed. In some embodiments, the one or more holes can be added to a layer using a laser. The holes can, for example, provide water and/or ions with limited access to the underlying structure, thereby helping to cause the underlying structure to disintegrate.
[0109] In some embodiments, the multi-layer structure comprises one or more non- polyelectrolyte layers. The non-polyelectrolyte layers can be biodisintegrable or biostable. Examples of non-polyelectrolyte biodisintegrable materials include polylactides such as polylactic acid (PLA), polyglycolides such as polyglycolic acid, poly(lactide-co-glycolides), polyanhydrides, and polyorthoesters. Accordingly, an endoprosthesis according to the present invention, can further include one or more non-polyelectrolyte layers, which can be added to it using, for example, a spraying technique. The non-polyelectrolyte layer(s) may be added on top of and/or underneath the multi-layered structure. In some embodiments, an endoprosthesis can include more than one multi-layered structure, and/or can include one or more non-polyelectrolyte layers located between the multi-layered structures. In some embodiments, the non-polyelectrolyte layer(s) may be thicker than one or more of the layers in the multi-layered structure(s). In certain embodiments, a non-polyelectrolyte layer may exhibit better adhesion to the surface of a tubular structure of an endoprosthesis than a polyelectrolyte layer.
[0110] In certain embodiments, a multi-layered structure may include at least two positively charged layers that are formed of different materials (e.g. , different polyelectrolytes) and/or at least two negatively charged layers that are formed of different materials (e.g., different polyelectrolytes).
[0111] In some other embodiments, one portion of the underlying structure may be coated with a multi-layered structure, while another portion of the underlying structure may not have any coatings on it, or may be coated with just one layer.
[0112] In certain embodiments, when it is desired to increase the permeability of the medical device to magnetic fields, charged layers of a multi-layer structure containing various polyelectrolytes can be interleaved with other layers that contain magnetic clusters. Examples of incorporating inorganic materials such as polyoxometalates in a multi-layered structure using a layer-by-layer method are described, for example, in Caruso et al, Langmuir (1998), 14, 3462-3465, and also in pending U.S. Patent Application Serial No. 10/985,242, both of which are incorporated herein by reference in their entirety.
[0113] A multi-layered structure in conjunction with a fiber meshwork can also be applied to the underlying structures of numerous medical devices. For example, they can be applied to grafts, filterwires, valves, filters (e.g., vena cava filters), aneurysm coils, distal protection devices, guidewires, and other implantable devices. In some embodiments, a multi-layered structure can be applied to a catheter (e.g., a renal or vascular catheter such as a balloon catheter). In certain embodiments, a multi-layered structure can be applied to a balloon. In some embodiments, a multi-layered structure such as multi-layered structure can be applied to a coil (e.g., an aneurysm coil). Coils are described, for example, in Twyford, Jr. et al., υ.S. Patent No. 5,304,195.
[0114] In some embodiments, the multi-layered structure can include nanoparticles. The nanoparticles can, for example, enhance the mechanical properties (e.g., strength) of the multi-layered structure. The nanoparticles can have at least one dimension (e.g., the thickness for a nanoplate, the diameter for a nanosphere, a nanocylinder and a nanotube) that is less than 1,000 nanometers (e.g., less than 100 nanometers). Nanoplates can have at least one dimension that is less than 1 ,000 nanometers; nano fibers can have at least two orthogonal dimensions (e.g., the diameter for a cylindrical nano fiber) that are less than 1,000 nanometers; and other nanoparticles can have three orthogonal dimensions (e.g., the diameter for nanospheres) that may be less than 1,000 nanometers.
Forming Layer-by-layer Structures
[0115] In certain embodiments, charged layers containing various polyelectrolytes can be interspersed with other layers to form a multi-layer structure using a method in which the layers electrostatically self-assemble. In this method, the so-called layer by layer method, a first layer comprising a first material having a first surface charge is deposited on an underlying structure or substrate, followed by a second layer comprising a second material having a second surface charge that is opposite in sign to the surface charge of the first layer. Thus, the charge on the outer layer is reversed upon deposition of each sequential layer. Additional layers, for example of first and second materials, can then be alternatingly deposited on the substrate to build a multi-layered structure to a predetermined or targeted thickness. This method allows a multi-layer structure to be formed on an underlying structure directly and/or, for example, on a flexible sleeve (e.g., a polymer sleeve) carried by the underlying structure, as well as on a fiber meshwork of the present invention. The layer-by- layer structure thus formed is capable of controlling the disintegration of the underlying structure, while allowing the device to remain flexible and adaptable to the vessel in which the device is implanted. Layer-by-layer self-assembly is described, for example, in Liu et al, Journal of Cluster Science, Vol. 14, No. 3, 405-419, (2003); and Caruso et al, Langmuir, 14, 3462-3465, (1998). The substrate can be the underlying structure, or the fiber meshwork.
[0116] Accordingly, once a layer having a preselected charge is provided on the underlying structure or fiber meshwork, the layer can be coated with a layer of an oppositely charged material. After each application of a successive layer, the device can be washed to remove excess material. A multi-layer structure can be formed by repeated treatment with alternating, oppositely charged, materials, e.g., a positive polyelectrolyte and a negative polyoxometalate, as described in pending U.S. Patent Application Serial No. 11/127,968, incorporated by reference herein. The respective layers self-assemble by electrostatic layer- by-layer deposition, thus forming a multi-layered structure over the underlying structure or the fiber meshwork of the device. [0117] In another embodiment, the multi-layer structure is formed by exposing a selected charged substrate (e.g. , the underlying structure of a stent, or a fiber meshwork) to solutions or suspensions that contain species of alternating net charge, such as solutions or suspensions that optionally contain charged magnetic clusters, charged therapeutic agents and/or nanoparticles. The concentration of the charged species within these solutions and suspensions, which can be dependent on the types of species being deposited, can range, for example, from about 0.01 mg/ml to about 30 mg/ml. The pH of these suspensions and solutions can be such that polyelectrolytes, optional magnetic clusters, and therapeutic agents and/or nanoparticles to be included within the layers maintain their charge. Buffer systems can be used to maintain the pH and thereby the charges of the respective species.
[0118] The solutions and suspensions containing the charged species can be applied to the charged substrate surface using a variety of methods. Examples of such methods include spraying methods, dipping methods, roll and brush coating methods, ink jet methods, spin coating methods, web coating methods, microstamping methods, and methods involving coating via mechanical suspension such as air suspension, as well as combinations of these methods. Layers can be applied over an underlying structure by immersing the entire structure into a solution or suspension containing the charged species, or by immersing half of the structure into the solution or suspension, flipping the structure through 180°, and immersing the other half of the substrate into the solution or suspension to complete the coating. In some embodiments, the substrate is rinsed after application of each charged species layer, for example, using a washing solution with a pH that maintains the charge of the outer layer.
[0119] In some embodiments, the substrate is itself charged. A fiber meshwork can therefore be composed of charged polymer molecules or, at least, carries a surface charge to facilitate deposition of a first layer of a layer-by-layer structure upon it. Examples of such polymers include PEI, polyamides, polyacrylic acid, carboxymethyl cellulose, chitosan, PEI, polyamides, and polystyrene. The last of these, polystyrene, can be dissolved in an organic solvent such as THF after the layer-by-layer coating is assembled, thereby giving rise to a hollow fiber that can be filled with one or more therapeutic agents. The extent of surface charge on the surface of a given material can be deduced by measuring the Zeta-potential of the material, using methods known to one of ordinary skill in the art. [0120] Using the methods described herein, multiple layers of alternating charge can thereby be applied to the fiber meshwork, or to an underlying structure. The number of layers varies according to application. In some embodiments, at least 10 layers (e.g., at least 20 layers, at least 30 layers, at least 50 layers, at least 100 layers, at least 200 layers) and/or at most 300 layers (e.g., at most 200 layers, at most 100 layers, at most 50 layers, at most 30 layers, at most 20 layers) can be applied over the substrate.
[0121] The total thickness of a multi-layered structure built up by a layer-by-layer process can be a function of the materials (e.g., polyelectrolytes) used, and can range, for example, from 5 nanometers to 1,500 nanometers. In some embodiments, the total thickness of the multi-layered structure can be at least five nanometers (e.g., at least 10 nanometers; at least 50 nanometers; at least 100 nanometers; at least 500 nanometers; at least 1,000 nanometers; at least 1,500 nanometers; at least 2,000 nanometers; at least 5,000 nanometers; at least 10,000 nanometers; at least 20,000 nanometers; at least 30,000 nanometers) and/or at most 40,000 nanometers (e.g., at most 30,000 nanometers; at most 20,000 nanometers; at most 10,000 nanometers; at most 5,000 nanometers; at most 2,000 nanometers; at most 1,500 nanometers; at most 1,000 nanometers, at most 500 nanometers, at most 100 nanometers, at most 50 nanometers, at most 10 nanometers).
[0122] The number of layers and/or the total thickness of a multi-layered structure deposited on a fiber meshwork, or an underlying structure, can be determined empirically and can be a function of, for example, the compositions of the layers and the type of medical device. For example, for a given medical device, the number of layers, their sequences and compositions, and/or the total thickness of multi-layered structure can be varied and the effectiveness of the multi-layered structure can be tested. After an effective combination is determined, the same combination can be repeatedly applied to other such devices.
[0123] In some embodiments, the multi-layered structure can be formed on a substrate, removed from the substrate, and subsequently applied (e.g., with an adhesive) to an underlying structure or a fiber meshwork of a medical device according to the present invention. When separating the multi-layered structure from the substrate, the substrate can be removed by destroying it, for example, by melting, sublimation, combustion, or dissolution, or a combination thereof, to free the multi-layered structure. For example, a removable substrate made of dental waxes (such as those available from MDL Dental Products, Inc., Seattle, WA, USA) or polyvinyl alcohol can be used. These materials can respectively melt at moderately elevated temperatures (e.g., 60 0C) and dissolve in hot water. Other methods of using a removable substrate are described in Sukhorukov et al, "Comparative Analysis of Hollow and Filled Polyelectrolyte Microcapsules Templated on Melamine Formaldehyde and Carbonate Cores" Macromo I. Chem. Phys., 205, 2004, 530- 535; and U.S. Patent Application Serial No. 10/849,742, both of which are incorporated herein by reference in their entirety.
[0124] Layers of a multi-layer structure may have the same thickness as one another or different thicknesses. In some embodiments, the thickness of a layer may depend on the molecular weight of the materials, such as polyelectrolyte(s), included in the layer, and/or the presence of other materials (e.g., nanoparticles) in the layer. For example, a layer comprising a relatively low molecular weight polyelectrolyte, such as low molecular weight heparin (e.g. , heparin having a molecular weight of from about 1,000 Daltons to about 10,000 Daltons) may be relatively thin. In certain embodiments, the thickness of a layer may depend on the conditions (e.g., salt concentration and/or pH) during the deposition of the layer. In some embodiments, an individual layer and/or an individual layer may have a thickness of at least about 0.2 nanometer (e.g., at least about 0.5 nanometer, at least about 1.0 nanometer, at least about 5.0 nanometers, at least about 10 nanometers, at least about 50 nanometers, at least about 100 nanometers, at least about 300 nanometers), and/or at most about 500 nanometers (e.g., at most about 300 nanometers, at most about 100 nanometers, at most about 50 nanometers, at most about 10 nanometers, at most about five nanometers at most about one nanometer, or at most about 0.5 nanometer).
[0125] In certain embodiments different regions of the medical device are coated with multi-layer structures having different numbers of layers. In some embodiments, the biodisintegrable material in a region of the underlying structure that is coated with a relatively large number of layers may begin to disintegrate after, and/or more slowly than, the biodisintegrable material in a region that includes a relatively small number of polyelectrolyte layers. Thus, the polyelectrolyte layers on an underlying structure may be used to provide different disintegration rates of biodisintegrable material in different regions of the medical device. In some embodiments, an endoprosthesis can include an arrangement of polyelectrolyte layers that causes one or both of the ends of the endoprosthesis to start disintegrating before the middle of the endoprosthesis. This may limit the likelihood of the medical device breaking apart into two or more pieces during disintegration. Further examples of such devices are found in pending U.S. Patent Application Serial No. 11/127,968.
[0126] Many embodiments of a medical device having different numbers of layers on one portion from another portion are possible. By "portion" is meant some non-vanishing part that is less than the whole. Thus, in some embodiments, one portion of a medical device includes a multi-layered structure with at least 10 layers (e.g., at least 20 layers, at least 30 layers, or at least 40 layers), and another portion of a medical device includes a multi-layered structure with at least 20 layers (e.g., at least 30 layers, at least 40 layers, or at least 50 layers). For example, one portion of a medical device may include a multi-layered structure with 10 layers and another portion of the medical device may include a multi-layered structure with 40 layers. In certain embodiments, a multi-layered structure on one portion of a medical device can include from five to 50 layers (e.g., from 10 to 30 layers) more than a multi-layered structure on another portion of the medical device.
[0127] In some embodiments, one or more portions of a medical device may not be coated with any layers at all.
[0128] In some embodiments, devices having portions with different numbers of layers on them can be formed by dipping one end (e.g., 2/3) of a device in one material, turning the device around, and dipping the other end (e.g., 2/3) of the device in another material, and repeating the process multiple times. The result is that the middle of the device (e.g., the middle 1/3 of it) receives more layers than either end of the device. In certain embodiments, devices having portions with different numbers of layers on them can be formed by other techniques, such as ink jet techniques, microstamping, spraying, roll coating, or brush coating.
[0129] The underlying structure or fiber meshwork can be pretreated prior to forming a multi-layer structure on it. For example, an underlying structure can be cleaned to remove surface contaminants, such as oil, that can affect the homogeneity of the multi-layered structure. The underlying structure or fiber meshwork can be cleaned, for example, in a solvent such as acetone, or in a mixture such as H2(VHCl, HCI/HNO3, H2SO4ZK2Cr2Oy, H2O2/NH3, and/or NaOH/NaOCl. The structure can also be pretreated with a solution including 10 Λ-2 z M SDS/0.12 N HCl for 15 minutes at 100 0C.
[0130] An embodiment of a method of making a device using a layer-by-layer technique includes pretreating an underlying structure for layer-by-layer deposition. Next, a charged layer, e.g., containing a polyelectrolyte, is applied to the underlying structure. A layer of opposite charge is then applied to the previously applied charged layer. The previous two steps can then be repeated to build a multi-layered structure of a desired thickness. In some embodiments, as described herein, multi-layered structure can further include one or more layers that contain a therapeutic agent, one or more layers that contain a radio-opaque material, and/or one or more layers capable of enhancing the mechanical properties of the underlying structure. These additional layers can be applied between layers of different charges in any combination.
[0131] In another example, the material can be provided with a positive charge by covalently attaching functional groups having a positive charge (e.g., amine, imine or other basic groups) or functional groups having a negative charge (e.g., carboxylic, phosphonic, phosphoric, sulfuric, sulfonic, or other acid groups) to it.
[0132] In yet another example, a surface charge can be provided by exposing the device to a charged amphiphilic substance. In certain embodiments, the amphiphilic substance includes at least one electrically charged group to provide the device surface with a net electrical charge. Therefore, the amphiphilic substances that are used herein can also be referred to as ionic amphiphilic substances.
[0133] Thus, a surface charge can be provided on a material by adsorbing cations (e.g., protamine sulfate, polyallylamine, polydiallyldimethylammonium species, polyethyleneimine, chitosan, gelatin, spermidine, and/or albumin) or by adsorbing anions (e.g., polyacrylic acid, sodium alginate, polystyrene sulfonate, eudragit, gelatin (an amphiphilic polymer that fits in both categories depending how it is being prepared), hyaluronic acid, carrageenan, chondroitin sulfate, and/or carboxymethylcellulose) to the surface of the material as a first charged layer or to impart a surface charge. As an example, poly(ethylene imine) (PEI, Aldrich, MW ~25 kD) can be dissolved in water in a concentration of about 0.5 g/L to apply a first coating. In some embodiments, more than one surface charge layer can be applied to provide complete coverage of the material. Application of surface charge layers is described in, e.g., "Multilayer on Solid Planar Substrates", Multi-layer Thin Films, Sequential Assembly of Nanocomposite Materials, Wiley-VCH ISBN 3-527-30440-1, Chapter 14; and "Surface-chemistry Technology for Microfluidics" Hau, Winky L. W. et al., J. Micromech. Microeng., 13, 272-278, (2003).
[0134] The species for establishing a surface charge can be applied to the material by a variety of methods. Examples of such methods include spraying methods, dipping methods, roll and brush coating methods, methods involving coating via mechanical suspension such as air suspension, ink jet methods, spin coating methods, web coating methods and combinations of these processes. Dipping and spraying methods (without masking) can be employed, for example, to apply the species to an entire device. Roll coating, brush coating and ink jet printing can be employed, for example, to apply the species only to selected portions of the device (e.g., in the form of a pattern).
[0135] In an embodiment, the polymer from which the fiber meshwork is made is charged. Thus, an oppositely-charged layer can be easily deposited thereon.
Delivery of therapeutic agents
[0136] In embodiments, the multi-layered structure includes one or more layers that contain a therapeutic agent. As an example, one or more therapeutic agents can be disposed on or within the multi-layered structure giving the medical device a drug releasing function upon implantation. Therapeutic agents may be used singly or in combination.
[0137] Examples of therapeutic agents can be found at cols. 4 - 6 of U.S. Patent No. 6,899,731 to Li et al, and at cols. 5 - 8 of U.S. Patent No. 6,923,996 to Epstein et al, the disclosures of which are incorporated by reference in their entirety. It is to be understood that the therapeutic agents that can be used are not limited to those found herein.
[0138] Examples of therapeutic agents and methods of incorporating such agents into a multi-layer structure are described in U.S. Patent Application No. 10/849,742, filed May 20, 2004. U.S. Patent No. 5,733,925, to Kunz et al., also provides general guidance for incorporating therapeutic agents into layers. [0139] The fiber meshwork or a multi-layer structure may instead or additionally be used to deliver an antimicrobial agent, such as for the purpose of preventing or limiting local infection in the vicinity of the device. Exemplary antimicrobial agents have broad-spectrum activity and include triclosan, chlorhexidine, silver sulfadiazine, silver ions, benzalkonium chloride, and zinc pyrithione, as well as broad-spectrum antibiotics such as quinolones, fluoroquinolones, aminoglycosides and sulfonamides. Antiseptics such as iodine, methenamine, nitrofurantoin, validixic acid and other acidifying agents, including acids extracted from cranberry juice may also be used.
[0140] The therapeutic agent can be charged, either because it is itself a charged molecule or because it becomes charged upon, for example, a change in ambient pH or upon association with a charged species. Examples of charged therapeutic agents include small molecule and polymeric therapeutic agents containing ionically dissociable groups. In some embodiments in which the therapeutic agent does not possess one or more charged groups, it can nevertheless be provided with a charge, for example, through non-covalent association with a charged species. Examples of non-covalent associations include hydrogen bonding, electrostatic, van der Waals, and hydrophobic/lipophilic interactions. For instance, a therapeutic agent can be associated with an ionic amphiphilic substance.
[0141] In certain embodiments in which a charged therapeutic agent is used, one or more layers consisting of the charged therapeutic agent are deposited during the course of assembling the multi-layer structure. Thus, in some embodiments an entire layer may be composed of a therapeutic agent. For example, the therapeutic agent can itself be a polyelectrolyte (e.g., where the therapeutic agent is a polypeptide or a polynucleotide) and is thereby used to create one or more polyelectrolyte layers within the multi-layer structure. In other embodiments, the charged therapeutic agent is not a polyelectrolyte (e.g., it may be a charged small molecule drug), but one or more layers of the charged therapeutic agent can be substituted for one or more layers of the same charge (i.e., positive or negative) during the layer-by-layer assembly process.
[0142] A wide range of therapeutic agent loadings can be used. The amount of such loading can be readily determined by those of ordinary skill in the art, and will ultimately depend upon the condition to be treated, the nature of the therapeutic agent itself, the avenue by which the therapeutic-agent-loaded layer-by-layer structure or fiber meshwork is administered to the intended subject, and so forth. The loaded fiber meshwork, or multi- layered structure, may comprise, for example, from about 1 wt. % to about 70 wt. % therapeutic agent.
[0143] The amount of the therapeutic agent may be limited by the propensity of such agent to cause an undesirable localized or systemic toxic reaction and by the impairment of mechanical properties necessary for proper functioning of the device.
[0144] In still other embodiments, the therapeutic agent can be provided within charged nanocapsules, which are formed, for example, using methods such as those described in U.S. Patent Application Publication No. 2005-0129727, entitled "Localized Drug Delivery Using Drug-Loaded Nanocapsules". In such embodiments, one or more layers of charged nanocapsules can be deposited during the course of the layer-by-layer assembly process.
[0145] In still other embodiments, the multi-layer structure is loaded with a therapeutic agent subsequent to its formation. For example, the porosity, and thus the permeability, of the multi-layer structure can be modified by adjusting the pH exposed to the structure, as described, for example, in Antipov, A. A., et al., "Polyelectrolyte multilayer capsule permeability control," Colloids and Surfaces A: Physicochemical and Engineering Aspects, 198-200, 535-541, (2002). A porous layer can absorb a therapeutic agent after the layer is in place.
Device materials
[0146] The underlying structure of the medical device of the present invention is, in some embodiments, formed of a biocompatible material, such as the materials described herein. Specific examples of biocompatible materials from which the underlying structure can be formed are described in U.S. patent application serial no. 10/440,063, filed May 15, 2003; and U.S. Patent Application Publication Nos. 2003-0018380, 2002-0144757, and 2003- 0077200. Still further examples of biocompatible materials are described, for example, in Weber et al. , U.S. Patent Application Publication No. 2004/0230290 Al , published on November 18, 2004; Craig et al, U.S. Patent Application Publication No. 2003/0018380 Al, published on January 23, 2003; Craig et al., U.S. Patent Application Publication No. US 2002/0144757 Al, published on October 10, 2002; and Craig et al, U.S. Patent Application Publication No. 2003/0077200 Al, published on April 24, 2003. [0147] The biocompatible material can be suitable for use in, for example, a balloon- expandable stent, a self-expandable stent, or a combination of both (see e.g., U.S. Patent No. 5,366,504). A self-expandable stent can be formed of a continuous solid mass of a relatively elastic biocompatible material, such as a superelastic or pseudo-elastic metal alloy, for example, a Nitinol (e.g., 55% nickel, 45% titanium). A self-expanding stent has a mechanical memory such that it can return to a preformed shape after it has been compressed or deformed. The stent is initially configured in its final desired shape and is then contracted by deforming or constraining it using any of several methods known in the art. It remains in a contracted state until it is delivered to the target site where it is allowed to expand to its initial state. Examples of materials that can be used for a balloon-expandable stent include noble metals, radiopaque materials, stainless steel, and alloys comprising stainless steel and one or more radiopaque materials.
[0148] The underlying structure can be formed of a biodisintegrable material, such as a biodisintegrable metal, a biodisintegrable metal alloy, or a biodisintegrable non-metal. Biodisintegrable materials are described, for example, in U.S. Patent No. 6,287,332 to BoIz; U.S. Patent Application Publication No. US 2002/0004060 Al to Heublein; U.S. Patent Nos. 5,587,507 and 6,475,477 to Kohn et al. Examples of biodisintegrable metals for use with the underlying structure include alkali metals, alkaline earth metals (e.g., magnesium), iron, zinc, and aluminum. Examples of biodisintegrable metal alloys include alkali metal alloys, alkaline earth metal alloys (e.g. , magnesium alloys), iron alloys (e.g. , alloys including iron and up to seven percent carbon), zinc alloys, and aluminum alloys.
[0149] In some embodiments, a biodisintegrable material from which the underlying structure is formed, can include at least one metallic component and at least one non-metallic component, or at least two different metallic components. In some embodiments, a biodisintegrable material can include at least one of the following: manganese, cobalt, nickel, chromium, copper, cadmium, lead, tin, thorium, zirconium, silver, gold, palladium, platinum, rhenium, silicon, calcium, lithium, aluminum, zinc, iron, carbon, and sulfur. In certain embodiments, a biodisintegrable material can include at least two of the following metals in proportions by weight of greater than about 1%: magnesium, titanium, zirconium, niobium, tantalum, zinc, or silicon, and lithium, sodium, potassium, calcium, iron, or manganese. In certain embodiments, the biodisintegrable material can include a first component selected from the group consisting of: magnesium, titanium, zirconium, niobium, tantalum, zinc, silicon, and another, different, component selected from the group consisting of: lithium, sodium, potassium, calcium, iron, manganese.
[0150] Examples of biodisintegrable non-metals include biodisintegrable polymers, such as polyiminocarbonates, polycarbonates, polyarylates, polylactides, or polyglycolic esters. In some embodiments, a biodisintegrable metal or metal alloy containing metals such as magnesium, iron, or zinc, can be sintered. In some embodiments, the biodisintegrable material can be a polymer, such as, without limitation, those described at cols. 8 - 9 of U.S. Patent No. 6,918,869 to Shaw et al.
[0151] In still other embodiments, the biodisintegrable material can be a ceramic such as an alumina-based ceramic, or a glass-based ceramic such as Macor®.
[0152] The properties of the underlying structure depend upon the material from which it is formed. Magnesium, for example, has a relatively low mass attenuation factor, and the CT visibility of the region (e.g., a body lumen) in which a magnesium structure is located can be relatively high.
[0153] The underlying structure of a medical device for use as described herein can be manufactured, or can be obtained commercially. Methods of making medical devices such as stents are described in, for example, U.S. Patent No. 5,780,807, and U.S. Patent Application Publication No. 2004-0000046-A1, both of which are incorporated herein by reference. Stents are also available, for example, from Boston Scientific Corporation, Natick, MA, USA, and Maple Grove, MN, USA.
[0154] Metallic materials from which the underlying structure is made may be made into filaments and then woven so that the underlying structure forms a regular network of metal mesh. Polymer filaments may also be used together with the metallic filaments to form a network. If the network is made of metal, the intersection between different filaments may formed by welding, twisting, bending, gluing, tying (with suture), heat sealing, or by any other manner known in the art.
[0155] As another example, although a stent may include a tubular structure that is formed entirely of a biodisintegrable material, in some embodiments, the tubular structure of a stent can include one or more biostable materials in addition to including one or more biodisintegrable materials. One or more polymers may be used (as described herein) to control the disintegration of one or more of the biodisintegrable regions of the stent. The polymers may be in the form of layers over the biodisintegrable and/or biostable regions of the stent or a fiber meshwork similarly disposed. Examples of biostable materials include stainless steel, tantalum, nickel-chrome, cobalt-chromium alloys such as Elgiloy® and Phynox®, Nitinol (e.g., 55% nickel, 45% titanium), and other alloys based on titanium, including nickel titanium alloys, thermo-memory alloy materials. Stents including biostable and biodisintegrable regions are described, for example, in U.S. Patent Application Serial No. 11/004,009, filed on December 3, 2004, and entitled "Medical Devices and Methods of Making the Same".
[0156] Devices, such as stents, may be formed from many known constructions such as cross-hatched or mesh filaments or interlocking loops.
Stents/Devices
[0157] The embodiments described herein may be used in conjunction with various medical devices, in particular endoprostheses. Exemplary medical devices are implantable or insertable medical devices, including catheters (for example, urinary catheters or vascular catheters such as balloon catheters), guide wires, balloons, filters (e.g., vena cava filters), stents of any desired shape and size (including coronary vascular stents, aortic stents, cerebral stents, urology stents such as urethral stents and ureteral stents, biliary stents, tracheal stents, gastrointestinal stents, peripheral vascular stents, neurology stents and esophageal stents), grafts such as stent grafts and vascular grafts, cerebral aneurysm filler coils (including GDC- Guglilmi detachable coils-and metal coils), filters, myocardial plugs, patches, pacemakers and pacemaker leads, heart valves, and biopsy devices. Indeed, embodiments herein can be suitably used with any underlying structure (which can be, for example, metallic, polymeric or ceramic, though typically metallic) which is coated with a fiber meshwork in accordance with methods herein and which is designed for use in a patient, either for procedural use or as an implant.
[0158] The medical devices may further include drug delivery medical devices for systemic treatment, or for treatment of any mammalian tissue or organ. Subjects can be mammalian subjects, such as human subjects. Non-limiting examples of tissues and organs for treatment include the heart, coronary or peripheral vascular system, lungs, trachea, esophagus, brain, liver, kidney, bladder, urethra and ureters, eye, intestines, stomach, colon, pancreas, ovary, prostate, gastrointestinal tract, biliary tract, urinary tract, skeletal muscle, smooth muscle, breast, cartilage, and bone.
[0159] In some embodiments, the medical device is used to temporarily treat a subject without permanently remaining in the body of the subject. For example, in some embodiments, the medical device can be used for a certain period of time (e.g., to support a lumen of a subject), and then can disintegrate after that period of time.
[0160] The underlying structure of the medical device can be generally tubular in shape and can be a part of a stent. Simple tubular structures having a single tube, or with complex structures, such as branched tubular structures, can be used.
[0161] Depending on specific application, stents can have a diameter of between, for example, 1 mm and 46 mm. In certain embodiments, a coronary stent can have an expanded diameter of from about 2 mm to about 6 mm. In some embodiments, a peripheral stent can have an expanded diameter of from about 4 mm to about 24 mm. In certain embodiments, a gastrointestinal and/or urology stent can have an expanded diameter of from about 6 mm to about 30 mm. In some embodiments, a neurology stent can have an expanded diameter of from about 1 mm to about 12 mm. An abdominal aortic aneurysm (AAA) stent and a thoracic aortic aneurysm (TAA) stent can have a diameter from about 20 mm to about 46 mm.
[0162] Stents can also be a part of a stent-graft or a covered stent. In other embodiments, stents can include and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene.
[0163] Stents can also be biodisintegrable, such as a biodisintegrable abdominal aortic aneurysm (AAA) stent, or a biodisintegrable vessel graft. EXAMPLES
Example 1: Collagen-based fiber meshwork on a stent
[0164] Collagen type I (Sigma- Aldrich (St. Louis, MO)) dissolves in 1,1,1,2,2,2- hexafluoro-2-propanol (HFIP). A solution was prepared making a 8% by weight solution of Collagen in HFIP. A stent (BSC, stainless steel, express stent, 16 mm length, 3.0 mm diameter), was crimped on a Teflon mandrel having diameter 3.0 mm, with a fine 10 micron gold wire (California Fine Wire, 338 So. Fourth Street, Grover Beach, CA 93433-0199) placed in between the stent and the mandrel such that there was electrical contact between the stent and the gold wire. The gold wire was grounded.
[0165] A nozzle with Syringe was placed at a distance of 7 cm from the stent surface and connected to a syringe pump (type SPlOIi, World Precision Instruments, Liegnitzer Str.15, D- 10999 Berlin, Germany), and a high voltage supply (Type CS2091, High Voltage Power Solutions, Inc. (HVPSI), Dallas, TX 75370). The mandrel was rotated at 5 Hz during the spraying process and moved along the axis in a cyclic movement at 12 Hz with an amplitude of 2 mm. The spraying was done at the following settings (18 kV, 0.02 ml/min, 10 seconds on cycle). This resulted in a 90 % porous fibrin structure being 10 micrometer thick covering the stent. The collagen nanofiber network spun in this way was crosslinked by glutaraldehyde vapor at room temperature for 12 hours (Sigma- Aldrich (St. Louis, MO)).
Example 2: Polyetherimide-based fiber meshwork on a stent
[0166] Polyetherimide (PEI) was purchased from Aldrich Co. (St. Louis, MO)), and Biopol™, polyhydroxybutyrate-valerate (PHBV) was purchased from Monsanto Company (800 North Lindbergh, St. Louis, MO 63167). Both components were mixed in chloroform making solutions having 23 wt.% PEI and 21 wt.% PHBV. These solutions were mixed to a ratio of 75/25 (PEI/PHBV)
[0167] A stent (Boston SciMed Corporation, stainless steel, express stent, 16 mm length, 3.0 mm diameter), was crimped on a Teflon mandrel diameter 3.0 mm with a fine 10 micron gold wire (California Fine Wire, 338 So. Fourth Street, Grover Beach, CA 93433-0199) placed in between the stent and the mandrel, such that there was electrical contact between the stent and the gold wire. The gold wire was grounded. [0168] A nozzle with syringe was placed at a distance of 15 cm from the stent surface and connected to a syringe pump (type SPlOIi, World Precision Instruments, Liegnitzer Str.15, D- 10999 Berlin, Germany), and a high voltage supply (Type CS2091, High Voltage Power Solutions, Inc. (HVPSI), High Voltage Power Solutions, Inc., Dallas, TX 75370). The mandrel was rotated at 5 Hz during the spraying process and moved along the axis in a cyclic movement at 12 Hz with an amplitude of 2 mm. The spraying was carried out at the following settings: 15 kV, 0.05 ml/min, 15 seconds on cycle. The stent sprayed in this way was thermally treated for 90 minutes at 210 0C in a nitrogen environment to decompose the PHBV component and leave behind a fiber meshwork made of porous PEI fibers.
[0169] The fibers created in this way were coated with a layer of Heparin via a polyelectrolyte self-assembly process. Heparin in sodium salt form, from Bioiberica (Barcelona, Spain) is negatively charged and binds readily to the positively charged PEI surface when the stent with fiber meshwork is dipped for 10 minutes in an aqueous(2 mg/ml) heparin solution followed drying with a stream of nitrogen.
[0170] The PEI fiber meshwork created in this way can also be used to deliver drug- filled liposome capsules (e.g., as described in Vermette et ah, "Immobilized liposome layers for drug delivery applications: inhibition of angiogenesis", J. Controlled Release, 80:179- 195 (2002), incorporated herein by reference in its entirety) or other polyelectrolyte capsules filled with various drugs. Leaving the stent with the electro-spun network on the Teflon mandrel while attaching the capsules will assure that they only attach to the outside and that, in use, they are therefore all trapped in between the stent and the wall of the vessel or body lumen.
Example 3: Collagen-based fiber meshwork modified with polyelectrolyte layers
[0171] In another embodiment, instead of using PEI fibers as in Example 2, the collagen fibers as discussed in Example 1 can also be coated with additional polyelectrolyte layers, but using only non-polymeric biological material such as collagen and alternating hyaluronic acid or heparin elements (see e.g., Zhang, et al, "Natural polyelectrolyte films based on layer-by- layer deposition of collagen and hyaluronic acid", Biomaterials, 26:3353-3361, (2005)). To those layers again, capsules are bound using polyelectrolyte constructions. [0172] All non-patent literature publications, patent applications, patent application publications, and patents, referred to in the instant application are incorporated herein by reference in their entirety.
[0173] Other embodiments are to be found within the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A medical device, comprising: an underlying structure having a fiber meshwork disposed thereon, wherein the underlying structure is biodisintegrable.
2. The medical device of claim 1, wherein the medical device is an endoprosthesis.
3. The medical device of claim 1 wherein the underlying structure comprises a metal framework.
4. The medical device of claim 3 wherein the framework is made of a metal selected from the group consisting of: alkali metals, alkaline earth metals, iron, zinc, and aluminum.
5. The medical device of claim 4 wherein the metal is magnesium
6. The medical device of claim 4 wherein the metal is iron.
7. The medical device of claim 3, wherein the framework comprises a metal alloy.
8. The medical device of claim 7, wherein the framework comprises an iron alloy.
9. The medical device of claim 7, wherein the framework comprises a magnesium alloy.
10. The medical device of claim 7, wherein the framework comprises nitinol.
11. The medical device of claim 3, wherein the framework comprises a first metal selected from the group consisting of magnesium, titanium, zirconium, niobium, tantalum, zinc, and silicon, and a second metal selected from the group consisting of lithium, sodium, potassium, calcium, iron, and manganese.
12. The medical device of claim 1, wherein the biodisintegrable material comprises a non-metal.
13. The medical device of claim 1, wherein the biodisintegrable material comprises a polymer.
14. The medical device of claim 13 wherein the polymer is selected from the group consisting of: PLG; PLA; poly(caprolactone); poly(hydroxybutyrate); poly(orthoester); poly(alkane anhydride); gelatin collagen; oxidized cellulose; and poly(phosphazene).
15. The medical device of claim 1 wherein the fiber meshwork comprises a polymeric material.
16. The medical device of claim 1 wherein the fiber meshwork is biodegradable.
17. The medical device of claim 1 wherein the fiber meshwork comprises two or more non-contiguous fibers.
18. The medical device of claim 1 wherein the fiber meshwork comprises an electro-spun polymeric material.
19. The medical device of claim 18 wherein the fiber meshwork is electro-spun by FFESS.
20. The medical device of claim 1 wherein the fiber meshwork comprises one or more fibers, wherein each of said one or more fibers has a diameter in the range 50 nm - 500 nm.
21. The medical device of claim 1 wherein the fiber meshwork comprises one or more fibers, wherein each of said one or more fibers has a diameter < 1 μm.
22. The medical device of claim 21 wherein each of said one or more fibers has a uniform diameter along its length.
23. The medical device of claim 1 wherein the fiber meshwork contains at least one pharmaceutically active ingredient.
24. The medical device of claim 20 wherein the fiber meshwork comprises at least two fibers, including a first fiber of a first type of material, and a second fiber of a second type of material.
25. The medical device of claim 24 wherein the first type of material has a first pharmaceutically active ingredient absorbed within it, and the second type of material has a second pharmaceutically active ingredient absorbed within it.
26. The medical device of claim 1, wherein the fiber meshwork comprises a composition selected from the group consisting of: poly(D,L-lactide-co-glycolide); magnesium; iron, or zinc.
27. The medical device of claim 1 further comprising a layer-by-layer coating situated on the fiber meshwork.
28. The medical device of claim 26, wherein the layer-by-layer coating comprises a first layer of a first polyelectrolyte, and a second layer of a second polyelectrolyte.
29. The medical device of claim 27, wherein the first polyelectrolyte is positively charged and the second polyelectrolyte is negatively charged, or vice versa.
30. The medical device of claim 26, wherein the layer-by-layer coating comprises at least 10 layers.
31. The medical device of claim 26, wherein the layer-by-layer coating comprises at most 300 layers.
32. The medical device of claim 26, wherein the layer-by-layer coating further comprises a therapeutic agent.
33. The medical device of claim 26, wherein the layer-by-layer coating further comprises nanoparticles.
34. The medical device of claim 1 wherein the underlying structure is generally tubular in shape.
35. The medical device of claim 1 wherein the underlying structure comprises a first ring and a second ring, wherein the first ring and the second ring are connected to one another by the fiber meshwork.
36. The medical device of claim 34 wherein the first ring is made of a first material and wherein the second ring is made of a second material, and wherein the first material and the second material are different from a material of which the fiber meshwork is comprised.
37. The medical device of claim 35 wherein the first material and the second material are each independently selected from the group consisting of: nitinol, magnesium, and steel.
38. A medical device for implantation into an organism, comprising: an underlying structure; and a fiber meshwork disposed upon the structure, wherein the fiber meshwork is configured to ensure steady biodisintegration of the underlying structure over a first period of time inside the organism.
39. The medical device of claim 38 wherein the first period of time is between about 60 days and about 1,000 days.
40. The medical device of claim 38 wherein the first period of time is between about 120 days and about 750 days.
41. The medical device of claim 38 wherein the first period of time is between about 180 days and about 600 days.
42. The medical device of claim 38 wherein the biodisintegration comprises a mass reduction of at least about 50% of the structure.
43. The medical device of claim 38, wherein the fiber meshwork additionally effects controlled release of a pharmaceutically active agent absorbed therein over a second period of time inside the organism.
44. The medical device of claim 43 wherein the second period of time is between about 60 days and about 1,000 days.
45. The medical device of claim 43 wherein the second period of time is between about 120 days and about 750 days.
46. The medical device of claim 43 wherein the second period of time is between about 180 days and about 600 days.
47. The medical device according to claim 38, further comprising a multi-layer structure disposed upon the fiber meshwork.
48. The medical device according to claim 47 wherein the multi-layer structure comprises alternating layers formed of molecules having opposite charges to one another.
49. The medical device of claim 38, wherein the device is an endoprosthesis.
50. A medical device comprising a fiber meshwork formed of a material that is deposited by FFESS on to an underlying structure.
51. The medical device of claim 50 wherein the underlying structure is biodisintegrable.
52. A method of making a medical device according to any one of claims 1, 38, or 50.
53. A method of using a medical device according to any one of claims 1, 38, or 50, comprising: implanting the medical device in a body passageway of an organism.
54. A method of achieving steady disintegration of a medical device in an organism, comprising: forming said device by depositing a fiber meshwork on to an underlying structure; and implanting the device into the organism; wherein the disintegration of the underlying structure occurs over a first period of time inside the organism.
55. The method of claim 54 wherein the fiber meshwork degrades over a second period of time, wherein the second period of time is different from the first period of time.
56. The method of claim 54 wherein the depositing is carried out by FFESS.
57. The method of claim 54 wherein the implanting is carried out by: disposing the device on a catheter; inserting the catheter, with the device thereon, into the body passageway; placing the device at a predetermined position in the body passageway; and removing the catheter.
58. The method of claim 54 wherein the device is compacted prior to the disposing, and wherein the placing further comprises expanding the device at the predetermined position.
59. A method of effecting controlled release of a pharmaceutically active agent from a medical device, wherein the medical device is implanted in an organism, comprising: depositing a fiber meshwork containing a therapeutic agent on an underlying structure, wherein the fiber meshwork degrades over a period of time inside the organism and simultaneously releases the therapeutic agent.
60. The method of claim 59, wherein the device is an endoprosthesis.
PCT/US2007/066568 2006-04-12 2007-04-12 Endoprosthesis having a fiber meshwork disposed thereon WO2007121323A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07760597A EP2010099A2 (en) 2006-04-12 2007-04-12 Endoprosthesis having a fiber meshwork disposed thereon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/403,344 US8048150B2 (en) 2006-04-12 2006-04-12 Endoprosthesis having a fiber meshwork disposed thereon
US11/403,344 2006-04-12

Publications (2)

Publication Number Publication Date
WO2007121323A2 true WO2007121323A2 (en) 2007-10-25
WO2007121323A3 WO2007121323A3 (en) 2007-12-13

Family

ID=38476073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/066568 WO2007121323A2 (en) 2006-04-12 2007-04-12 Endoprosthesis having a fiber meshwork disposed thereon

Country Status (3)

Country Link
US (1) US8048150B2 (en)
EP (1) EP2010099A2 (en)
WO (1) WO2007121323A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103768655A (en) * 2014-02-17 2014-05-07 苏州大学 Preparation method of porous tantalum skeleton
CN105664259A (en) * 2016-01-18 2016-06-15 铜仁学院 Method for constructing slow release system for medicament on surface of medical titanium alloy implant
CN107137788A (en) * 2017-04-28 2017-09-08 淮阴工学院 A kind of method for preparing chitosan/test tube of hepari graphene oxide composite multilayer membrane in medical magnesium alloy surface

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8458879B2 (en) * 2001-07-03 2013-06-11 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Method of fabricating an implantable medical device
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
US11207457B2 (en) * 2004-08-27 2021-12-28 Edwards Lifesciences Corporation Device and method for establishing an artificial arterio-venous fistula
WO2006099020A2 (en) * 2005-03-09 2006-09-21 The University Of Tennessee Research Foundation Barrier stent and use thereof
DE102005047235A1 (en) * 2005-10-01 2007-04-05 Grönemeyer, Dietrich H. W., Prof. Dr.med. MR-compatible vascular endoprosthesis
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070203564A1 (en) * 2006-02-28 2007-08-30 Boston Scientific Scimed, Inc. Biodegradable implants having accelerated biodegradation properties in vivo
US20070224235A1 (en) 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
WO2008002778A2 (en) 2006-06-29 2008-01-03 Boston Scientific Limited Medical devices with selective coating
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
JP2010503469A (en) 2006-09-14 2010-02-04 ボストン サイエンティフィック リミテッド Medical device having drug-eluting film
CA2663220A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices and methods of making the same
US20080071340A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Implantable electrodes with polyoxometalates
US8128689B2 (en) * 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
JP2010503489A (en) 2006-09-15 2010-02-04 ボストン サイエンティフィック リミテッド Biodegradable endoprosthesis and method for producing the same
CA2663271A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
WO2008036548A2 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
US7981150B2 (en) * 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US7991483B1 (en) * 2006-12-21 2011-08-02 Boston Scientific Neuromodulation Corporation Implantable electrodes containing polyoxometalate anions and methods of manufacture and use
EP2125065B1 (en) 2006-12-28 2010-11-17 Boston Scientific Limited Bioerodible endoprostheses and methods of making same
US7758635B2 (en) * 2007-02-13 2010-07-20 Boston Scientific Scimed, Inc. Medical device including cylindrical micelles
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US20100070020A1 (en) 2008-06-11 2010-03-18 Nanovasc, Inc. Implantable Medical Device
US20100331957A1 (en) * 2007-06-11 2010-12-30 Nanovasc, Inc. Implantable medical device
US20090018643A1 (en) * 2007-06-11 2009-01-15 Nanovasc, Inc. Stents
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
EP2187988B1 (en) 2007-07-19 2013-08-21 Boston Scientific Limited Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
JP2010535541A (en) 2007-08-03 2010-11-25 ボストン サイエンティフィック リミテッド Coating for medical devices with large surface area
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US8118857B2 (en) * 2007-11-29 2012-02-21 Boston Scientific Corporation Medical articles that stimulate endothelial cell migration
EP2271380B1 (en) 2008-04-22 2013-03-20 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
JP5140857B2 (en) * 2008-05-12 2013-02-13 株式会社大野興業 Method for producing soft blood vessel model for surgical simulation
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
CN102196826A (en) * 2008-08-27 2011-09-21 波士顿科学医学有限公司 Medical devices having inorganic coatings for therapeutic agent delivery
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8389083B2 (en) * 2008-10-17 2013-03-05 Boston Scientific Scimed, Inc. Polymer coatings with catalyst for medical devices
US9427304B2 (en) * 2008-10-27 2016-08-30 St. Jude Medical, Cardiology Division, Inc. Multi-layer device with gap for treating a target site and associated method
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8257640B2 (en) 2009-08-07 2012-09-04 Zeus Industrial Products, Inc. Multilayered composite structure with electrospun layer
CN102282301B (en) 2009-01-16 2014-07-30 Zeus工业品公司 Electrospinning of ptfe with high viscosity materials
US20130268062A1 (en) 2012-04-05 2013-10-10 Zeus Industrial Products, Inc. Composite prosthetic devices
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
WO2010108124A2 (en) * 2009-03-19 2010-09-23 Nanostatics Corporation Fluid formulations for electric-field-driven spinning of fibers
WO2010123668A1 (en) * 2009-04-20 2010-10-28 Rox Medical, Inc. Device and method for establishing an artificial arterio-venous fistula
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US9889012B2 (en) 2009-07-23 2018-02-13 Didier NIMAL Biomedical device, method for manufacturing the same and use thereof
EP2456473B1 (en) * 2009-07-23 2016-02-17 Didier Nimal Biomedical device, method for manufacturing the same and use thereof
US9114197B1 (en) 2014-06-11 2015-08-25 Silver Bullett Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US10265435B2 (en) 2009-08-27 2019-04-23 Silver Bullet Therapeutics, Inc. Bone implant and systems and coatings for the controllable release of antimicrobial metal ions
WO2011031548A2 (en) 2009-08-27 2011-03-17 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US9821094B2 (en) 2014-06-11 2017-11-21 Silver Bullet Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US8927004B1 (en) 2014-06-11 2015-01-06 Silver Bullet Therapeutics, Inc. Bioabsorbable substrates and systems that controllably release antimicrobial metal ions
FR2949688B1 (en) * 2009-09-04 2012-08-24 Sofradim Production FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER
WO2011119573A1 (en) 2010-03-23 2011-09-29 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
RU2012157314A (en) * 2010-05-27 2014-07-10 Хемотек Аг APPLICATIONS FOR ENDOPROTHESIS OF COATING CONSISTING OF A DENSE NET OF POLYMERIC FIBERS
KR20130125287A (en) 2010-05-29 2013-11-18 애쉴리 에스. 스코트 Apparatus, methods, and fluid compositions for electrostatically-driven solvent ejection or particle formation
WO2012009661A2 (en) * 2010-07-15 2012-01-19 Fibralign Corporation Conductive biopolymer implant for enhancing tissue repair and regeneration using electromagnetic fields
WO2012034110A2 (en) 2010-09-10 2012-03-15 Fibralign Corp. Biodegradable multilayer constructs
JP2013520584A (en) 2010-10-14 2013-06-06 ゼウス インダストリアル プロダクツ インコーポレイテッド Antibacterial substrate
WO2012064402A1 (en) 2010-11-12 2012-05-18 Silver Bullet Therapeutics, Inc. Bone implant and systems that controllably releases silver
US10653511B2 (en) 2011-01-28 2020-05-19 Merit Medical Systems, Inc. Electrospun PTFE coated stent and method of use
KR101208286B1 (en) * 2011-04-26 2012-12-05 삼성전기주식회사 A Multi-Layered thin film for ceramic electronic parts and a manufacturing method thereof
TWI424860B (en) * 2011-05-31 2014-02-01 Far Eastern New Century Corp High water absorption antibacterial dressing
WO2013013648A1 (en) * 2011-07-27 2013-01-31 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Implant
GB201116879D0 (en) * 2011-09-30 2011-11-16 Magnus Stent Ic Endoprosthesis
US11623438B2 (en) 2012-01-16 2023-04-11 Merit Medical Systems, Inc. Rotational spun material covered medical appliances and methods of manufacture
US10507268B2 (en) 2012-09-19 2019-12-17 Merit Medical Systems, Inc. Electrospun material covered medical appliances and methods of manufacture
US9198999B2 (en) 2012-09-21 2015-12-01 Merit Medical Systems, Inc. Drug-eluting rotational spun coatings and methods of use
CN102988122B (en) * 2012-11-13 2013-11-06 浦易(上海)生物技术有限公司 Prosthetic system for treating nasosinusitis or allergic rhinitis
GB2528404A (en) * 2013-03-11 2016-01-20 Univ North Carolina State Functionalized environmentally benign nanoparticles
EP2967929B1 (en) 2013-03-13 2017-11-29 Merit Medical Systems, Inc. Methods, systems, and apparatuses for manufacturing rotational spun appliances
EP3988278A1 (en) 2013-03-13 2022-04-27 Merit Medical Systems, Inc. Serially deposited fiber materials and associated devices and methods
CA2933486C (en) * 2013-12-12 2022-05-03 Hollister Incorporated Water disintegrable flushable catheter with a hydrophilic coating
WO2015100238A1 (en) * 2013-12-27 2015-07-02 Neograft Technologies, Inc. Artificial graft devices and related systems and methods
WO2015157281A1 (en) 2014-04-08 2015-10-15 Boston Scientific Scimed, Inc. Partially coated stents
US9452242B2 (en) 2014-06-11 2016-09-27 Silver Bullet Therapeutics, Inc. Enhancement of antimicrobial silver, silver coatings, or silver platings
KR20170122733A (en) 2015-02-26 2017-11-06 메리트 메디컬 시스템즈, 인크. Multilayer medical devices and methods
WO2017015571A1 (en) 2015-07-23 2017-01-26 Novaflux, Inc. Implants and constructs including hollow fibers
JP2017029300A (en) * 2015-07-30 2017-02-09 グンゼ株式会社 Reinforcement member of artificial blood vessel
US10201567B2 (en) 2015-10-15 2019-02-12 Under Armour, Inc. Article of apparel for topical delivery of bioresorbable material
CN109069279B (en) * 2016-01-09 2021-05-11 埃因霍温科技大学 Fibrous tubular catheter for stent applications
CN107449819B (en) * 2016-06-06 2020-12-22 青岛大学 Anti-protein adsorption capillary column and preparation method thereof
US10201639B2 (en) * 2017-05-01 2019-02-12 480 Biomedical, Inc. Drug-eluting medical implants
CN110064074A (en) * 2018-01-23 2019-07-30 苏州博创同康生物工程有限公司 A kind of compound support frame material and its preparation method and application
CN111569160B (en) * 2020-05-26 2021-05-11 四川大学 Multifunctional stent coating based on recombinant human collagen and preparation method thereof
US11744702B1 (en) * 2020-07-01 2023-09-05 Aortic Innovations, Llc Transcatheter aortic valve repair and replacement
EP4032560A1 (en) * 2021-01-25 2022-07-27 Centre National pour la Recherche Scientifique Implantable material in contact with blood and uses thereof
WO2023125434A1 (en) * 2021-12-31 2023-07-06 元心科技(深圳)有限公司 Covered stent system and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923912A2 (en) * 1997-12-18 1999-06-23 Schneider (Usa) Inc. Stent-graft with bioabsorbable structural support

Family Cites Families (1107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2950187A (en) 1958-09-05 1960-08-23 Res Inst Iron Steel Iron-calcium base alloy
US3560362A (en) * 1966-08-03 1971-02-02 Japan Atomic Energy Res Inst Method and apparatus for promoting chemical reactions by means of radioactive inert gases
US3569660A (en) 1968-07-29 1971-03-09 Nat Res Dev Laser cutting apparatus
GB1237035A (en) 1969-08-20 1971-06-30 Tsi Travmatologii I Ortopedii Magnesium-base alloy for use in bone surgery
US3758396A (en) 1971-08-31 1973-09-11 Research Corp Ition preparation of immobilized enzymemembrane complexes by electrocodepos
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3868578A (en) * 1972-10-02 1975-02-25 Canadian Patents Dev Method and apparatus for electroanalysis
US3910819A (en) 1974-02-19 1975-10-07 California Inst Of Techn Treatment of surfaces to stimulate biological cell adhesion and growth
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3952334A (en) 1974-11-29 1976-04-27 General Atomic Company Biocompatible carbon prosthetic devices
US4002877A (en) * 1974-12-13 1977-01-11 United Technologies Corporation Method of cutting with laser radiation and liquid coolant
US4101984A (en) 1975-05-09 1978-07-25 Macgregor David C Cardiovascular prosthetic devices and implants with porous systems
DE2620907C3 (en) 1976-05-12 1984-09-20 Battelle-Institut E.V., 6000 Frankfurt Anchoring for highly stressed endoprostheses
US4143661A (en) 1977-12-12 1979-03-13 Andros Incorporated Power supply for body implant and method for operation
DE2827529C2 (en) 1978-06-23 1982-09-30 Battelle-Institut E.V., 6000 Frankfurt Implantable bone replacement material consisting of a metal core and bioactive, sintered calcium phosphate ceramic particles and a process for its production
US4713070A (en) 1978-11-30 1987-12-15 Sumitom Electric Industries, Ltd. Porous structure of polytetrafluoroethylene and process for production thereof
US4237559A (en) 1979-05-11 1980-12-09 General Electric Company Bone implant embodying a composite high and low density fired ceramic construction
US4334327A (en) 1979-12-21 1982-06-15 University Of Utah Ureteral prosthesis
US4308868A (en) * 1980-05-27 1982-01-05 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Implantable electrical device
CH649578A5 (en) 1981-03-27 1985-05-31 Ulvac Corp HIGH-SPEED CATHODE SPRAYING DEVICE.
US4542539A (en) 1982-03-12 1985-09-24 Artech Corp. Surgical implant having a graded porous coating
SE445884B (en) 1982-04-30 1986-07-28 Medinvent Sa DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION
US4539061A (en) 1983-09-07 1985-09-03 Yeda Research And Development Co., Ltd. Process for the production of built-up films by the stepwise adsorption of individual monolayers
US4657544A (en) 1984-04-18 1987-04-14 Cordis Corporation Cardiovascular graft and method of forming same
US5938903A (en) 1984-05-09 1999-08-17 Research Foundation Of The City University Of New York Microelectrodes and their use in an electrochemical arrangement with telemetric application
US4532929A (en) 1984-07-23 1985-08-06 Ethicon, Inc. Dry coating of surgical filaments
US4634502A (en) 1984-11-02 1987-01-06 The Standard Oil Company Process for the reductive deposition of polyoxometallates
US4585652A (en) 1984-11-19 1986-04-29 Regents Of The University Of Minnesota Electrochemical controlled release drug delivery system
US4665896A (en) 1985-07-22 1987-05-19 Novacor Medical Corporation Power supply for body implant and method of use
DE3682734D1 (en) 1985-08-23 1992-01-16 Kanegafuchi Chemical Ind ARTIFICIAL VESSEL.
US4705502A (en) 1985-11-06 1987-11-10 The Kendall Company Suprapubic catheter with dual balloons
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4767418A (en) 1986-02-13 1988-08-30 California Institute Of Technology Luminal surface fabrication for cardiovascular prostheses
DE3608158A1 (en) 1986-03-12 1987-09-17 Braun Melsungen Ag VESSELED PROSTHESIS IMPREGNATED WITH CROSSLINED GELATINE AND METHOD FOR THE PRODUCTION THEREOF
SE453258B (en) 1986-04-21 1988-01-25 Medinvent Sa ELASTIC, SELF-EXPANDING PROTEST AND PROCEDURE FOR ITS MANUFACTURING
CH670760A5 (en) 1986-06-02 1989-07-14 Sulzer Ag
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4827940A (en) 1987-04-13 1989-05-09 Cardiac Pacemakers, Inc. Soluble covering for cardiac pacing electrode
US5059211A (en) 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US5527337A (en) 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US5024671A (en) 1988-09-19 1991-06-18 Baxter International Inc. Microporous vascular graft
US5091205A (en) 1989-01-17 1992-02-25 Union Carbide Chemicals & Plastics Technology Corporation Hydrophilic lubricious coatings
CH678393A5 (en) 1989-01-26 1991-09-13 Ulrich Prof Dr Med Sigwart
US5163958A (en) 1989-02-02 1992-11-17 Cordis Corporation Carbon coated tubular endoprosthesis
US4994071A (en) 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5073365A (en) 1989-06-01 1991-12-17 Advanced Polymer Systems Clinical and personal care articles enhanced by lubricants and adjuvants
US5061914A (en) 1989-06-27 1991-10-29 Tini Alloy Company Shape-memory alloy micro-actuator
DE69027061T2 (en) 1989-06-30 1997-01-02 Tdk Corp Substitute material for living hard tissue, its manufacture and manufacture of a shaped body
US5091024A (en) 1989-07-13 1992-02-25 Carpenter Technology Corporation Corrosion resistant, magnetic alloy article
US5649951A (en) 1989-07-25 1997-07-22 Smith & Nephew Richards, Inc. Zirconium oxide and zirconium nitride coated stents
ATE91638T1 (en) 1989-09-25 1993-08-15 Schneider Usa Inc MULTI-LAYER EXTRUSION AS A PROCESS FOR MANUFACTURING BALLOONS FOR VESSEL PLASTIC.
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
US5477864A (en) 1989-12-21 1995-12-26 Smith & Nephew Richards, Inc. Cardiovascular guidewire of enhanced biocompatibility
US5545208A (en) 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5236413B1 (en) 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
EP0484533B1 (en) 1990-05-19 1995-01-25 Anatoly Nikiforovich Papyrin Method and device for coating
US5079203A (en) 1990-05-25 1992-01-07 Board Of Trustees Operating Michigan State University Polyoxometalate intercalated layered double hydroxides
US5587507A (en) 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
US5120322A (en) 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5102403A (en) 1990-06-18 1992-04-07 Eckhard Alt Therapeutic medical instrument for insertion into body
US5236447A (en) 1990-06-29 1993-08-17 Nissho Corporation Artificial tubular organ
US5549664A (en) 1990-07-31 1996-08-27 Ube Industries, Ltd. Artificial blood vessel
US4976692A (en) 1990-09-13 1990-12-11 Travenol Laboratories (Israel) Ltd. Catheter particularly useful for inducing labor and/or for the application of a pharmaceutical substance to the cervix of the uterus
US5160790A (en) 1990-11-01 1992-11-03 C. R. Bard, Inc. Lubricious hydrogel coatings
US6524274B1 (en) 1990-12-28 2003-02-25 Scimed Life Systems, Inc. Triggered release hydrogel drug delivery system
US5205921A (en) 1991-02-04 1993-04-27 Queen's University At Kingston Method for depositing bioactive coatings on conductive substrates
DE4104359A1 (en) * 1991-02-13 1992-08-20 Implex Gmbh CHARGING SYSTEM FOR IMPLANTABLE HOERHILFEN AND TINNITUS MASKERS
USRE38653E1 (en) 1991-03-08 2004-11-16 Kabushikikaisha Igaki Iryo Sekkei Luminal stent, holding structure therefor and device for attaching luminal stent
US5195969A (en) 1991-04-26 1993-03-23 Boston Scientific Corporation Co-extruded medical balloons and catheter using such balloons
US5147370A (en) 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
US5258098A (en) 1991-06-17 1993-11-02 Cycam, Inc. Method of production of a surface adapted to promote adhesion
US5292558A (en) 1991-08-08 1994-03-08 University Of Texas At Austin, Texas Process for metal deposition for microelectronic interconnections
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US6107004A (en) 1991-09-05 2000-08-22 Intra Therapeutics, Inc. Method for making a tubular stent for use in medical applications
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5464450A (en) 1991-10-04 1995-11-07 Scimed Lifesystems Inc. Biodegradable drug delivery vascular stent
US5500013A (en) 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
WO1993006792A1 (en) 1991-10-04 1993-04-15 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5234457A (en) 1991-10-09 1993-08-10 Boston Scientific Corporation Impregnated stent
US5366504A (en) 1992-05-20 1994-11-22 Boston Scientific Corporation Tubular medical prosthesis
JP2961287B2 (en) 1991-10-18 1999-10-12 グンゼ株式会社 Biological duct dilator, method for producing the same, and stent
WO1993007924A1 (en) 1991-10-18 1993-04-29 Spire Corporation Bactericidal coatings for implants
CA2079417C (en) 1991-10-28 2003-01-07 Lilip Lau Expandable stents and method of making same
US5314453A (en) 1991-12-06 1994-05-24 Spinal Cord Society Position sensitive power transfer antenna
EP0791333B1 (en) 1991-12-12 1999-12-01 Target Therapeutics, Inc. Detachable pusher-vasoocclusive coil assembly with interlocking coupling
US5348553A (en) 1991-12-18 1994-09-20 Whitney Douglass G Method for promoting blood vessel healing
US5193540A (en) 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5360440A (en) 1992-03-09 1994-11-01 Boston Scientific Corporation In situ apparatus for generating an electrical current in a biological environment
DE69326631T2 (en) 1992-03-19 2000-06-08 Medtronic Inc Intraluminal expansion device
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5282823A (en) 1992-03-19 1994-02-01 Medtronic, Inc. Intravascular radially expandable stent
US5591224A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Bioelastomeric stent
US5779904A (en) 1992-03-31 1998-07-14 Inrad Synthesis of inorganic membranes on supports
JPH07505316A (en) 1992-03-31 1995-06-15 ボストン サイエンティフィック コーポレーション medical wire
GEP20002074B (en) * 1992-05-19 2000-05-10 Westaim Tech Inc Ca Modified Material and Method for its Production
CA2074318A1 (en) * 1992-07-22 1994-01-23 Morteza Shirkhanzadeh Prosthetic implant with self-generated current for early fixation in skeletal bone
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5447533A (en) 1992-09-03 1995-09-05 Pacesetter, Inc. Implantable stimulation lead having an advanceable therapeutic drug delivery system
US5458627A (en) 1992-10-15 1995-10-17 Electro-Biology, Inc. Electrochemically controlled faradic stimulation of osteogenesis
US5449382A (en) 1992-11-04 1995-09-12 Dayton; Michael P. Minimally invasive bioactivated endoprosthesis for vessel repair
US5578075B1 (en) 1992-11-04 2000-02-08 Daynke Res Inc Minimally invasive bioactivated endoprosthesis for vessel repair
US5322520A (en) 1992-11-12 1994-06-21 Implemed, Inc. Iontophoretic structure for medical devices
US5385776A (en) * 1992-11-16 1995-01-31 Alliedsignal Inc. Nanocomposites of gamma phase polymers containing inorganic particulate material
US5342348A (en) 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5443458A (en) 1992-12-22 1995-08-22 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method of manufacture
JP2746755B2 (en) 1993-01-19 1998-05-06 シュナイダー(ユーエスエー)インク Clad composite stent
US5607463A (en) 1993-03-30 1997-03-04 Medtronic, Inc. Intravascular medical device
US5380298A (en) * 1993-04-07 1995-01-10 The United States Of America As Represented By The Secretary Of The Navy Medical device with infection preventing feature
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5824048A (en) 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
US5518767A (en) 1993-07-01 1996-05-21 Massachusetts Institute Of Technology Molecular self-assembly of electrically conductive polymers
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
ES2157977T3 (en) 1993-07-23 2001-09-01 Cook Inc FLEXIBLE PROBE THAT HAS A CONFORMED CONFIGURATION FROM A MATERIAL SHEET.
US6776094B1 (en) 1993-10-04 2004-08-17 President & Fellows Of Harvard College Kit For Microcontact Printing
US5776748A (en) 1993-10-04 1998-07-07 President And Fellows Of Harvard College Method of formation of microstamped patterns on plates for adhesion of cells and other biological materials, devices and uses therefor
US6176874B1 (en) 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
US5721049A (en) 1993-11-15 1998-02-24 Trustees Of The University Of Pennsylvania Composite materials using bone bioactive glass and ceramic fibers
US5397307A (en) 1993-12-07 1995-03-14 Schneider (Usa) Inc. Drug delivery PTCA catheter and method for drug delivery
US5462575A (en) 1993-12-23 1995-10-31 Crs Holding, Inc. Co-Cr-Mo powder metallurgy articles and process for their manufacture
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5449373A (en) 1994-03-17 1995-09-12 Medinol Ltd. Articulated stent
JPH07257079A (en) 1994-03-25 1995-10-09 Dainippon Printing Co Ltd Optical card
CA2188563C (en) 1994-04-29 2005-08-02 Andrew W. Buirge Stent with collagen
US5468574A (en) 1994-05-23 1995-11-21 Dais Corporation Fuel cell incorporating novel ion-conducting membrane
US6185457B1 (en) 1994-05-31 2001-02-06 Galvani, Ltd. Method and apparatus for electrically forcing cardiac output in an arrhythmia patient
US5629077A (en) 1994-06-27 1997-05-13 Advanced Cardiovascular Systems, Inc. Biodegradable mesh and film stent
US5788979A (en) 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
US5891108A (en) 1994-09-12 1999-04-06 Cordis Corporation Drug delivery stent
US5649977A (en) 1994-09-22 1997-07-22 Advanced Cardiovascular Systems, Inc. Metal reinforced polymer stent
KR100386182B1 (en) 1994-10-24 2004-02-25 소니 가부시끼 가이샤 Electron gun of cathode ray tube and manufacturing method of cathode ray tube
US5836964A (en) 1996-10-30 1998-11-17 Medinol Ltd. Stent fabrication method
DE4440386A1 (en) 1994-11-11 1996-05-15 Pacesetter Ab Electrodes for medical applications
CA2163824C (en) 1994-11-28 2000-06-20 Richard J. Saunders Method and apparatus for direct laser cutting of metal stents
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5755722A (en) 1994-12-22 1998-05-26 Boston Scientific Corporation Stent placement device with medication dispenser and method
US6017577A (en) * 1995-02-01 2000-01-25 Schneider (Usa) Inc. Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices
US6981986B1 (en) * 1995-03-01 2006-01-03 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
US7204848B1 (en) 1995-03-01 2007-04-17 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
US6124523A (en) 1995-03-10 2000-09-26 Impra, Inc. Encapsulated stent
US6306144B1 (en) 1996-11-01 2001-10-23 Scimed Life Systems, Inc. Selective coating of a balloon catheter with lubricious material for stent deployment
US5605696A (en) 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
WO1996031306A1 (en) 1995-04-03 1996-10-10 Mitsubishi Materials Corporation Porous metallic body with large specific surface area, process for producing the same, porous metallic platy material, and electrode of alkaline secondary battery
CA2216943C (en) 1995-04-19 2003-06-17 Schneider (Usa) Inc. Drug release coated stent
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6027742A (en) 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
AU720963B2 (en) 1995-05-26 2000-06-15 Surmodics, Inc. Method and implantable article for promoting endothelialization
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7550005B2 (en) 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US5676685A (en) 1995-06-22 1997-10-14 Razavi; Ali Temporary stent
US5840387A (en) 1995-07-28 1998-11-24 Aegis Biosciences L.L.C. Sulfonated multiblock copolymer and uses therefor
NZ315995A (en) 1995-09-01 1999-09-29 Millenium Biologix Inc Artificial sintered composition comprising stabilised calcium phosphate phases capable of supporting bone cell activity
EP0765660A3 (en) 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules comprising 2-piperazinone-1-acetic acid compounds
EP0957979B1 (en) 1995-09-29 2007-05-23 Vyteris, Inc. Low-cost electrodes for an iontophoretic device
AU716594B2 (en) 1995-09-29 2000-03-02 Medtronic, Inc. Adaptive search AV and auto PVARP adaptation to same with additional benefit
US5758562A (en) 1995-10-11 1998-06-02 Schneider (Usa) Inc. Process for manufacturing braided composite prosthesis
DE19539449A1 (en) 1995-10-24 1997-04-30 Biotronik Mess & Therapieg Process for the production of intraluminal stents from bioresorbable polymer material
US5603556A (en) 1995-11-20 1997-02-18 Technical Services And Marketing, Inc. Rail car load sensor
US5788626A (en) 1995-11-21 1998-08-04 Schneider (Usa) Inc Method of making a stent-graft covered with expanded polytetrafluoroethylene
DE19544750A1 (en) 1995-11-30 1997-06-05 Christoph Rehberg Implantable device with internal electrode to promote tissue growth
US5658327A (en) 1995-12-19 1997-08-19 Ventritex, Inc. Intracardiac lead having a compliant fixation device
US5800512A (en) 1996-01-22 1998-09-01 Meadox Medicals, Inc. PTFE vascular graft
WO1997027959A1 (en) 1996-01-30 1997-08-07 Medtronic, Inc. Articles for and methods of making stents
US5672242A (en) 1996-01-31 1997-09-30 Integrated Device Technology, Inc. High selectivity nitride to oxide etch process
WO1997029802A2 (en) 1996-02-20 1997-08-21 Advanced Bionics Corporation Improved implantable microstimulator and systems employing the same
US5951458A (en) 1996-02-29 1999-09-14 Scimed Life Systems, Inc. Local application of oxidizing agents to prevent restenosis
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
CA2199890C (en) 1996-03-26 2002-02-05 Leonard Pinchuk Stents and stent-grafts having enhanced hoop strength and methods of making the same
US5976454A (en) 1996-04-01 1999-11-02 Basf Aktiengesellschaft Process for producing open-celled, inorganic sintered foam products
US5880661A (en) 1996-04-01 1999-03-09 Emf Therapeutics, Inc. Complex magnetic field generating device
US5922021A (en) 1996-04-26 1999-07-13 Jang; G. David Intravascular stent
US20040106985A1 (en) 1996-04-26 2004-06-03 Jang G. David Intravascular stent
US6783543B2 (en) 2000-06-05 2004-08-31 Scimed Life Systems, Inc. Intravascular stent with increasing coating retaining capacity
US5891191A (en) 1996-04-30 1999-04-06 Schneider (Usa) Inc Cobalt-chromium-molybdenum alloy stent and stent-graft
US6592617B2 (en) 1996-04-30 2003-07-15 Boston Scientific Scimed, Inc. Three-dimensional braided covered stent
US5951881A (en) 1996-07-22 1999-09-14 President And Fellows Of Harvard College Fabrication of small-scale cylindrical articles
US5693928A (en) 1996-06-27 1997-12-02 International Business Machines Corporation Method for producing a diffusion barrier and polymeric article having a diffusion barrier
US5769884A (en) 1996-06-27 1998-06-23 Cordis Corporation Controlled porosity endovascular implant
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6253252B1 (en) 1996-07-11 2001-06-26 Andrew Schofield Method and apparatus for asynchronously calling and implementing objects
US5941843A (en) 1996-07-12 1999-08-24 Empi, Inc. Iontophoresis electrode
US5741331A (en) 1996-07-29 1998-04-21 Corvita Corporation Biostable elastomeric polymers having quaternary carbons
US6120535A (en) 1996-07-29 2000-09-19 Radiance Medical Systems, Inc. Microporous tubular prosthesis
US5830217A (en) 1996-08-09 1998-11-03 Thomas J. Fogarty Soluble fixation device and method for stent delivery catheters
US6174329B1 (en) * 1996-08-22 2001-01-16 Advanced Cardiovascular Systems, Inc. Protective coating for a stent with intermediate radiopaque coating
US6756060B1 (en) 1996-09-19 2004-06-29 Usbiomaterials Corp. Anti-inflammatory and antimicrobial uses for bioactive glass compositions
US6953594B2 (en) 1996-10-10 2005-10-11 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
EP0941079B1 (en) 1996-10-16 2007-12-19 Etex Corporation Bioceramic compositions
US5761775A (en) 1996-10-17 1998-06-09 Legome; Mark J. Mushroom and loop material closure system for high shear strength and low peel strength applications
US5824045A (en) 1996-10-21 1998-10-20 Inflow Dynamics Inc. Vascular and endoluminal stents
US6099561A (en) 1996-10-21 2000-08-08 Inflow Dynamics, Inc. Vascular and endoluminal stents with improved coatings
US6387121B1 (en) 1996-10-21 2002-05-14 Inflow Dynamics Inc. Vascular and endoluminal stents with improved coatings
US6000601A (en) 1996-10-22 1999-12-14 Boston Scientific Corporation Welding method
US6530951B1 (en) 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US5852277A (en) 1996-10-24 1998-12-22 Spectralytics, Inc. Laser cutting tool for cutting elongated hollow workpieces
US5869141A (en) 1996-11-04 1999-02-09 The Boeing Company Surface pretreatment for sol coating of metals
US6106473A (en) 1996-11-06 2000-08-22 Sts Biopolymers, Inc. Echogenic coatings
US6447540B1 (en) 1996-11-15 2002-09-10 Cook Incorporated Stent deployment device including splittable sleeve containing the stent
US6114099A (en) 1996-11-21 2000-09-05 Virginia Tech Intellectual Properties, Inc. Patterned molecular self-assembly
ZA9710342B (en) 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6021347A (en) 1996-12-05 2000-02-01 Herbst; Ewa Electrochemical treatment of malignant tumors
US6251980B1 (en) 1996-12-06 2001-06-26 Amcol International Corporation Nanocomposites formed by onium ion-intercalated clay and rigid anhydride-cured epoxy resins
US5871437A (en) 1996-12-10 1999-02-16 Inflow Dynamics, Inc. Radioactive stent for treating blood vessels to prevent restenosis
US5906759A (en) 1996-12-26 1999-05-25 Medinol Ltd. Stent forming apparatus with stent deforming blades
IT1289815B1 (en) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa ANGIOPLASTIC STENT AND RELATED PRODUCTION PROCESS
US6013591A (en) * 1997-01-16 2000-01-11 Massachusetts Institute Of Technology Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production
US5858556A (en) * 1997-01-21 1999-01-12 Uti Corporation Multilayer composite tubular structure and method of making
EP0961597B8 (en) 1997-01-24 2005-12-28 Paragon Intellectual Properties, LLC Bistable spring construction for a stent
US8663311B2 (en) 1997-01-24 2014-03-04 Celonova Stent, Inc. Device comprising biodegradable bistable or multistable cells and methods of use
WO1998034673A1 (en) 1997-02-12 1998-08-13 Prolifix Medical, Inc. Apparatus for removal of material from stents
US6164284A (en) 1997-02-26 2000-12-26 Schulman; Joseph H. System of implantable devices for monitoring and/or affecting body parameters
US6139573A (en) 1997-03-05 2000-10-31 Scimed Life Systems, Inc. Conformal laminate stent device
US20020133222A1 (en) 1997-03-05 2002-09-19 Das Gladwin S. Expandable stent having a plurality of interconnected expansion modules
US5830229A (en) 1997-03-07 1998-11-03 Micro Therapeutics Inc. Hoop stent
US5815904A (en) 1997-03-13 1998-10-06 Intratherapeutics, Inc. Method for making a stent
US5977204A (en) 1997-04-11 1999-11-02 Osteobiologics, Inc. Biodegradable implant material comprising bioactive ceramic
US8172897B2 (en) 1997-04-15 2012-05-08 Advanced Cardiovascular Systems, Inc. Polymer and metal composite implantable medical devices
US10028851B2 (en) 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6240616B1 (en) 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
IT1292295B1 (en) 1997-04-29 1999-01-29 Sorin Biomedica Cardio Spa ANGIOPLASTIC STENT
DE19724223C1 (en) 1997-04-30 1998-12-24 Schering Ag Production of radioactive coated stent, especially at point of use
US5879697A (en) 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US5980554A (en) 1997-05-05 1999-11-09 Micro Therapeutics, Inc. Wire frame partial flow obstruction for aneurysm treatment
WO1998051238A1 (en) 1997-05-14 1998-11-19 Novo Rps Ulc Expandable stent and method for production of same
US6025036A (en) 1997-05-28 2000-02-15 The United States Of America As Represented By The Secretary Of The Navy Method of producing a film coating by matrix assisted pulsed laser deposition
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
US6203536B1 (en) 1997-06-17 2001-03-20 Medtronic, Inc. Medical device for delivering a therapeutic substance and method therefor
US5749809A (en) 1997-06-20 1998-05-12 Lin; Ting Fung Stepping and swinging exerciser
US6500174B1 (en) 1997-07-08 2002-12-31 Atrionix, Inc. Circumferential ablation device assembly and methods of use and manufacture providing an ablative circumferential band along an expandable member
US20020169493A1 (en) 1997-07-10 2002-11-14 Widenhouse Christopher W. Anti-thrombogenic coatings for biomedical devices
US5817046A (en) 1997-07-14 1998-10-06 Delcath Systems, Inc. Apparatus and method for isolated pelvic perfusion
FR2766092B1 (en) 1997-07-16 1999-10-08 Centre Nat Rech Scient IMPLANTABLE DEVICE COATED WITH A POLYMER CAPABLE OF RELEASING BIOLOGICALLY ACTIVE SUBSTANCES
DE19731021A1 (en) 1997-07-18 1999-01-21 Meyer Joerg In vivo degradable metallic implant
US5972192A (en) 1997-07-23 1999-10-26 Advanced Micro Devices, Inc. Pulse electroplating copper or copper alloys
US6245103B1 (en) 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
US6174330B1 (en) * 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
US5980564A (en) 1997-08-01 1999-11-09 Schneider (Usa) Inc. Bioabsorbable implantable endoprosthesis with reservoir
US5899935A (en) 1997-08-04 1999-05-04 Schneider (Usa) Inc. Balloon expandable braided stent with restraint
DE19734972A1 (en) 1997-08-13 1999-02-18 Cerdec Ag Gold-containing nanoporous alumina membranes, process for their preparation and their use
US6316522B1 (en) 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6143370A (en) 1997-08-27 2000-11-07 Northeastern University Process for producing polymer coatings with various porosities and surface areas
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6342507B1 (en) * 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US5972027A (en) 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
DE19746735C2 (en) 1997-10-13 2003-11-06 Simag Gmbh Systeme Und Instr F NMR imaging method for the display, position determination or functional control of a device inserted into an examination object and device for use in such a method
CA2218983C (en) 1997-10-21 2001-05-08 Mag R&D, Inc. Cathodic protective coating on magnesium or its alloys and method of producing the same
US6273908B1 (en) 1997-10-24 2001-08-14 Robert Ndondo-Lay Stents
KR100258043B1 (en) * 1997-10-27 2000-06-01 에릭 발리베 The control system for the auxiliary power unit of hybrid electrical vehicle
US6309414B1 (en) 1997-11-04 2001-10-30 Sorin Biomedica Cardio S.P.A. Angioplasty stents
ATE307110T1 (en) 1997-11-07 2005-11-15 Univ Rutgers RADIATION TRANSPARENT POLYMERIC BIOMATERIAL
CA2308177C (en) 1997-11-07 2005-01-25 Expandable Grafts Partnership Intravascular stent and method for manufacturing an intravascular stent
NO311781B1 (en) * 1997-11-13 2002-01-28 Medinol Ltd Metal multilayer stents
US5957975A (en) 1997-12-15 1999-09-28 The Cleveland Clinic Foundation Stent having a programmed pattern of in vivo degradation
US5976169A (en) 1997-12-16 1999-11-02 Cardiovasc, Inc. Stent with silver coating and method
US6212434B1 (en) 1998-07-22 2001-04-03 Cardiac Pacemakers, Inc. Single pass lead system
US6140740A (en) 1997-12-30 2000-10-31 Remon Medical Technologies, Ltd. Piezoelectric transducer
US6486588B2 (en) 1997-12-30 2002-11-26 Remon Medical Technologies Ltd Acoustic biosensor for monitoring physiological conditions in a body implantation site
US6120660A (en) 1998-02-11 2000-09-19 Silicon Genesis Corporation Removable liner design for plasma immersion ion implantation
CA2316945A1 (en) 1998-02-23 1999-08-26 Mnemoscience Gmbh Shape memory polymers
AU2891899A (en) 1998-03-05 1999-09-20 Boston Scientific Limited Intraluminal stent
US6139585A (en) 1998-03-11 2000-10-31 Depuy Orthopaedics, Inc. Bioactive ceramic coating and method
DE19811033C1 (en) 1998-03-13 1999-08-05 Aesculap Ag & Co Kg Lightweight surgical instrument, e.g. tweezers, forceps or scissors
US7547445B2 (en) 1998-03-19 2009-06-16 Surmodics, Inc. Crosslinkable macromers
EP0972563A1 (en) 1998-07-15 2000-01-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates
DE69904307T2 (en) 1998-03-19 2003-09-04 Max Planck Gesellschaft MANUFACTURE OF MULTILAYER-COATED PARTICLES AND HOLLOW SHELLS BY ELECTROSTATIC SELF-ORGANIZATION OF NANOCOMPOSITE MULTIPLE LAYERS ON DEGRADABLE STENCILS
US6241762B1 (en) * 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US5980566A (en) 1998-04-11 1999-11-09 Alt; Eckhard Vascular and endoluminal stents with iridium oxide coating
US6364856B1 (en) 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
US6206916B1 (en) 1998-04-15 2001-03-27 Joseph G. Furst Coated intraluminal graft
US20020099438A1 (en) 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US6436133B1 (en) 1998-04-15 2002-08-20 Joseph G. Furst Expandable graft
US6264687B1 (en) 1998-04-20 2001-07-24 Cordis Corporation Multi-laminate stent having superelastic articulated sections
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6270831B2 (en) 1998-04-30 2001-08-07 Medquest Products, Inc. Method and apparatus for providing a conductive, amorphous non-stick coating
ATE358456T1 (en) 1998-05-05 2007-04-15 Boston Scient Ltd STENT WITH SMOOTH ENDS
US6280411B1 (en) 1998-05-18 2001-08-28 Scimed Life Systems, Inc. Localized delivery of drug agents
US8177743B2 (en) 1998-05-18 2012-05-15 Boston Scientific Scimed, Inc. Localized delivery of drug agents
US6206283B1 (en) 1998-12-23 2001-03-27 At&T Corp. Method and apparatus for transferring money via a telephone call
US6086773A (en) 1998-05-22 2000-07-11 Bmc Industries, Inc. Method and apparatus for etching-manufacture of cylindrical elements
DE19856983A1 (en) 1998-06-25 1999-12-30 Biotronik Mess & Therapieg Implantable, bioresorbable vascular wall support, in particular coronary stent
DE59913189D1 (en) 1998-06-25 2006-05-04 Biotronik Ag Implantable, bioabsorbable vessel wall support, in particular coronary stent
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6652581B1 (en) 1998-07-07 2003-11-25 Boston Scientific Scimed, Inc. Medical device with porous surface for controlled drug release and method of making the same
US6261319B1 (en) 1998-07-08 2001-07-17 Scimed Life Systems, Inc. Stent
US6096175A (en) 1998-07-17 2000-08-01 Micro Therapeutics, Inc. Thin film stent
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US20040088041A1 (en) 1999-07-20 2004-05-06 Stanford Ulf Harry Expandable stent with array of relief cuts
US20020038146A1 (en) 1998-07-29 2002-03-28 Ulf Harry Expandable stent with relief cuts for carrying medicines and other materials
US20010032011A1 (en) 1999-07-20 2001-10-18 Stanford Ulf Harry Expandable stent with array of relief cuts
WO2000010622A1 (en) 1998-08-20 2000-03-02 Cook Incorporated Coated implantable medical device
US7235096B1 (en) 1998-08-25 2007-06-26 Tricardia, Llc Implantable device for promoting repair of a body lumen
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6755856B2 (en) 1998-09-05 2004-06-29 Abbott Laboratories Vascular Enterprises Limited Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation
US6206915B1 (en) 1998-09-29 2001-03-27 Medtronic Ave, Inc. Drug storing and metering stent
US6358276B1 (en) 1998-09-30 2002-03-19 Impra, Inc. Fluid containing endoluminal stent
US6245104B1 (en) 1999-02-28 2001-06-12 Inflow Dynamics Inc. Method of fabricating a biocompatible stent
US6217607B1 (en) 1998-10-20 2001-04-17 Inflow Dynamics Inc. Premounted stent delivery system for small vessels
DE19855421C2 (en) 1998-11-02 2001-09-20 Alcove Surfaces Gmbh Implant
US6348960B1 (en) 1998-11-06 2002-02-19 Kimotot Co., Ltd. Front scattering film
US6214042B1 (en) 1998-11-10 2001-04-10 Precision Vascular Systems, Inc. Micro-machined stent for vessels, body ducts and the like
US6477268B1 (en) 1998-11-17 2002-11-05 Industrial Technology Research Institute Producing transitions between vistas
US6984404B1 (en) * 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
US6263249B1 (en) 1999-02-26 2001-07-17 Medtronic, Inc. Medical electrical lead having controlled texture surface and method of making same
US6063101A (en) 1998-11-20 2000-05-16 Precision Vascular Systems, Inc. Stent apparatus and method
CN1145632C (en) * 1998-11-26 2004-04-14 因芬尼昂技术股份公司 Complex compound of element of sub-group IV
US20060178727A1 (en) 1998-12-03 2006-08-10 Jacob Richter Hybrid amorphous metal alloy stent
SE9804536D0 (en) 1998-12-23 1998-12-23 A & Science Invest Ab Biological implant and method of production thereof
US6517571B1 (en) 1999-01-22 2003-02-11 Gore Enterprise Holdings, Inc. Vascular graft with improved flow surfaces
US6955661B1 (en) 1999-01-25 2005-10-18 Atrium Medical Corporation Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US6264595B1 (en) 1999-02-04 2001-07-24 Mobeta, Inc. Radioactive transition metal stents
RU2218242C2 (en) 1999-02-11 2003-12-10 Физический институт им. П.Н. Лебедева РАН Method for making medical implants from biologically compatible materials
WO2000048530A1 (en) 1999-02-16 2000-08-24 Talison Research, Inc. Multilayer and multifunction vascular graft
US6231597B1 (en) 1999-02-16 2001-05-15 Mark E. Deem Apparatus and methods for selectively stenting a portion of a vessel wall
DE19948783C2 (en) 1999-02-18 2001-06-13 Alcove Surfaces Gmbh Implant
US6162238A (en) 1999-02-24 2000-12-19 Aaron V. Kaplan Apparatus and methods for control of body lumens
US6296604B1 (en) 1999-03-17 2001-10-02 Stereotaxis, Inc. Methods of and compositions for treating vascular defects
US6214037B1 (en) 1999-03-18 2001-04-10 Fossa Industries, Llc Radially expanding stent
US6364903B2 (en) 1999-03-19 2002-04-02 Meadox Medicals, Inc. Polymer coated stent
US6558422B1 (en) 1999-03-26 2003-05-06 University Of Washington Structures having coated indentations
US6312457B1 (en) 1999-04-01 2001-11-06 Boston Scientific Corporation Intraluminal lining
US6425855B2 (en) 1999-04-06 2002-07-30 Cordis Corporation Method for making a multi-laminate stent having superelastic articulated sections
US6325825B1 (en) 1999-04-08 2001-12-04 Cordis Corporation Stent with variable wall thickness
US6366808B1 (en) 2000-03-13 2002-04-02 Edward A. Schroeppel Implantable device and method for the electrical treatment of cancer
US6258117B1 (en) 1999-04-15 2001-07-10 Mayo Foundation For Medical Education And Research Multi-section stent
US6368658B1 (en) 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6607598B2 (en) 1999-04-19 2003-08-19 Scimed Life Systems, Inc. Device for protecting medical devices during a coating process
US6192271B1 (en) 1999-04-20 2001-02-20 Michael Hayman Radiotherapy stent
US6287335B1 (en) 1999-04-26 2001-09-11 William J. Drasler Intravascular folded tubular endoprosthesis
US6461731B1 (en) 1999-05-03 2002-10-08 Guardian Industries Corp. Solar management coating system including protective DLC
US6201991B1 (en) 1999-05-07 2001-03-13 Heart Care Associates, Llc Method of prevention and treatment of atherosclerosis and article of manufacture therefor
US6726712B1 (en) 1999-05-14 2004-04-27 Boston Scientific Scimed Prosthesis deployment device with translucent distal end
US6610035B2 (en) 1999-05-21 2003-08-26 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising a hybrid top coat
US6689160B1 (en) 1999-05-31 2004-02-10 Sumitomo Electric Industries, Ltd. Prosthesis for blood vessel
US6368346B1 (en) 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
WO2001000109A1 (en) 1999-06-24 2001-01-04 Biocompatibles Limited Balloon expandable stent
US6139913A (en) 1999-06-29 2000-10-31 National Center For Manufacturing Sciences Kinetic spray coating method and apparatus
US6409754B1 (en) 1999-07-02 2002-06-25 Scimed Life Systems, Inc. Flexible segmented stent
NO312106B1 (en) 1999-07-02 2002-03-18 Norsk Hydro As Method of improving the corrosion resistance of magnesium-aluminum-silicon alloys and magnesium alloy with improved corrosion resistance
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US20040073155A1 (en) 2000-01-14 2004-04-15 Broncus Technologies, Inc. Methods and devices for maintaining patency of surgically created channels in tissue
IT1307263B1 (en) 1999-08-05 2001-10-30 Sorin Biomedica Cardio Spa ANGIOPLASTIC STENT WITH RESTENOSIS ANTAGONIST ACTION, RELATED KIT AND COMPONENTS.
US6458162B1 (en) 1999-08-13 2002-10-01 Vita Special Purpose Corporation Composite shaped bodies and methods for their production and use
US6869701B1 (en) 1999-08-16 2005-03-22 Carolyn Aita Self-repairing ceramic coatings
US6503556B2 (en) * 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US6287628B1 (en) 1999-09-03 2001-09-11 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
DE19950386A1 (en) 1999-10-19 2001-05-10 Miladin Lazarov Biocompatible item
DE19951477A1 (en) 1999-10-26 2001-05-03 Biotronik Mess & Therapieg Stent
US8808272B2 (en) 1999-10-28 2014-08-19 Boston Scientific Scimed, Inc. Biocompatible medical devices
US6521284B1 (en) 1999-11-03 2003-02-18 Scimed Life Systems, Inc. Process for impregnating a porous material with a cross-linkable composition
US6733513B2 (en) 1999-11-04 2004-05-11 Advanced Bioprosthetic Surfaces, Ltd. Balloon catheter having metal balloon and method of making same
US7226475B2 (en) 1999-11-09 2007-06-05 Boston Scientific Scimed, Inc. Stent with variable properties
EP1690527B1 (en) 1999-11-17 2015-01-07 Boston Scientific Limited Microfabricated devices for the delivery of molecules into a carrier fluid
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US6936066B2 (en) 1999-11-19 2005-08-30 Advanced Bio Prosthetic Surfaces, Ltd. Complaint implantable medical devices and methods of making same
US6379383B1 (en) 1999-11-19 2002-04-30 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal device exhibiting improved endothelialization and method of manufacture thereof
US6458153B1 (en) * 1999-12-31 2002-10-01 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US7235092B2 (en) 1999-11-19 2007-06-26 Advanced Bio Prosthetic Surfaces, Ltd. Guidewires and thin film catheter-sheaths and method of making same
US7335426B2 (en) 1999-11-19 2008-02-26 Advanced Bio Prosthetic Surfaces, Ltd. High strength vacuum deposited nitinol alloy films and method of making same
US6849085B2 (en) 1999-11-19 2005-02-01 Advanced Bio Prosthetic Surfaces, Ltd. Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same
US7300457B2 (en) 1999-11-19 2007-11-27 Advanced Bio Prosthetic Surfaces, Ltd. Self-supporting metallic implantable grafts, compliant implantable medical devices and methods of making same
US6277078B1 (en) 1999-11-19 2001-08-21 Remon Medical Technologies, Ltd. System and method for monitoring a parameter associated with the performance of a heart
US7195641B2 (en) 1999-11-19 2007-03-27 Advanced Bio Prosthetic Surfaces, Ltd. Valvular prostheses having metal or pseudometallic construction and methods of manufacture
US6537310B1 (en) 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US20060013850A1 (en) * 1999-12-03 2006-01-19 Domb Abraham J Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom
ATE317711T1 (en) 1999-12-03 2006-03-15 Yissum Res Dev Co ELECTROPOLYMERIZABLE MONOMERS AND POLYMER COATINGS ON IMPLANTABLE DEVICES
US6602287B1 (en) 1999-12-08 2003-08-05 Advanced Cardiovascular Systems, Inc. Stent with anti-thrombogenic coating
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6554854B1 (en) 1999-12-10 2003-04-29 Scimed Life Systems, Inc. Process for laser joining dissimilar metals and endoluminal stent with radiopaque marker produced thereby
US6338739B1 (en) * 1999-12-22 2002-01-15 Ethicon, Inc. Biodegradable stent
US6613432B2 (en) 1999-12-22 2003-09-02 Biosurface Engineering Technologies, Inc. Plasma-deposited coatings, devices and methods
US6908624B2 (en) 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6471721B1 (en) 1999-12-30 2002-10-29 Advanced Cardiovascular Systems, Inc. Vascular stent having increased radiopacity and method for making same
WO2001049338A1 (en) 1999-12-30 2001-07-12 Li Wei Pin Controlled delivery of therapeutic agents by insertable medical devices
US6451177B1 (en) 2000-01-21 2002-09-17 Applied Materials, Inc. Vault shaped target and magnetron operable in two sputtering modes
EP1264001A1 (en) * 2000-01-25 2002-12-11 Boston Scientific Limited Manufacturing medical devices by vapor deposition
US6312463B1 (en) 2000-02-01 2001-11-06 Endotex Interventional Systems, Inc. Micro-porous mesh stent with hybrid structure
US6375826B1 (en) 2000-02-14 2002-04-23 Advanced Cardiovascular Systems, Inc. Electro-polishing fixture and electrolyte solution for polishing stents and method
US6440503B1 (en) 2000-02-25 2002-08-27 Scimed Life Systems, Inc. Laser deposition of elements onto medical devices
CA2337565A1 (en) 2000-02-25 2001-08-25 Cordis Corporation Use of cladribine on a stent to prevent restenosis
EP1132058A1 (en) * 2000-03-06 2001-09-12 Advanced Laser Applications Holding S.A. Intravascular prothesis
US6290722B1 (en) 2000-03-13 2001-09-18 Endovascular Technologies, Inc. Tacky attachment method of covered materials on stents
US6379382B1 (en) 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
KR100860860B1 (en) 2000-03-15 2008-09-29 오르버스네이치 메디칼 인코포레이티드 Coating that promotes endothelial cell adherence
US20160287708A9 (en) 2000-03-15 2016-10-06 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US6695865B2 (en) 2000-03-20 2004-02-24 Advanced Bio Prosthetic Surfaces, Ltd. Embolic protection device
US6315708B1 (en) 2000-03-31 2001-11-13 Cordis Corporation Stent with self-expanding end sections
US6527801B1 (en) 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US6327504B1 (en) 2000-05-10 2001-12-04 Thoratec Corporation Transcutaneous energy transfer with circuitry arranged to avoid overheating
US8845713B2 (en) 2000-05-12 2014-09-30 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same
KR100360364B1 (en) 2000-05-22 2002-11-13 주식회사 정성메디칼 A metal stent for installation in the coronary artery
US6673385B1 (en) * 2000-05-31 2004-01-06 Advanced Cardiovascular Systems, Inc. Methods for polymeric coatings stents
US6395326B1 (en) 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US20040211362A1 (en) 2000-05-31 2004-10-28 Daniel Castro System for coating a stent
JP4545888B2 (en) 2000-06-08 2010-09-15 株式会社泉精器製作所 Solid-liquid separator
WO2001095834A1 (en) 2000-06-13 2001-12-20 Scimed Life Systems, Inc. Disintegrating stent and method of making same
US6418337B1 (en) 2000-06-15 2002-07-09 Autolitt Inc. MRI guided hyperthermia surgery
JP4656697B2 (en) 2000-06-16 2011-03-23 キヤノンアネルバ株式会社 High frequency sputtering equipment
US6585765B1 (en) 2000-06-29 2003-07-01 Advanced Cardiovascular Systems, Inc. Implantable device having substances impregnated therein and a method of impregnating the same
DE10032220A1 (en) 2000-07-03 2002-01-24 Sanatis Gmbh Magnesium ammonium phosphate cements, their manufacture and use
US20030077200A1 (en) 2000-07-07 2003-04-24 Craig Charles H. Enhanced radiopaque alloy stent
US20020144757A1 (en) 2000-07-07 2002-10-10 Craig Charles Horace Stainless steel alloy with improved radiopaque characteristics
US20030018380A1 (en) * 2000-07-07 2003-01-23 Craig Charles H. Platinum enhanced alloy and intravascular or implantable medical devices manufactured therefrom
WO2002003883A2 (en) * 2000-07-10 2002-01-17 Epion Corporation Improving effectiveness of medical stents by gcib
US6709451B1 (en) 2000-07-14 2004-03-23 Norman Noble, Inc. Channeled vascular stent apparatus and method
US20030021854A1 (en) 2001-04-23 2003-01-30 Burrell Robert Edward Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US6451373B1 (en) 2000-08-04 2002-09-17 Advanced Cardiovascular Systems, Inc. Method of forming a therapeutic coating onto a surface of an implantable prosthesis
US6629992B2 (en) 2000-08-04 2003-10-07 Advanced Cardiovascular Systems, Inc. Sheath for self-expanding stent
KR100902625B1 (en) 2000-08-15 2009-06-15 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 Microparticles
US6390967B1 (en) 2000-09-14 2002-05-21 Xoft Microtube, Inc. Radiation for inhibiting hyperplasia after intravascular intervention
US7402173B2 (en) 2000-09-18 2008-07-22 Boston Scientific Scimed, Inc. Metal stent with surface layer of noble metal oxide and method of fabrication
US6478815B1 (en) 2000-09-18 2002-11-12 Inflow Dynamics Inc. Vascular and endoluminal stents
US7101391B2 (en) 2000-09-18 2006-09-05 Inflow Dynamics Inc. Primarily niobium stent
US6805898B1 (en) 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device
US6254632B1 (en) 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US20020051730A1 (en) 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
KR200227881Y1 (en) 2000-09-29 2001-06-15 주식회사이오니아테크놀로지 Image storag system of dental diagnosis
US6628989B1 (en) 2000-10-16 2003-09-30 Remon Medical Technologies, Ltd. Acoustic switch and apparatus and methods for using acoustic switches within a body
US6506437B1 (en) 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US6979347B1 (en) 2000-10-23 2005-12-27 Advanced Cardiovascular Systems, Inc. Implantable drug delivery prosthesis
US6663664B1 (en) 2000-10-26 2003-12-16 Advanced Cardiovascular Systems, Inc. Self-expanding stent with time variable radial force
US6558733B1 (en) 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US7416559B2 (en) 2000-10-27 2008-08-26 Poly-Med, Inc. Micromantled drug-eluting stent
US6758859B1 (en) 2000-10-30 2004-07-06 Kenny L. Dang Increased drug-loading and reduced stress drug delivery device
JP4583756B2 (en) 2000-10-31 2010-11-17 クック インコーポレイテッド Medical instruments
US6770086B1 (en) 2000-11-02 2004-08-03 Scimed Life Systems, Inc. Stent covering formed of porous polytetraflouroethylene
DE10055686A1 (en) 2000-11-03 2002-05-08 Biotronik Mess & Therapieg Device for influencing cell proliferation mechanisms in vessels of the human or animal body
US6517888B1 (en) 2000-11-28 2003-02-11 Scimed Life Systems, Inc. Method for manufacturing a medical device having a coated portion by laser ablation
US7498042B2 (en) 2000-11-30 2009-03-03 Kyoto Medical Planning Co., Ltd. Stent for blood vessel and material for stent for blood vessel
US7192445B2 (en) 2000-12-06 2007-03-20 Astra Tech Ab Medical prosthetic devices and implants having improved biocompatibility
US6545097B2 (en) 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
WO2002047581A1 (en) 2000-12-15 2002-06-20 Badari Narayan Nagarada Gadde Stent with drug-delivery system
ES2253325T3 (en) * 2000-12-15 2006-06-01 ANGIOMED GMBH &amp; CO. MEDIZINTECHNIK KG ENDOVASCULAR PROTESIS WITH VALVE.
DE10064596A1 (en) 2000-12-18 2002-06-20 Biotronik Mess & Therapieg Application of a marker element to an implant, especially a stent, comprises introducing a solidifiable material into a recess and solidifying the material in the recess
US20040030377A1 (en) * 2001-10-19 2004-02-12 Alexander Dubson Medicated polymer-coated stent assembly
US7244272B2 (en) 2000-12-19 2007-07-17 Nicast Ltd. Vascular prosthesis and method for production thereof
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US20030033007A1 (en) 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US6398806B1 (en) 2000-12-26 2002-06-04 Scimed Life Systems, Inc. Monolayer modification to gold coated stents to reduce adsorption of protein
US6913617B1 (en) 2000-12-27 2005-07-05 Advanced Cardiovascular Systems, Inc. Method for creating a textured surface on an implantable medical device
US6663662B2 (en) 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US6641607B1 (en) 2000-12-29 2003-11-04 Advanced Cardiovascular Systems, Inc. Double tube stent
US6635082B1 (en) 2000-12-29 2003-10-21 Advanced Cardiovascular Systems Inc. Radiopaque stent
US20020087123A1 (en) 2001-01-02 2002-07-04 Hossainy Syed F.A. Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices
WO2002053193A2 (en) 2001-01-02 2002-07-11 The Charles Stark Draper Laboratory, Inc. Tissue engineering of three-dimensional vascularized using microfabricated polymer assembly technology
US6544582B1 (en) 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Method and apparatus for coating an implantable device
DE50107779D1 (en) 2001-01-05 2006-03-02 Jacqueline Yvonne Hausdorf BY CORROSION DERIVABLE METALLIC MEDICAL IMPLANTS
GB0100760D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US20010044650A1 (en) * 2001-01-12 2001-11-22 Simso Eric J. Stent for in-stent restenosis
US20020092583A1 (en) 2001-01-16 2002-07-18 Pelton Alan R. Medical devices, particularly stents, and methods for their manufacture
US6752829B2 (en) 2001-01-30 2004-06-22 Scimed Life Systems, Inc. Stent with channel(s) for containing and delivering a biologically active material and method for manufacturing the same
US20040220660A1 (en) * 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
US6767360B1 (en) 2001-02-08 2004-07-27 Inflow Dynamics Inc. Vascular stent with composite structure for magnetic reasonance imaging capabilities
US6563080B2 (en) 2001-02-15 2003-05-13 Scimed Life Systems, Inc. Laser cutting of stents and other medical devices
WO2002065947A2 (en) 2001-02-16 2002-08-29 Abbott Laboratories Vascular Enterprises Limited Implants with fk506 for prophylaxis and treatment of restonoses
US6998060B2 (en) 2001-03-01 2006-02-14 Cordis Corporation Flexible stent and method of manufacture
US20050102025A1 (en) 2001-03-02 2005-05-12 Gaetan Laroche Plasma surface graft process for reducing thrombogenicity
US7238199B2 (en) 2001-03-06 2007-07-03 The Board Of Regents Of The University Of Texas System Method and apparatus for stent deployment with enhanced delivery of bioactive agents
US20020133224A1 (en) 2001-03-13 2002-09-19 Clara Bajgar Drug eluting encapsulated stent
US20020138131A1 (en) 2001-03-20 2002-09-26 Solovay Kenneth S. Rail stent
US6913765B2 (en) 2001-03-21 2005-07-05 Scimed Life Systems, Inc. Controlling resorption of bioresorbable medical implant material
US20020138136A1 (en) 2001-03-23 2002-09-26 Scimed Life Systems, Inc. Medical device having radio-opacification and barrier layers
DE20220502U1 (en) 2001-03-23 2003-10-02 Alcove Surfaces Gmbh implant
US6613077B2 (en) 2001-03-27 2003-09-02 Scimed Life Systems, Inc. Stent with controlled expansion
US6780424B2 (en) 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US6673105B1 (en) * 2001-04-02 2004-01-06 Advanced Cardiovascular Systems, Inc. Metal prosthesis coated with expandable ePTFE
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US7048939B2 (en) 2001-04-20 2006-05-23 The Board Of Trustees Of The Leland Stanford Junior University Methods for the inhibition of neointima formation
US7056339B2 (en) * 2001-04-20 2006-06-06 The Board Of Trustees Of The Leland Stanford Junior University Drug delivery platform
US6712845B2 (en) 2001-04-24 2004-03-30 Advanced Cardiovascular Systems, Inc. Coating for a stent and a method of forming the same
US7232460B2 (en) 2001-04-25 2007-06-19 Xillus, Inc. Nanodevices, microdevices and sensors on in-vivo structures and method for the same
US6887857B2 (en) 2001-04-27 2005-05-03 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
US6660034B1 (en) 2001-04-30 2003-12-09 Advanced Cardiovascular Systems, Inc. Stent for increasing blood flow to ischemic tissues and a method of using the same
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7105199B2 (en) 2001-05-11 2006-09-12 Exogenesis Corporation Methods of adhering drugs to the surface of medical devices through ion beam surface modification
US6827966B2 (en) 2001-05-30 2004-12-07 Novartis Ag Diffusion-controllable coatings on medical device
WO2002096389A1 (en) 2001-05-30 2002-12-05 Microchips, Inc. Conformal coated microchip reservoir devices
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US6712844B2 (en) 2001-06-06 2004-03-30 Advanced Cardiovascular Systems, Inc. MRI compatible stent
WO2002100454A1 (en) 2001-06-11 2002-12-19 Boston Scientific Limited COMPOSITE ePTFE/TEXTILE PROSTHESIS
US7560006B2 (en) 2001-06-11 2009-07-14 Boston Scientific Scimed, Inc. Pressure lamination method for forming composite ePTFE/textile and ePTFE/stent/textile prostheses
US7201940B1 (en) 2001-06-12 2007-04-10 Advanced Cardiovascular Systems, Inc. Method and apparatus for thermal spray processing of medical devices
US6527938B2 (en) 2001-06-21 2003-03-04 Syntheon, Llc Method for microporous surface modification of implantable metallic medical articles
US6844028B2 (en) 2001-06-26 2005-01-18 Accelr8 Technology Corporation Functional surface coating
US20030003127A1 (en) * 2001-06-27 2003-01-02 Ethicon, Inc. Porous ceramic/porous polymer layered scaffolds for the repair and regeneration of tissue
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
US6656216B1 (en) * 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
US6585755B2 (en) * 2001-06-29 2003-07-01 Advanced Cardiovascular Polymeric stent suitable for imaging by MRI and fluoroscopy
US6676987B2 (en) 2001-07-02 2004-01-13 Scimed Life Systems, Inc. Coating a medical appliance with a bubble jet printing head
US20030050687A1 (en) 2001-07-03 2003-03-13 Schwade Nathan D. Biocompatible stents and method of deployment
EP1273314A1 (en) 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
ATE330564T1 (en) 2001-07-20 2006-07-15 Sorin Biomedica Cardio Srl STENT
US6921390B2 (en) 2001-07-23 2005-07-26 Boston Scientific Scimed, Inc. Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface
US20040249440A1 (en) 2001-08-08 2004-12-09 Arno Bucker Metallic endoprosthesis compatible with magnetic resonance
US6979346B1 (en) 2001-08-08 2005-12-27 Advanced Cardiovascular Systems, Inc. System and method for improved stent retention
GB0119652D0 (en) 2001-08-11 2001-10-03 Stanmore Implants Worldwide Surgical implant
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20040249443A1 (en) 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
US6632231B2 (en) 2001-08-23 2003-10-14 Scimed Life Systems, Inc. Segmented balloon catheter blade
GB0121980D0 (en) 2001-09-11 2001-10-31 Cathnet Science Holding As Expandable stent
US6589286B1 (en) 2001-09-12 2003-07-08 Jason Litner Eustachian tube stent
WO2003024357A2 (en) 2001-09-14 2003-03-27 Martin Francis J Microfabricated nanopore device for sustained release of therapeutic agent
US20030158598A1 (en) 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
IN2014DN10834A (en) 2001-09-17 2015-09-04 Psivida Inc
US6669980B2 (en) 2001-09-18 2003-12-30 Scimed Life Systems, Inc. Method for spray-coating medical devices
US7776379B2 (en) 2001-09-19 2010-08-17 Medlogics Device Corporation Metallic structures incorporating bioactive materials and methods for creating the same
US20030060873A1 (en) 2001-09-19 2003-03-27 Nanomedical Technologies, Inc. Metallic structures incorporating bioactive materials and methods for creating the same
US6908622B2 (en) 2001-09-24 2005-06-21 Boston Scientific Scimed, Inc. Optimized dosing for drug coated stents
US7195640B2 (en) 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US6827737B2 (en) 2001-09-25 2004-12-07 Scimed Life Systems, Inc. EPTFE covering for endovascular prostheses and method of manufacture
US6753071B1 (en) 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
DE10150995A1 (en) 2001-10-08 2003-04-10 Biotronik Mess & Therapieg Implant e.g. a stent, comprises a decomposable substance which allows contact between the cell proliferation inhibitor and the stent surroundings only after a specified time
US7157096B2 (en) * 2001-10-12 2007-01-02 Inframat Corporation Coatings, coated articles and methods of manufacture thereof
US6709397B2 (en) 2001-10-16 2004-03-23 Envisioneering, L.L.C. Scanning probe
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US7722894B2 (en) 2001-10-22 2010-05-25 Massachusetts Institute Of Technology Biodegradable polymer
US8562664B2 (en) 2001-10-25 2013-10-22 Advanced Cardiovascular Systems, Inc. Manufacture of fine-grained material for use in medical devices
US8740973B2 (en) 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US20030083614A1 (en) 2001-10-30 2003-05-01 Boehringer Ingelheim Pharma Kg Controlled release endoprosthetic device
US20030088307A1 (en) 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US6730282B2 (en) 2001-11-05 2004-05-04 N Vara Technology S.R.L. Sol-gel process for the manufacture of nanocomposite photoluminescent materials
US6764709B2 (en) 2001-11-08 2004-07-20 Scimed Life Systems, Inc. Method for making and measuring a coating on the surface of a medical device using an ultraviolet laser
US6807440B2 (en) 2001-11-09 2004-10-19 Scimed Life Systems, Inc. Ceramic reinforcement members for MRI devices
EP1310242A1 (en) 2001-11-13 2003-05-14 SORIN BIOMEDICA CARDIO S.p.A. Carrier and kit for endoluminal delivery of active principles
US6729336B2 (en) 2001-11-27 2004-05-04 Pearl Technology Holdings, Llc In-stent restenosis detection device
US20030100830A1 (en) 2001-11-27 2003-05-29 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US7014654B2 (en) 2001-11-30 2006-03-21 Scimed Life Systems, Inc. Stent designed for the delivery of therapeutic substance or other agents
US6752826B2 (en) 2001-12-14 2004-06-22 Thoratec Corporation Layered stent-graft and methods of making the same
US6939374B2 (en) 2001-12-21 2005-09-06 Scimed Life Systems, Inc. Stents, stenting systems, and related methods for agent delivery
DE10163107C1 (en) 2001-12-24 2003-07-10 Univ Hannover Magnesium workpiece and method for forming a corrosion-protective top layer of a magnesium workpiece
US6866805B2 (en) 2001-12-27 2005-03-15 Advanced Cardiovascular Systems, Inc. Hybrid intravascular stent
US6743388B2 (en) 2001-12-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Process of making polymer articles
US20030135265A1 (en) 2002-01-04 2003-07-17 Stinson Jonathan S. Prostheses implantable in enteral vessels
US6506972B1 (en) * 2002-01-22 2003-01-14 Nanoset, Llc Magnetically shielded conductor
WO2003061755A2 (en) 2002-01-22 2003-07-31 Nanoset, Llc Nanomagnetically shielded substrate
US6864418B2 (en) 2002-12-18 2005-03-08 Nanoset, Llc Nanomagnetically shielded substrate
US6906256B1 (en) 2002-01-22 2005-06-14 Nanoset, Llc Nanomagnetic shielding assembly
WO2003062824A1 (en) 2002-01-23 2003-07-31 Boditech Inc. Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor
US7060089B2 (en) 2002-01-23 2006-06-13 Boston Scientific Scimed, Inc. Multi-layer stent
US7326245B2 (en) 2002-01-31 2008-02-05 Boston Scientific Scimed, Inc. Medical device for delivering biologically active material
ATE362741T1 (en) 2002-01-31 2007-06-15 Radi Medical Systems DISSOLVING STENT
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US20030153901A1 (en) 2002-02-08 2003-08-14 Atrium Medical Corporation Drug delivery panel
JP4472348B2 (en) 2002-02-15 2010-06-02 ギリアード・パロ・アルト・インコーポレイテッド Polymer coating for medical devices
DE10207161B4 (en) 2002-02-20 2004-12-30 Universität Hannover Process for the production of implants
US20030170605A1 (en) 2002-03-11 2003-09-11 Egan Visual Inc. Vapor deposited writing surfaces
US6586705B1 (en) 2002-03-15 2003-07-01 The Boeing Company Anti-spatter tube
US7022334B1 (en) 2002-03-20 2006-04-04 Advanced Cardiovascular Systems, Inc. Therapeutic composition and a method of coating implantable medical devices
US7927368B2 (en) 2002-03-25 2011-04-19 Kieran Murphy Llc Device viewable under an imaging beam
US6743463B2 (en) 2002-03-28 2004-06-01 Scimed Life Systems, Inc. Method for spray-coating a medical device having a tubular wall such as a stent
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
EP1348402A1 (en) * 2002-03-29 2003-10-01 Advanced Laser Applications Holding S.A. Intraluminal endoprosthesis, radially expandable, perforated for drug delivery
US7799467B2 (en) 2002-04-08 2010-09-21 Massachusetts Institute Of Technology Solid polymer electrolytes from ethylene oxide-containing, layer-by-layer assembled films
US20050187605A1 (en) 2002-04-11 2005-08-25 Greenhalgh Skott E. Electrospun skin capable of controlling drug release rates and method
US20030211135A1 (en) 2002-04-11 2003-11-13 Greenhalgh Skott E. Stent having electrospun covering and method
US20030204239A1 (en) 2002-04-26 2003-10-30 Wenda Carlyle Endovascular stent with a preservative coating
AU2003228858A1 (en) 2002-05-02 2003-11-17 Scimed Life Systems, Inc. Energetically-controlled delivery of biologically active material from an implanted medical device
WO2003092554A1 (en) 2002-05-03 2003-11-13 The General Hospital Corporation Involuted endovascular valve and method of construction
EP1505931A1 (en) 2002-05-20 2005-02-16 Orbus Medical Technologies, Inc. Drug eluting implantable medical device
US20040000540A1 (en) * 2002-05-23 2004-01-01 Soboyejo Winston O. Laser texturing of surfaces for biomedical implants
US7048767B2 (en) 2002-06-11 2006-05-23 Spire Corporation Nano-crystalline, homo-metallic, protective coatings
US20030236513A1 (en) 2002-06-19 2003-12-25 Scimed Life Systems, Inc. Implantable or insertable medical devices for controlled delivery of a therapeutic agent
US7789908B2 (en) 2002-06-25 2010-09-07 Boston Scientific Scimed, Inc. Elastomerically impregnated ePTFE to enhance stretch and recovery properties for vascular grafts and coverings
US6865810B2 (en) * 2002-06-27 2005-03-15 Scimed Life Systems, Inc. Methods of making medical devices
US6696666B2 (en) 2002-07-03 2004-02-24 Scimed Life Systems, Inc. Tubular cutting process and system
US20040004063A1 (en) * 2002-07-08 2004-01-08 Merdan Kenneth M. Vertical stent cutting process
AU2003250913A1 (en) 2002-07-08 2004-01-23 Abbott Laboratories Vascular Enterprises Limited Drug eluting stent and methods of manufacture
US20050096731A1 (en) 2002-07-11 2005-05-05 Kareen Looi Cell seeded expandable body
JP4727987B2 (en) 2002-07-12 2011-07-20 クック インコーポレイテッド Coated medical devices
US6964817B2 (en) 2002-07-15 2005-11-15 Hitachi Metals, Ltd. Porous sintered metal and filter thereof, and method for producing porous sintered metal
US20040137039A1 (en) 2002-07-22 2004-07-15 Trustees Of Stevens Institute Of Technology Methods for controlled release of molecules from layered polymer films
US7067606B2 (en) 2002-07-30 2006-06-27 University Of Connecticut Nonionic telechelic polymers incorporating polyhedral oligosilsesquioxane (POSS) and uses thereof
DE10235689A1 (en) 2002-07-31 2004-02-19 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Implant to administer small doses of an active agent directly into the bloodstream at a blood vessel, comprising a base body against the blood vessel wall with micro-injectors through the artery wall
US20050163821A1 (en) 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US20040024448A1 (en) 2002-08-05 2004-02-05 Chang James W. Thermoplastic fluoropolymer-coated medical devices
US7255710B2 (en) 2002-08-06 2007-08-14 Icon Medical Corp. Helical stent with micro-latches
US6962822B2 (en) 2002-08-07 2005-11-08 International Business Machines Corporation Discrete nano-textured structures in biomolecular arrays, and method of use
DE10237571A1 (en) 2002-08-13 2004-02-26 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endovascular implant with active coating
DE10237572A1 (en) 2002-08-13 2004-02-26 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Stent with a polymer coating
EP1550477B1 (en) 2002-08-23 2015-11-04 National Cerebral and Cardiovascular Center Stent and process for producing the same
US7029495B2 (en) 2002-08-28 2006-04-18 Scimed Life Systems, Inc. Medical devices and methods of making the same
US6951053B2 (en) 2002-09-04 2005-10-04 Reva Medical, Inc. Method of manufacturing a prosthesis
US7758636B2 (en) 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
ATE392864T1 (en) 2002-09-20 2008-05-15 Abbott Lab Vascular Entpr Ltd STENT PROVIDED WITH A ROUGH SURFACE AND METHOD OF PRODUCTION THEREOF
US7001422B2 (en) 2002-09-23 2006-02-21 Cordis Neurovascular, Inc Expandable stent and delivery system
US7060051B2 (en) 2002-09-24 2006-06-13 Scimed Life Systems, Inc. Multi-balloon catheter with hydrogel coating
US20040059409A1 (en) 2002-09-24 2004-03-25 Stenzel Eric B. Method of applying coatings to a medical device
WO2004028347A2 (en) 2002-09-26 2004-04-08 Advanced Bio Prosthetic Surfaces, Ltd. Implantable materials having engineered surfaces and method of making same
US6971813B2 (en) 2002-09-27 2005-12-06 Labcoat, Ltd. Contact coating of prostheses
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
WO2004029313A1 (en) 2002-09-30 2004-04-08 Nano Technology Institute, Inc Nano-crystal austenitic metal bulk material having high hardness, high strength and toughness , and method for production thereof
ATE499396T1 (en) 2002-10-11 2011-03-15 Univ Connecticut SHAPE MEMORY POLYMERS BASED ON SEMICRYSTALLINE THERMOPLASTIC POLYURETHANES THAT HAVE NANOSTRUCTURED HARD SEGMENTS
US7976936B2 (en) 2002-10-11 2011-07-12 University Of Connecticut Endoprostheses
US7794494B2 (en) 2002-10-11 2010-09-14 Boston Scientific Scimed, Inc. Implantable medical devices
US20060271168A1 (en) 2002-10-30 2006-11-30 Klaus Kleine Degradable medical device
US20040088038A1 (en) 2002-10-30 2004-05-06 Houdin Dehnad Porous metal for drug-loaded stents
SE0203224D0 (en) 2002-10-31 2002-10-31 Cerbio Tech Ab Method of making structured ceramic coatings and coated devices prepared with the method
US8221495B2 (en) 2002-11-07 2012-07-17 Abbott Laboratories Integration of therapeutic agent into a bioerodible medical device
US20040142014A1 (en) 2002-11-08 2004-07-22 Conor Medsystems, Inc. Method and apparatus for reducing tissue damage after ischemic injury
US20040143321A1 (en) 2002-11-08 2004-07-22 Conor Medsystems, Inc. Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
DE10253633B4 (en) 2002-11-13 2011-08-11 BIOTRONIK GmbH & Co. KG, 12359 supporting structure
US7144422B1 (en) 2002-11-13 2006-12-05 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and methods of making the same
DE10253634A1 (en) 2002-11-13 2004-05-27 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin endoprosthesis
US20050070989A1 (en) 2002-11-13 2005-03-31 Whye-Kei Lye Medical devices having porous layers and methods for making the same
JP2006514848A (en) 2002-11-13 2006-05-18 セタゴン インコーポレーティッド Medical device having porous layer and method for producing the same
US20060121080A1 (en) 2002-11-13 2006-06-08 Lye Whye K Medical devices having nanoporous layers and methods for making the same
EP1567221A1 (en) 2002-11-15 2005-08-31 GMP Cardiac Care, Inc. Rail stent
US8449601B2 (en) 2002-11-19 2013-05-28 Boston Scientific Scimed, Inc. Medical devices
US6696667B1 (en) 2002-11-22 2004-02-24 Scimed Life Systems, Inc. Laser stent cutting
JP4119230B2 (en) 2002-11-26 2008-07-16 株式会社 日立ディスプレイズ Display device
US6918869B2 (en) 2002-12-02 2005-07-19 Scimed Life Systems System for administering a combination of therapies to a body lumen
US7776926B1 (en) 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
DE10261822A1 (en) 2002-12-20 2004-07-01 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Helix bridge connection
US6926735B2 (en) 2002-12-23 2005-08-09 Scimed Life Systems, Inc. Multi-lumen vascular grafts having improved self-sealing properties
US7846198B2 (en) 2002-12-24 2010-12-07 Novostent Corporation Vascular prosthesis and methods of use
US7666216B2 (en) 2002-12-24 2010-02-23 Novostent Corporation Delivery catheter for ribbon-type prosthesis and methods of use
US6725901B1 (en) 2002-12-27 2004-04-27 Advanced Cardiovascular Systems, Inc. Methods of manufacture of fully consolidated or porous medical devices
US7316710B1 (en) 2002-12-30 2008-01-08 Advanced Cardiovascular Systems, Inc. Flexible stent
EP1583561A3 (en) 2002-12-30 2005-12-07 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US6803070B2 (en) 2002-12-30 2004-10-12 Scimed Life Systems, Inc. Apparatus and method for embedding nanoparticles in polymeric medical devices
US7105018B1 (en) 2002-12-30 2006-09-12 Advanced Cardiovascular Systems, Inc. Drug-eluting stent cover and method of use
US6896697B1 (en) 2002-12-30 2005-05-24 Advanced Cardiovascular Systems, Inc. Intravascular stent
US20040236415A1 (en) 2003-01-02 2004-11-25 Richard Thomas Medical devices having drug releasing polymer reservoirs
US20040143317A1 (en) 2003-01-17 2004-07-22 Stinson Jonathan S. Medical devices
US6852122B2 (en) 2003-01-23 2005-02-08 Cordis Corporation Coated endovascular AAA device
WO2004069169A2 (en) 2003-01-31 2004-08-19 Scimed Life Systems, Inc. Localized drug delivery using drug-loaded nanocapsules and implantable device coated with the same
US7311727B2 (en) 2003-02-05 2007-12-25 Board Of Trustees Of The University Of Arkansas Encased stent
US7172624B2 (en) 2003-02-06 2007-02-06 Boston Scientific Scimed, Inc. Medical device with magnetic resonance visibility enhancing structure
US20080038146A1 (en) 2003-02-10 2008-02-14 Jurgen Wachter Metal alloy for medical devices and implants
FR2851181B1 (en) 2003-02-17 2006-05-26 Commissariat Energie Atomique METHOD FOR COATING A SURFACE
AU2004213021B2 (en) 2003-02-18 2010-12-09 Medtronic, Inc. Occlusion resistant hydrocephalic shunt
US20050079199A1 (en) 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
US20040167572A1 (en) 2003-02-20 2004-08-26 Roth Noah M. Coated medical devices
ATE485847T1 (en) 2003-02-21 2010-11-15 Sorin Biomedica Cardio Srl METHOD FOR PRODUCING A STENT AND CORRESPONDING STENT
US20080051866A1 (en) 2003-02-26 2008-02-28 Chao Chin Chen Drug delivery devices and methods
US7001421B2 (en) 2003-02-28 2006-02-21 Medtronic Vascular, Inc. Stent with phenoxy primer coating
US6699282B1 (en) 2003-03-06 2004-03-02 Gelsus Research And Consulting, Inc. Method and apparatus for delivery of medication
US6932930B2 (en) 2003-03-10 2005-08-23 Synecor, Llc Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same
US8281737B2 (en) * 2003-03-10 2012-10-09 Boston Scientific Scimed, Inc. Coated medical device and method for manufacturing the same
DE10311729A1 (en) 2003-03-18 2004-09-30 Schultheiss, Heinz-Peter, Prof. Dr. Endovascular implant with an at least sectionally active coating of ratjadon and / or a ratjadon derivative
US20040202692A1 (en) 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device and method for in situ selective modulation of agent delivery
US20050022627A1 (en) 2003-04-03 2005-02-03 Cheng-Han Chen Oxidation resistant treatment for metallic medical devices
US20050149169A1 (en) 2003-04-08 2005-07-07 Xingwu Wang Implantable medical device
US7163555B2 (en) 2003-04-08 2007-01-16 Medtronic Vascular, Inc. Drug-eluting stent for controlled drug delivery
US20050079132A1 (en) 2003-04-08 2005-04-14 Xingwu Wang Medical device with low magnetic susceptibility
US20050070996A1 (en) 2003-04-08 2005-03-31 Dinh Thomas Q. Drug-eluting stent for controlled drug delivery
US20040254419A1 (en) 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
US20050216075A1 (en) 2003-04-08 2005-09-29 Xingwu Wang Materials and devices of enhanced electromagnetic transparency
US20050107870A1 (en) 2003-04-08 2005-05-19 Xingwu Wang Medical device with multiple coating layers
US7731747B2 (en) 2003-04-14 2010-06-08 Tryton Medical, Inc. Vascular bifurcation prosthesis with multiple thin fronds
US7717953B2 (en) 2004-10-13 2010-05-18 Tryton Medical, Inc. Delivery system for placement of prosthesis at luminal OS
US20060041182A1 (en) 2003-04-16 2006-02-23 Forbes Zachary G Magnetically-controllable delivery system for therapeutic agents
US20050221072A1 (en) 2003-04-17 2005-10-06 Nanosys, Inc. Medical device applications of nanostructured surfaces
US20040230176A1 (en) 2003-04-23 2004-11-18 Medtronic Vascular, Inc. System for treating a vascular condition that inhibits restenosis at stent ends
JP4734236B2 (en) 2003-04-25 2011-07-27 ボストン サイエンティフィック サイムド,インコーポレイテッド Device for the storage and controlled release of solid drugs and method of manufacturing the same
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
AU2004237774B2 (en) 2003-05-02 2009-09-10 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
US6923996B2 (en) 2003-05-06 2005-08-02 Scimed Life Systems, Inc. Processes for producing polymer coatings for release of therapeutic agent
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US6846323B2 (en) * 2003-05-15 2005-01-25 Advanced Cardiovascular Systems, Inc. Intravascular stent
US20040230290A1 (en) 2003-05-15 2004-11-18 Jan Weber Medical devices and methods of making the same
KR20060009934A (en) 2003-05-16 2006-02-01 블루 멤브레인스 게엠베하 Method for coating substrates with a carbon-based material
DE10323628A1 (en) 2003-05-20 2004-12-30 Biotronik Ag Stents made of a material with low elongation at break
US20040236416A1 (en) 2003-05-20 2004-11-25 Robert Falotico Increased biocompatibility of implantable medical devices
US20050211680A1 (en) 2003-05-23 2005-09-29 Mingwei Li Systems and methods for laser texturing of surfaces of a substrate
US20030216803A1 (en) 2003-05-28 2003-11-20 Ledergerber Walter J. Textured and drug eluting stent-grafts
US7041127B2 (en) 2003-05-28 2006-05-09 Ledergerber Walter J Textured and drug eluting coronary artery stent
US7297644B2 (en) 2003-05-28 2007-11-20 Air Products Polymers, L.P. Nonwoven binders with high wet/dry tensile strength ratio
US7270679B2 (en) 2003-05-30 2007-09-18 Warsaw Orthopedic, Inc. Implants based on engineered metal matrix composite materials having enhanced imaging and wear resistance
US6904658B2 (en) 2003-06-02 2005-06-14 Electroformed Stents, Inc. Process for forming a porous drug delivery layer
US6979348B2 (en) 2003-06-04 2005-12-27 Medtronic Vascular, Inc. Reflowed drug-polymer coated stent and method thereof
US7169179B2 (en) 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
EP1650868A1 (en) 2003-07-02 2006-04-26 Sony Corporation Mems type oscillator, process for fabricating the same, filter, and communication unit
FI20045223A (en) * 2004-06-15 2005-12-16 Bioretec Oy A multifunctional biodegradable composite and a surgical implant comprising said composite
US20050021127A1 (en) * 2003-07-21 2005-01-27 Kawula Paul John Porous glass fused onto stent for drug retention
US20050021128A1 (en) * 2003-07-24 2005-01-27 Medtronic Vascular, Inc. Compliant, porous, rolled stent
US7682603B2 (en) * 2003-07-25 2010-03-23 The Trustees Of The University Of Pennsylvania Polymersomes incorporating highly emissive probes
EP1648935A2 (en) 2003-07-25 2006-04-26 Amgen Inc. Antagonists and agonists of ldcam and methods of use
US20050027350A1 (en) 2003-07-30 2005-02-03 Biotronik Mess-Und Therapiegeraete Gmbh & Co Ingenieurbuero Berlin Endovascular implant for the injection of an active substance into the media of a blood vessel
US20050033417A1 (en) 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
EP1652550A1 (en) 2003-08-05 2006-05-03 Kaneka Corporation Stent to be placed in vivo
US7479157B2 (en) 2003-08-07 2009-01-20 Boston Scientific Scimed, Inc. Stent designs which enable the visibility of the inside of the stent during MRI
US7364585B2 (en) 2003-08-11 2008-04-29 Boston Scientific Scimed, Inc. Medical devices comprising drug-loaded capsules for localized drug delivery
US20050037047A1 (en) 2003-08-11 2005-02-17 Young-Ho Song Medical devices comprising spray dried microparticles
US20050038501A1 (en) 2003-08-12 2005-02-17 Moore James E. Dynamic stent
US20050055085A1 (en) 2003-09-04 2005-03-10 Rivron Nicolas C. Implantable medical devices having recesses
US20050055080A1 (en) 2003-09-05 2005-03-10 Naim Istephanous Modulated stents and methods of making the stents
US7544381B2 (en) 2003-09-09 2009-06-09 Boston Scientific Scimed, Inc. Lubricious coatings for medical device
WO2005025449A2 (en) 2003-09-10 2005-03-24 Spheric Products, Ltd Cardiovascular stent with anti-platelet and angiogenic material
US7488343B2 (en) 2003-09-16 2009-02-10 Boston Scientific Scimed, Inc. Medical devices
US20050060020A1 (en) 2003-09-17 2005-03-17 Scimed Life Systems, Inc. Covered stent with biologically active material
US7235098B2 (en) 2003-09-18 2007-06-26 Advanced Bio Prosthetic Surfaces, Ltd. Medical devices having MEMs functionality and methods of making same
US8801692B2 (en) 2003-09-24 2014-08-12 Medtronic Vascular, Inc. Gradient coated stent and method of fabrication
US7060319B2 (en) 2003-09-24 2006-06-13 Boston Scientific Scimed, Inc. method for using an ultrasonic nozzle to coat a medical appliance
US20050070990A1 (en) 2003-09-26 2005-03-31 Stinson Jonathan S. Medical devices and methods of making same
US7055237B2 (en) 2003-09-29 2006-06-06 Medtronic Vascular, Inc. Method of forming a drug eluting stent
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7618647B2 (en) 2003-10-03 2009-11-17 Boston Scientific Scimed, Inc. Using bucky paper as a therapeutic aid in medical applications
US7284677B2 (en) 2003-10-08 2007-10-23 Elizabeth Ann Guevara Bottle holding appliance and method for its use
CA2543737A1 (en) 2003-10-30 2005-05-12 Applied Medical Resources Corporation Surface treatments and modifications using nanostructure materials
US20050129731A1 (en) 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US7208172B2 (en) 2003-11-03 2007-04-24 Medlogics Device Corporation Metallic composite coating for delivery of therapeutic agents from the surface of implantable devices
WO2005046747A2 (en) 2003-11-10 2005-05-26 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20050100577A1 (en) 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
ES2716941T3 (en) 2003-11-14 2019-06-18 Wild River Consulting Group Llc Metal and polymer composite that has improved properties
US20050113904A1 (en) 2003-11-25 2005-05-26 Shank Peter J. Composite stent with inner and outer stent elements and method of using the same
US20060085062A1 (en) 2003-11-28 2006-04-20 Medlogics Device Corporation Implantable stent with endothelialization factor
US20050119723A1 (en) 2003-11-28 2005-06-02 Medlogics Device Corporation Medical device with porous surface containing bioerodable bioactive composites and related methods
EP1535952B1 (en) * 2003-11-28 2013-01-16 Universite Louis Pasteur Method for preparing crosslinked polyelectrolyte multilayer films
DE10357281A1 (en) 2003-12-05 2005-07-14 Hassel, Thomas, Dipl.-Ing. Degradable stent for blood vessel support made of magnesium material, comprises degradation-inhibiting biocompatible coating
DE10357334A1 (en) 2003-12-05 2005-07-07 Grönemeyer, Dietrich H. W., Prof. Dr.med. MR compatible medical implant
US20050131522A1 (en) 2003-12-10 2005-06-16 Stinson Jonathan S. Medical devices and methods of making the same
WO2005061023A1 (en) 2003-12-12 2005-07-07 C. R. Bard, Inc. Implantable medical devices with fluorinated polymer coatings, and methods of coating thereof
DE10358502B3 (en) 2003-12-13 2005-04-07 Daimlerchrysler Ag Production of a hollow profile used as a branched part for pipes comprises stamping a secondary molding element to connect to a further component in a pre-curved region before winding
US7220816B2 (en) 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US8017178B2 (en) 2003-12-16 2011-09-13 Cardiac Pacemakers, Inc. Coatings for implantable electrodes
US20050137679A1 (en) 2003-12-17 2005-06-23 Pfizer Inc Modified stent useful for delivery of drugs along stent strut
US20050137677A1 (en) 2003-12-17 2005-06-23 Rush Scott L. Endovascular graft with differentiable porosity along its length
EP1701910A4 (en) 2003-12-18 2013-04-03 Massachusetts Inst Technology Bioprocesse enhanced by magnetic nanoparticles
US8652502B2 (en) 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US20070027532A1 (en) 2003-12-22 2007-02-01 Xingwu Wang Medical device
US7261732B2 (en) 2003-12-22 2007-08-28 Henri Justino Stent mounted valve
DE10361941A1 (en) 2003-12-24 2005-07-28 Restate Patent Ag Coating for the outer surface of a medical implant, especially a stent or electrode, comprises magnesium, a magnesium alloy or a magnesium salt
DE10361940A1 (en) 2003-12-24 2005-07-28 Restate Patent Ag Degradation control of biodegradable implants by coating
EP1706070B1 (en) 2004-01-20 2011-02-23 Cook Incorporated Multiple stitches for attaching stent to graft
US20050159805A1 (en) 2004-01-20 2005-07-21 Jan Weber Functional coatings and designs for medical implants
US20050159809A1 (en) 2004-01-21 2005-07-21 Medtronic Vascular, Inc. Implantable medical devices for treating or preventing restenosis
US7632299B2 (en) 2004-01-22 2009-12-15 Boston Scientific Scimed, Inc. Medical devices
US7854756B2 (en) 2004-01-22 2010-12-21 Boston Scientific Scimed, Inc. Medical devices
US8620406B2 (en) 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
US7393589B2 (en) 2004-01-30 2008-07-01 Ionbond, Inc. Dual layer diffusion bonded chemical vapor coating for medical implants
ITTO20040056A1 (en) 2004-02-05 2004-05-05 Sorin Biomedica Cardio Spa STENT FOR THE ENDOLIMINAL DELIVERY OF PRINCIPLES OR ACTIVE AGENTS
DE102004029611A1 (en) 2004-02-06 2005-08-25 Restate Patent Ag Implant for e.g. releasing active substances into a vessel through which body fluids flow, comprises a base consisting of a biodegradable material as the carrier of the active substances
US7442681B2 (en) 2004-02-10 2008-10-28 University Of Virginia Patent Foundation Method of inhibiting vascular permeability
WO2005079339A2 (en) * 2004-02-12 2005-09-01 The University Of Akron Improved stent for use in arteries
US20050180919A1 (en) 2004-02-12 2005-08-18 Eugene Tedeschi Stent with radiopaque and encapsulant coatings
US8057841B2 (en) 2004-02-12 2011-11-15 University Of Akron Mechanically attached medical device coatings
US8049137B2 (en) 2004-02-13 2011-11-01 Boston Scientific Scimed, Inc. Laser shock peening of medical devices
US7294145B2 (en) 2004-02-26 2007-11-13 Boston Scientific Scimed, Inc. Stent with differently coated inside and outside surfaces
US8137397B2 (en) 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
US6979473B2 (en) 2004-03-15 2005-12-27 Boston Scientific Scimed, Inc. Method for fine bore orifice spray coating of medical devices and pre-filming atomization
US7744644B2 (en) 2004-03-19 2010-06-29 Boston Scientific Scimed, Inc. Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release
US8435287B2 (en) * 2004-03-30 2013-05-07 Toyo Advanced Technologies Co., Ltd. Stent and method for fabricating the same
US8715340B2 (en) 2004-03-31 2014-05-06 Merlin Md Pte Ltd. Endovascular device with membrane
US20050222671A1 (en) 2004-03-31 2005-10-06 Schaeffer Darin G Partially biodegradable stent
US20050220853A1 (en) 2004-04-02 2005-10-06 Kinh-Luan Dao Controlled delivery of therapeutic agents from medical articles
US20050244459A1 (en) 2004-04-06 2005-11-03 Dewitt David M Coating compositions for bioactive agents
US20050228477A1 (en) 2004-04-09 2005-10-13 Xtent, Inc. Topographic coatings and coating methods for medical devices
US20050228491A1 (en) 2004-04-12 2005-10-13 Snyder Alan J Anti-adhesive surface treatments
CA2502018A1 (en) 2004-04-16 2005-10-16 Conor Medsystems, Inc. Bioresorbable stent delivery system
US7070576B2 (en) 2004-04-30 2006-07-04 Boston Scientific Scimed, Inc. Directional cutting balloon
US20050251245A1 (en) 2004-05-05 2005-11-10 Karl Sieradzki Methods and apparatus with porous materials
US7955371B2 (en) 2004-05-12 2011-06-07 Medtronic Vascular, Inc. System and method for stent deployment and infusion of a therapeutic agent into tissue adjacent to the stent ends
US20060100696A1 (en) 2004-11-10 2006-05-11 Atanasoska Ljiljana L Medical devices and methods of making the same
US7758892B1 (en) 2004-05-20 2010-07-20 Boston Scientific Scimed, Inc. Medical devices having multiple layers
JP5026970B2 (en) 2004-05-20 2012-09-19 ボストン サイエンティフィック リミテッド Medical device and method of making the same
EP1761178B1 (en) 2004-05-21 2010-12-08 Micro Therapeutics, Inc. Metallic coils enlaced with biological or biodegradable or synthetic polymers or fibers for embolization of a body cavity
DE102004026104A1 (en) 2004-05-25 2005-12-15 Restate Patent Ag Implant to the vessel ligature
US20050266039A1 (en) 2004-05-27 2005-12-01 Jan Weber Coated medical device and method for making the same
WO2005118019A1 (en) 2004-05-28 2005-12-15 Cook Incorporated Implantable bioabsorbable valve support frame
US20050266040A1 (en) 2004-05-28 2005-12-01 Brent Gerberding Medical devices composed of porous metallic materials for delivering biologically active materials
US7695775B2 (en) 2004-06-04 2010-04-13 Applied Microstructures, Inc. Controlled vapor deposition of biocompatible coatings over surface-treated substrates
US7794490B2 (en) 2004-06-22 2010-09-14 Boston Scientific Scimed, Inc. Implantable medical devices with antimicrobial and biodegradable matrices
DE602005017177D1 (en) * 2004-07-05 2009-11-26 Ziscoat N V BIOKOMPATIBLE COATING OF MEDICAL DEVICES WITH MOLECULAR SCREENS
US20060009839A1 (en) * 2004-07-12 2006-01-12 Scimed Life Systems, Inc. Composite vascular graft including bioactive agent coating and biodegradable sheath
US7078108B2 (en) * 2004-07-14 2006-07-18 The Regents Of The University Of California Preparation of high-strength nanometer scale twinned coating and foil
US20060015361A1 (en) * 2004-07-16 2006-01-19 Jurgen Sattler Method and system for customer contact reporting
US7269700B2 (en) * 2004-07-26 2007-09-11 Integrated Device Technology, Inc. Status bus accessing only available quadrants during loop mode operation in a multi-queue first-in first-out memory system
US20060025848A1 (en) 2004-07-29 2006-02-02 Jan Weber Medical device having a coating layer with structural elements therein and method of making the same
US20060275554A1 (en) 2004-08-23 2006-12-07 Zhibo Zhao High performance kinetic spray nozzle
US7507433B2 (en) 2004-09-03 2009-03-24 Boston Scientific Scimed, Inc. Method of coating a medical device using an electrowetting process
DE102004043231A1 (en) 2004-09-07 2006-03-09 Biotronik Vi Patent Ag Endoprosthesis made of magnesium alloy
DE502005008226D1 (en) 2004-09-07 2009-11-12 Biotronik Vi Patent Ag Endoprosthesis made of magnesium alloy
DE102004043232A1 (en) 2004-09-07 2006-03-09 Biotronik Vi Patent Ag Endoprosthesis made of magnesium alloy
DE102004044679A1 (en) 2004-09-09 2006-03-16 Biotronik Vi Patent Ag Implant with low radial strength
US7229471B2 (en) 2004-09-10 2007-06-12 Advanced Cardiovascular Systems, Inc. Compositions containing fast-leaching plasticizers for improved performance of medical devices
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US9011831B2 (en) 2004-09-30 2015-04-21 Advanced Cardiovascular Systems, Inc. Methacrylate copolymers for medical devices
US20060075044A1 (en) 2004-09-30 2006-04-06 Fox Kevin D System and method for electronic contact list-based search and display
US20060075092A1 (en) 2004-10-06 2006-04-06 Kabushiki Kaisha Toshiba System and method for determining the status of users and devices from access log information
US7344560B2 (en) 2004-10-08 2008-03-18 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US20060085065A1 (en) 2004-10-15 2006-04-20 Krause Arthur A Stent with auxiliary treatment structure
US7862835B2 (en) 2004-10-27 2011-01-04 Boston Scientific Scimed, Inc. Method of manufacturing a medical device having a porous coating thereon
US20060088566A1 (en) 2004-10-27 2006-04-27 Scimed Life Systems, Inc.,A Corporation Method of controlling drug release from a coated medical device through the use of nucleating agents
US7958840B2 (en) 2004-10-27 2011-06-14 Surmodics, Inc. Method and apparatus for coating of substrates
US8029563B2 (en) 2004-11-29 2011-10-04 Gore Enterprise Holdings, Inc. Implantable devices with reduced needle puncture site leakage
US20060122694A1 (en) 2004-12-03 2006-06-08 Stinson Jonathan S Medical devices and methods of making the same
US20060129215A1 (en) 2004-12-09 2006-06-15 Helmus Michael N Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery
US7632390B2 (en) 2004-12-10 2009-12-15 Ryszard Rokicki Apparatus and method for enhancing electropolishing utilizing magnetic fields
DE202004020318U1 (en) 2004-12-10 2005-03-24 Europ Fuel Cell Gmbh Heating device for polymer membrane fuel cells has a gas-processing unit with inlet/outlet pipes for re-circulating a renewed hydrogenous reformate
US20080140172A1 (en) 2004-12-13 2008-06-12 Robert Hunt Carpenter Multi-Wall Expandable Device Capable Of Drug Delivery Related Applications
US20060129225A1 (en) 2004-12-15 2006-06-15 Kopia Gregory A Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
US20080003431A1 (en) * 2006-06-20 2008-01-03 Thomas John Fellinger Coated fibrous nodules and insulation product
DK1674117T3 (en) 2004-12-24 2018-12-10 Hexacath MECHANICAL SUBJECT WITH IMPROVED DEFORMABILITY
US7432327B2 (en) 2004-12-30 2008-10-07 Sabic Innovative Plastics Ip B.V. Transparent polymeric compositions comprising polysiloxane-polycarbonate copolymer, articles made therefrom and methods of making same
US20060149363A1 (en) 2005-01-06 2006-07-06 Scimed Life Systems, Inc. Optimally expanded, collagen sealed ePTFE graft with improved tissue ingrowth
US7727273B2 (en) 2005-01-13 2010-06-01 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
CA2593789A1 (en) 2005-01-14 2006-07-20 National Research Council Of Canada Implantable biomimetic prosthetic bone
DE102005003188A1 (en) 2005-01-20 2006-07-27 Restate Patent Ag Medical implant made of an amorphous or nanocrystalline alloy
US8057543B2 (en) 2005-01-28 2011-11-15 Greatbatch Ltd. Stent coating for eluting medication
WO2006080381A1 (en) 2005-01-28 2006-08-03 Terumo Kabushiki Kaisha Intravascular implant
US20060177480A1 (en) 2005-02-10 2006-08-10 Hsing-Wen Sung Drug-eluting biodegradable stent
US20070003589A1 (en) * 2005-02-17 2007-01-04 Irina Astafieva Coatings for implantable medical devices containing attractants for endothelial cells
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US8323333B2 (en) 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US20060198869A1 (en) 2005-03-03 2006-09-07 Icon Medical Corp. Bioabsorable medical devices
US20060200229A1 (en) 2005-03-03 2006-09-07 Robert Burgermeister Geometry and material for use in high strength, high flexibility, controlled recoil drug eluting stents
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US7727278B2 (en) 2005-03-04 2010-06-01 Rti Biologics, Inc. Self fixing assembled bone-tendon-bone graft
US20060200232A1 (en) 2005-03-04 2006-09-07 Phaneuf Matthew D Nanofibrous materials as drug, protein, or genetic release vehicles
US20060199876A1 (en) 2005-03-04 2006-09-07 The University Of British Columbia Bioceramic composite coatings and process for making same
GB2424223C (en) * 2005-03-07 2011-02-02 Massachusetts Inst Technology Biomaterial.
US20060204445A1 (en) 2005-03-11 2006-09-14 Anthony Atala Cell scaffold matrices with image contrast agents
US7531503B2 (en) 2005-03-11 2009-05-12 Wake Forest University Health Sciences Cell scaffold matrices with incorporated therapeutic agents
DE102005013221A1 (en) 2005-03-17 2006-09-21 Biotronik Vi Patent Ag System for the treatment of extensive obliterating diseases of a vessel
BRPI0608506A2 (en) 2005-03-18 2010-01-05 Cinv Ag process for preparing sintered porous metal materials
US9056157B2 (en) 2005-03-24 2015-06-16 Medtronic Vascular, Inc. Hybrid biodegradable/non-biodegradable stent, delivery system and method of treating a vascular condition
US20060229715A1 (en) 2005-03-29 2006-10-12 Sdgi Holdings, Inc. Implants incorporating nanotubes and methods for producing the same
US9125968B2 (en) 2005-03-30 2015-09-08 Boston Scientific Scimed, Inc. Polymeric/ceramic composite materials for use in medical devices
EP1863408B1 (en) 2005-03-31 2012-07-04 Innovational Holdings, LLC System and method for loading a beneficial agent into a medical device
US7641983B2 (en) 2005-04-04 2010-01-05 Boston Scientific Scimed, Inc. Medical devices including composites
CA2604419C (en) 2005-04-05 2015-03-24 Elixir Medical Corporation Degradable implantable medical devices
US20060233941A1 (en) 2005-04-15 2006-10-19 Boston Scientific Scimed, Inc. Method of coating a medical device utilizing an ion-based thin film deposition technique, a system for coating a medical device, and a medical device produced by the method
EP1883372A2 (en) * 2005-04-26 2008-02-06 Christodoulos Stefanadis Method and devices for treatment of vulnerable (unstable) and/or stable atherosclerotic plaque by disrupting pathologic vasa vasorum of the atherosclerotic plaque
US8734851B2 (en) 2005-04-29 2014-05-27 Wisconsin Alumni Research Foundation Localized delivery of nucleic acid by polyelectrolyte assemblies
US7637941B1 (en) 2005-05-11 2009-12-29 Advanced Cardiovascular Systems, Inc. Endothelial cell binding coatings for rapid encapsulation of bioerodable stents
DE102005024151A1 (en) 2005-05-23 2006-11-30 Thomas Nicola Device for peritoneal dialysis
US20060276875A1 (en) * 2005-05-27 2006-12-07 Stinson Jonathan S Medical devices
CA2611117C (en) 2005-06-06 2015-03-31 Innovational Holdings Llc Implantable medical device with openings for delivery of beneficial agents with combination release kinetics
FI20055304L (en) 2005-06-13 2007-02-20 Bioretec Oy A bioabsorbable implant with variable properties
US8273117B2 (en) 2005-06-22 2012-09-25 Integran Technologies Inc. Low texture, quasi-isotropic metallic stent
JP2008544820A (en) 2005-06-30 2008-12-11 エムシー3, インコーポレイテッド Nitric oxide coating for medical devices
DE102005031868A1 (en) 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Drug depot for parenteral, especially intravascular drug release
US20070038176A1 (en) 2005-07-05 2007-02-15 Jan Weber Medical devices with machined layers for controlled communications with underlying regions
DE102005032604A1 (en) 2005-07-13 2007-01-18 Gfe Medizintechnik Gmbh Absorbable, insertable into the body medical element, in particular resorbable implant
US20070123131A1 (en) 2005-07-25 2007-05-31 Hien Nguyen Low-density, non-woven structures and methods of making the same
DE602005024718D1 (en) 2005-07-25 2010-12-23 Invatec Spa ENDOLUMINAL PROSTHESIS WITH BIORESORBABLE SECTIONS
US7778684B2 (en) 2005-08-08 2010-08-17 Boston Scientific Scimed, Inc. MRI resonator system with stent implant
US20070034615A1 (en) 2005-08-15 2007-02-15 Klaus Kleine Fabricating medical devices with an ytterbium tungstate laser
US20070038290A1 (en) 2005-08-15 2007-02-15 Bin Huang Fiber reinforced composite stents
US7597924B2 (en) 2005-08-18 2009-10-06 Boston Scientific Scimed, Inc. Surface modification of ePTFE and implants using the same
US9248034B2 (en) 2005-08-23 2016-02-02 Advanced Cardiovascular Systems, Inc. Controlled disintegrating implantable medical devices
US20070045252A1 (en) 2005-08-23 2007-03-01 Klaus Kleine Laser induced plasma machining with a process gas
US20070050009A1 (en) 2005-08-30 2007-03-01 Aiden Flanagan Bioabsorbable stent
US20070048350A1 (en) 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
US20070065418A1 (en) 2005-09-20 2007-03-22 Franco Vallana Method and device for cellular therapy
US20070073385A1 (en) 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
US20070073390A1 (en) 2005-09-23 2007-03-29 Medlogics Device Corporation Methods and devices for enhanced adhesion between metallic substrates and bioactive material-containing coatings
US20070264199A1 (en) 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
EP1932497A1 (en) 2005-10-05 2008-06-18 Kaneka Corporation Stent to be placed in the living body
US20070141106A1 (en) 2005-10-19 2007-06-21 Bonutti Peter M Drug eluting implant
US7563277B2 (en) 2005-10-24 2009-07-21 Cook Incorporated Removable covering for implantable frame projections
US8369950B2 (en) 2005-10-28 2013-02-05 Cardiac Pacemakers, Inc. Implantable medical device with fractal antenna
US20070104753A1 (en) 2005-11-04 2007-05-10 Aiden Flanagan Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
US9440003B2 (en) 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
US20070106347A1 (en) 2005-11-09 2007-05-10 Wun-Chen Lin Portable medical and cosmetic photon emission adjustment device and method using the same
EP1959025B1 (en) 2005-11-16 2012-03-21 National Institute for Materials Science Magnesium-based biodegradable metal material
US20070135908A1 (en) 2005-12-08 2007-06-14 Zhao Jonathon Z Absorbable stent comprising coating for controlling degradation and maintaining pH neutrality
US20070134288A1 (en) 2005-12-13 2007-06-14 Edward Parsonage Anti-adhesion agents for drug coatings
US8518100B2 (en) 2005-12-19 2013-08-27 Advanced Cardiovascular Systems, Inc. Drug eluting stent for the treatment of dialysis graft stenoses
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
JP2009522022A (en) 2005-12-30 2009-06-11 シー・アール・バード・インコーポレーテッド Stent with bioabsorbable connector and stent placement method
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20070160641A1 (en) 2006-01-12 2007-07-12 Eun-Hyun Jang Coated medical devices and methods of making the same
US20070173923A1 (en) 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070184083A1 (en) 2006-02-07 2007-08-09 Medtronic Vascular, Inc. Drug-Eluting Device for Treatment of Chronic Total Occlusions
US20070190104A1 (en) 2006-02-13 2007-08-16 Kamath Kalpana R Coating comprising an adhesive polymeric material for a medical device and method of preparing the same
US20070191931A1 (en) 2006-02-16 2007-08-16 Jan Weber Bioerodible endoprostheses and methods of making the same
US9526814B2 (en) 2006-02-16 2016-12-27 Boston Scientific Scimed, Inc. Medical balloons and methods of making the same
ATE551966T1 (en) 2006-02-28 2012-04-15 Straumann Holding Ag TWO-PIECE IMPLANT WITH HYDROXYLATED CONTACT SURFACE FOR SOFT TISSUE
AU2007248387A1 (en) 2006-03-03 2007-11-15 C. R. Bard, Inc. Antimicrobial coating
US8585753B2 (en) 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
US8597341B2 (en) 2006-03-06 2013-12-03 David Elmaleh Intravascular device with netting system
EP1834606B1 (en) 2006-03-16 2013-04-24 CID S.p.A. Stents
EP1835042A1 (en) 2006-03-18 2007-09-19 Acrostak Corp. Magnesium-based alloy with improved combination of mechanical and corrosion characteristics
JPWO2007108450A1 (en) 2006-03-20 2009-08-06 独立行政法人物質・材料研究機構 Degradation time control method for medical biodegradable device
US20070224244A1 (en) 2006-03-22 2007-09-27 Jan Weber Corrosion resistant coatings for biodegradable metallic implants
US20070225799A1 (en) 2006-03-24 2007-09-27 Medtronic Vascular, Inc. Stent, intraluminal stent delivery system, and method of treating a vascular condition
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
DE102006015457A1 (en) 2006-03-31 2007-10-04 Biotronik Vi Patent Ag Magnesium alloy and related manufacturing process
ES2381701T3 (en) 2006-04-12 2012-05-30 Arterial Remodeling Technologies S.A. Improved surface smoothing and polishing methods of polymeric stents to reduce biologically active sites
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US20070244541A1 (en) 2006-04-18 2007-10-18 Medtronic Vascular, Inc., A Delaware Corporation Methods and Devices for Contributing to Improved Stent Graft Fixation
US20070250155A1 (en) 2006-04-24 2007-10-25 Advanced Cardiovascular Systems, Inc. Bioabsorbable medical device
US7955383B2 (en) 2006-04-25 2011-06-07 Medtronics Vascular, Inc. Laminated implantable medical device having a metallic coating
US9155646B2 (en) 2006-04-27 2015-10-13 Brs Holdings, Llc Composite stent with bioremovable ceramic flakes
US20080051335A1 (en) 2006-05-02 2008-02-28 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
US20070264303A1 (en) 2006-05-12 2007-11-15 Liliana Atanasoska Coating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent
WO2007133782A1 (en) 2006-05-15 2007-11-22 Tyco Healthcare Group Lp Antimicrobial coatings
EP2040771A2 (en) 2006-05-16 2009-04-01 Medtronic Vascular, Inc. Bioabsorbable magnesium-reinforced polymer stents
US20090177273A1 (en) 2006-05-17 2009-07-09 Laurent-Dominique Piveteau Anisotropic nanoporous coatings for medical implants
US20070270942A1 (en) 2006-05-19 2007-11-22 Medtronic Vascular, Inc. Galvanic Corrosion Methods and Devices for Fixation of Stent Grafts
US20070282432A1 (en) 2006-05-31 2007-12-06 Stinson Jonathan S Implantable medical endoprostheses
US20070281073A1 (en) 2006-06-01 2007-12-06 Gale David C Enhanced adhesion of drug delivery coatings on stents
US20070281117A1 (en) 2006-06-02 2007-12-06 Xtent, Inc. Use of plasma in formation of biodegradable stent coating
CN105288742A (en) 2006-06-05 2016-02-03 防菌公司 A polymer matrix, uses thereof and a method of manufacturing the same
GB0612028D0 (en) 2006-06-16 2006-07-26 Imp Innovations Ltd Bioactive glass
DE102006029247A1 (en) 2006-06-26 2007-12-27 Biotronik Vi Patent Ag Implant with a coating comprises one or more components such as cholesterol or cholesterol ester
US8815275B2 (en) * 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
WO2008002778A2 (en) * 2006-06-29 2008-01-03 Boston Scientific Limited Medical devices with selective coating
DE102006030588A1 (en) 2006-07-03 2008-01-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Liquid-jet-guided etching process for removing material from solids and its use
US9265866B2 (en) 2006-08-01 2016-02-23 Abbott Cardiovascular Systems Inc. Composite polymeric and metallic stent with radiopacity
US20080124373A1 (en) 2006-08-02 2008-05-29 Inframat Corporation Lumen - supporting devices and methods of making and using
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
WO2008016712A2 (en) 2006-08-02 2008-02-07 Inframat Corporation Medical devices and methods of making and using
US20080033522A1 (en) 2006-08-03 2008-02-07 Med Institute, Inc. Implantable Medical Device with Particulate Coating
DE102006038233A1 (en) 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Marker composite for medical implants
DE102006038238A1 (en) 2006-08-07 2008-02-14 Biotronik Vi Patent Ag X-ray marker for medical implants made of a biocorrodible metallic material
DE102006038235A1 (en) 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Improving the stability of biodegradable metallic stents, methods and use
DE102006038237A1 (en) 2006-08-07 2008-02-14 Biotronik Vi Patent Ag marker alloy
DE102006038231A1 (en) 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Implant of a biocorrodible metallic material with a coating of an organosilicon compound
DE102006038232A1 (en) 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Endoprosthesis and method for producing such
DE102006038241A1 (en) 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Stent with a genisteinhaltigen coating or Kavitätenfüllung
DE102006038236A1 (en) 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Biodegradable stent with an active coating
US20080058921A1 (en) 2006-08-09 2008-03-06 Lindquist Jeffrey S Improved adhesion of a polymeric coating of a drug eluting stent
DE102006039346A1 (en) 2006-08-22 2008-03-13 Biotronik Vi Patent Ag Biocorrodible metallic implant with a coating or cavity filling of a PEG / PLGA copolymer
US20080050413A1 (en) 2006-08-23 2008-02-28 Ronald Adrianus Maria Horvers Medical stent provided with a combination of melatonin and paclitaxel
US20080051881A1 (en) 2006-08-24 2008-02-28 Feng James Q Medical devices comprising porous layers for the release of therapeutic agents
DE102006042313A1 (en) 2006-09-06 2008-03-27 Biotronik Vi Patent Ag Biocorrodible metallic implant with a coating or cavity filling made of gelatin
US20080057105A1 (en) 2006-09-06 2008-03-06 Boston Scientific Scimed, Inc. Medical devices having nanostructured coating for macromolecule delivery
JP2010503469A (en) 2006-09-14 2010-02-04 ボストン サイエンティフィック リミテッド Medical device having drug-eluting film
JP2010503481A (en) 2006-09-15 2010-02-04 ボストン サイエンティフィック リミテッド Medical instruments
US20080071353A1 (en) 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Endoprosthesis containing magnetic induction particles
US20080086201A1 (en) 2006-09-15 2008-04-10 Boston Scientific Scimed, Inc. Magnetized bioerodible endoprosthesis
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
CA2663220A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices and methods of making the same
CA2663303A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Endoprosthesis with adjustable surface features
CA2663271A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
JP2010503489A (en) 2006-09-15 2010-02-04 ボストン サイエンティフィック リミテッド Biodegradable endoprosthesis and method for producing the same
WO2008036548A2 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
JP2010503486A (en) 2006-09-18 2010-02-04 ボストン サイエンティフィック リミテッド Endoprosthesis
EP2073764A2 (en) 2006-09-18 2009-07-01 Boston Scientific Limited Controlling biodegradation of a medical instrument
US20080071349A1 (en) 2006-09-18 2008-03-20 Boston Scientific Scimed, Inc. Medical Devices
US20080069858A1 (en) 2006-09-20 2008-03-20 Boston Scientific Scimed, Inc. Medical devices having biodegradable polymeric regions with overlying hard, thin layers
US20100075162A1 (en) 2006-09-22 2010-03-25 Seok-Jo Yang Implants comprising biodegradable metals and method for manufacturing the same
US7557167B2 (en) 2006-09-28 2009-07-07 Gore Enterprise Holdings, Inc. Polyester compositions, methods of manufacturing said compositions, and articles made therefrom
US8394488B2 (en) 2006-10-06 2013-03-12 Cordis Corporation Bioabsorbable device having composite structure for accelerating degradation
DE102006048819A1 (en) 2006-10-10 2008-04-17 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Device with a basic body
US20080090097A1 (en) 2006-10-11 2008-04-17 The Penn State Research Foundation Chemically and physically tailored structured thin film assemblies for corrosion prevention or promotion
US20080097577A1 (en) 2006-10-20 2008-04-24 Boston Scientific Scimed, Inc. Medical device hydrogen surface treatment by electrochemical reduction
WO2008057991A2 (en) 2006-11-03 2008-05-15 Boston Scientific Limited Ion bombardment of medical devices
US20080243113A1 (en) 2006-11-08 2008-10-02 Shastri V Prasad Modification of stent surfaces to impart functionality
US20080294236A1 (en) 2007-05-23 2008-11-27 Boston Scientific Scimed, Inc. Endoprosthesis with Select Ceramic and Polymer Coatings
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US7919137B2 (en) 2006-11-13 2011-04-05 Boston Scientific Scimed, Inc. Medical devices having adherent polymeric layers with depth-dependent properties
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20090093551A1 (en) 2006-12-08 2009-04-09 Bhatia Sangeeta N Remotely triggered release from heatable surfaces
US20080148002A1 (en) 2006-12-13 2008-06-19 Fleming Matthew D Method and Apparatus for Allocating A Dynamic Data Structure
AU2007331453A1 (en) 2006-12-15 2008-06-19 Coloplast A/S Coatings prepared from poly(ethylene oxide) and photo-initator-containing scaffolds
US7651527B2 (en) * 2006-12-15 2010-01-26 Medtronic Vascular, Inc. Bioresorbable stent
DE102006060501A1 (en) 2006-12-19 2008-06-26 Biotronik Vi Patent Ag Forming corrosion-inhibiting anodized coating on bio-corrodible magnesium alloy implant, treats implant in aqueous or alcoholic solution containing specified ion concentration
JP2010512947A (en) 2006-12-20 2010-04-30 ボストン サイエンティフィック リミテッド Stent with coating for delivering therapeutic agent
US7939095B2 (en) 2006-12-21 2011-05-10 Cordis Corporation Crosslinked silane coating for medical devices
EP2125065B1 (en) 2006-12-28 2010-11-17 Boston Scientific Limited Bioerodible endoprostheses and methods of making same
EP2114480B1 (en) 2006-12-28 2016-01-06 Boston Scientific Limited Medical devices and methods of making the same
US20080171929A1 (en) 2007-01-11 2008-07-17 Katims Jefferson J Method for standardizing spacing between electrodes, and medical tape electrodes
BRPI0806899A2 (en) 2007-01-19 2014-06-17 Cinv Ag PARTIALLY BIOABSIBLE IMPLANT
EP2104472A1 (en) 2007-01-19 2009-09-30 Cinvention Ag Porous, degradable implant made by powder molding
DE102007003708A1 (en) 2007-01-25 2008-07-31 Biotronik Vi Patent Ag Stent comprises stent carrier, one or multiple anchor groups on surface of stent carrier, and one or multiple biomolecules, which are connected to anchor groups, where same or different anchor groups are selected from compounds
US20080183278A1 (en) 2007-01-26 2008-07-31 Boston Scientific Scimed, Inc. Implantable medical endoprostheses
JP5391082B2 (en) 2007-01-30 2014-01-15 ヘモテック アーゲー Biodegradable vascular support
DE102007004589A1 (en) 2007-01-30 2008-07-31 Orlowski, Michael, Dr. Reabsorbable implant stent for blood vessels, urinary passages, respiratory system, biliary tract or digestive tract, comprises magnesium alloy containing magnesium, calcium or yattrium
US7758635B2 (en) 2007-02-13 2010-07-20 Boston Scientific Scimed, Inc. Medical device including cylindrical micelles
WO2008098927A2 (en) 2007-02-13 2008-08-21 Cinvention Ag Degradable reservoir implants
WO2008098922A2 (en) 2007-02-13 2008-08-21 Cinvention Ag Biodegradable porous stent
EP2111482A2 (en) 2007-02-13 2009-10-28 Cinvention Ag Medical devices with extended or multiple reservoirs
US8273402B2 (en) 2007-02-26 2012-09-25 Medtronic Vascular, Inc. Drug coated stent with magnesium topcoat
US20080208352A1 (en) 2007-02-27 2008-08-28 Medtronic Vascular, Inc. Stent Having Controlled Porosity for Improved Ductility
US20080208308A1 (en) 2007-02-27 2008-08-28 Medtronic Vascular, Inc. High Temperature Oxidation-Reduction Process to Form Porous Structures on a Medical Implant
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
EP2124847B1 (en) 2007-03-23 2012-05-16 Invatec Technology Center GMBH Endoluminal prosthesis
US20080243240A1 (en) 2007-03-26 2008-10-02 Medtronic Vascular, Inc. Biodegradable Metal Barrier Layer for a Drug-Eluting Stent
US20080243234A1 (en) 2007-03-27 2008-10-02 Medtronic Vascular, Inc. Magnesium Alloy Stent
DE102007015670A1 (en) 2007-03-31 2008-10-02 Biotronik Vi Patent Ag Stent with radially expandable body
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US20080249600A1 (en) 2007-04-06 2008-10-09 Boston Scientific Scimed, Inc. Stents with drug reservoir layer and methods of making and using the same
JP2010524653A (en) 2007-04-25 2010-07-22 ボストン サイエンティフィック サイムド,インコーポレイテッド Medical device for therapeutic drug release and method of manufacturing the same
DE102007019703A1 (en) 2007-04-26 2008-10-30 Biotronik Vi Patent Ag stent
US7888719B2 (en) 2007-05-23 2011-02-15 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor memory structures
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
DE602007009369D1 (en) 2007-05-28 2010-11-04 Acrostak Corp Bvi Magnesium based alloys
US20080306584A1 (en) 2007-06-05 2008-12-11 Pamela Kramer-Brown Implantable medical devices for local and regional treatment
US7632305B2 (en) * 2007-07-06 2009-12-15 Boston Scientific Scimed, Inc. Biodegradable connectors
US8002823B2 (en) * 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) * 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
DE102007032686A1 (en) * 2007-07-13 2009-01-15 Biotronik Vi Patent Ag Stent with a coating
US8205317B2 (en) * 2007-07-16 2012-06-26 Medtronic Vascular, Inc. Method of manufacturing a controlled porosity stent
EP2187988B1 (en) 2007-07-19 2013-08-21 Boston Scientific Limited Endoprosthesis having a non-fouling surface
US20090035351A1 (en) 2007-07-20 2009-02-05 Medtronic Vascular, Inc. Bioabsorbable Hypotubes for Intravascular Drug Delivery
DE102007034041A1 (en) * 2007-07-20 2009-01-22 Biotronik Vi Patent Ag Medication depots for medical implants
DE102007034019A1 (en) * 2007-07-20 2009-01-22 Biotronik Vi Patent Ag Stent with a coating or filling of a cavity
US20090024209A1 (en) * 2007-07-20 2009-01-22 Medtronic Vascular, Inc. Hypotubes for Intravascular Drug Delivery
US20090028785A1 (en) * 2007-07-23 2009-01-29 Boston Scientific Scimed, Inc. Medical devices with coatings for delivery of a therapeutic agent
DE102007034364A1 (en) * 2007-07-24 2009-01-29 Biotronik Vi Patent Ag Degradable metal stent with active ingredient-containing coating
DE102007034363A1 (en) * 2007-07-24 2009-01-29 Biotronik Vi Patent Ag endoprosthesis
US20090157172A1 (en) 2007-07-24 2009-06-18 Boston Scientific Scrimed, Inc. Stents with polymer-free coatings for delivering a therapeutic agent
US20090030504A1 (en) * 2007-07-27 2009-01-29 Boston Scientific Scimed, Inc. Medical devices comprising porous inorganic fibers for the release of therapeutic agents
US20090030500A1 (en) * 2007-07-27 2009-01-29 Jan Weber Iron Ion Releasing Endoprostheses
US20090043330A1 (en) 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Embolic protection devices and methods
US20090043380A1 (en) 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
DE102007038799A1 (en) 2007-08-17 2009-02-19 Biotronik Vi Patent Ag Implant made of a biocorrodible magnesium alloy and coated with a biocorrodible polyphosphazene
DE102007042451A1 (en) 2007-09-06 2009-03-12 Biotronik Vi Patent Ag Stent with a body made of a biocorrodible alloy
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
DE102007043883A1 (en) 2007-09-14 2009-03-26 Biotronik Vi Patent Ag Stent with a coating
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8998978B2 (en) 2007-09-28 2015-04-07 Abbott Cardiovascular Systems Inc. Stent formed from bioerodible metal-bioceramic composite
JP2009082353A (en) 2007-09-28 2009-04-23 Terumo Corp In-vivo indwelling stent and living organ dilator
US20090093871A1 (en) 2007-10-08 2009-04-09 Medtronic Vascular, Inc. Medical Implant With Internal Drug Delivery System
US20090287302A1 (en) 2008-05-16 2009-11-19 Chameleon Scientific Corporation Polymer coated spinulose metal surfaces
US20090118818A1 (en) 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis with coating
US20090157165A1 (en) 2007-11-02 2009-06-18 Boston Scientific Scimed, Inc. Degradable Endoprosthesis
US20090118812A1 (en) 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US20090118823A1 (en) 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis with porous reservoir
US20090118813A1 (en) 2007-11-02 2009-05-07 Torsten Scheuermann Nano-patterned implant surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US20090118809A1 (en) 2007-11-02 2009-05-07 Torsten Scheuermann Endoprosthesis with porous reservoir and non-polymer diffusion layer
US20090118815A1 (en) 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Stent
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090118821A1 (en) 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis with porous reservoir and non-polymer diffusion layer
US20090143855A1 (en) 2007-11-29 2009-06-04 Boston Scientific Scimed, Inc. Medical Device Including Drug-Loaded Fibers
EP2067494A1 (en) 2007-12-04 2009-06-10 Charité-Universitätsmedizin Berlin Sheet or tubular structure consisting of elastic biocompatible material and its use
US20100008970A1 (en) * 2007-12-14 2010-01-14 Boston Scientific Scimed, Inc. Drug-Eluting Endoprosthesis
DE102007061647A1 (en) 2007-12-20 2009-07-02 Biotronik Vi Patent Ag Implant with a body made of a biocorrodible alloy
US8317857B2 (en) * 2008-01-10 2012-11-27 Telesis Research, Llc Biodegradable self-expanding prosthesis
DE102008006455A1 (en) 2008-01-29 2009-07-30 Biotronik Vi Patent Ag Implant comprising a body made of a biocorrodible alloy and a corrosion-inhibiting coating
DE102008006654A1 (en) 2008-01-30 2009-08-06 Biotronik Vi Patent Ag Implant with a body made of a biocorrodible alloy
JP2009178293A (en) 2008-01-30 2009-08-13 Terumo Corp Medical implant
US20090196899A1 (en) 2008-01-31 2009-08-06 Medtronic Vascular, Inc. Controlled Alloy Stent
DE102008002601A1 (en) 2008-02-05 2009-08-06 Biotronik Vi Patent Ag Implant with a body made of a biocorrodible iron alloy
US20090204203A1 (en) 2008-02-07 2009-08-13 Medtronic Vascular, Inc. Bioabsorbable Stent Having a Radiopaque Marker
WO2009102787A2 (en) 2008-02-12 2009-08-20 Boston Scientific Scimed, Inc. Medical implants with polysaccharide drug eluting coatings
US20100047324A1 (en) 2008-02-22 2010-02-25 Celonova Biosciences, Inc. Multi-Functional Wound Dressing Matrices and Related Methods
US20100042206A1 (en) 2008-03-04 2010-02-18 Icon Medical Corp. Bioabsorbable coatings for medical devices
US20090228037A1 (en) 2008-03-07 2009-09-10 Medtronic Vascular, Inc Vascular Closure Implant
US20090240323A1 (en) 2008-03-20 2009-09-24 Medtronic Vascular, Inc. Controlled Degradation of Magnesium Stents
US20090259300A1 (en) 2008-04-10 2009-10-15 Boston Scientific Scimed, Inc. Medical Devices With an Interlocking Coating and Methods of Making the Same
DE102008020415A1 (en) 2008-04-24 2009-10-29 Biotronik Vi Patent Ag Biodegradable metallic stents with wax layer
DE102008021894A1 (en) 2008-05-02 2009-11-05 Biotronik Vi Patent Ag Implant comprising a surface with reduced thrombogenicity
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US20090287301A1 (en) 2008-05-16 2009-11-19 Boston Scientific, Scimed Inc. Coating for medical implants
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
JP2011524209A (en) 2008-06-13 2011-09-01 ピボット・メディカル,インコーポレーテッド Method and apparatus for joint distraction
DE102008002471A1 (en) 2008-06-17 2009-12-24 Biotronik Vi Patent Ag Stent with a coating or a base body containing a lithium salt, and use of lithium salts for restenosis prophylaxis
EP2307068A2 (en) 2008-06-25 2011-04-13 Boston Scientific Scimed, Inc. Medical devices having surface coatings
US8114148B2 (en) 2008-06-25 2012-02-14 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agent in conjunction with galvanic corrosion
DE102008040253A1 (en) * 2008-07-08 2010-01-14 Biotronik Vi Patent Ag Implant system with a functional implant made of degradable metal material
DE102008040356A1 (en) * 2008-07-11 2010-01-14 Biotronik Vi Patent Ag Stent with biodegradable stent struts and drug depots
US8361139B2 (en) * 2008-07-16 2013-01-29 Boston Scientific Scimed, Inc. Medical devices having metal coatings for controlled drug release
JP2011528939A (en) * 2008-07-23 2011-12-01 ボストン サイエンティフィック サイムド,インコーポレイテッド Medical device having an inorganic barrier coating
DE102008040787A1 (en) * 2008-07-28 2010-02-04 Biotronik Vi Patent Ag Biocorrodible implant with a coating containing a hydrogel
DE102008040786A1 (en) * 2008-07-28 2010-02-04 Biotronik Vi Patent Ag Biocorrodible implant with a coating containing a drug-carrying polymer matrix
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
EP2323709A2 (en) 2008-08-14 2011-05-25 Boston Scientific Scimed, Inc. Medical devices having electrodeposited conductive polymer coatings
DE102008038367A1 (en) 2008-08-19 2010-02-25 Biotronik Vi Patent Ag Stent and method and apparatus for making the stent
DE102008038368A1 (en) 2008-08-19 2010-02-25 Biotronik Vi Patent Ag Use of organic gold complexes as bioactive and radioopaque stent coating for permanent and degradable vascular implants
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
CN102196826A (en) 2008-08-27 2011-09-21 波士顿科学医学有限公司 Medical devices having inorganic coatings for therapeutic agent delivery
WO2010027679A2 (en) 2008-08-27 2010-03-11 Boston Scientific Scimed, Inc. Medical devices having coatings for therapeutic agent delivery
US20100057188A1 (en) 2008-08-28 2010-03-04 Boston Scientific Scimed, Inc. Endoprostheses with porous regions and non-polymeric coating
US9119906B2 (en) 2008-09-24 2015-09-01 Integran Technologies, Inc. In-vivo biodegradable medical implant
DE602008006079D1 (en) 2008-09-30 2011-05-19 Biotronik Vi Patent Ag Implant made of a biodegradable magnesium alloy
DE102008042578A1 (en) 2008-10-02 2010-04-08 Biotronik Vi Patent Ag Implant with a body made of a biocorrodible manganese alloy
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
DE102008042603A1 (en) 2008-10-06 2010-04-08 Biotronik Vi Patent Ag Implant and method for producing a demodulation-inhibiting layer on a body surface of an implant
DE102009002709A1 (en) 2008-10-06 2010-04-08 Biotronik Vi Patent Ag Implant and method of making the same
US8337936B2 (en) 2008-10-06 2012-12-25 Biotronik Vi Patent Ag Implant and method for manufacturing same
US20100092535A1 (en) 2008-10-10 2010-04-15 Medtronic Vascular, Inc. Nanoporous Drug Delivery System
DE102008043277A1 (en) 2008-10-29 2010-05-06 Biotronik Vi Patent Ag Implant made of a biocorrodible iron or magnesium alloy
DE102008043642A1 (en) 2008-11-11 2010-05-12 Biotronik Vi Patent Ag endoprosthesis
DE102008043724A1 (en) 2008-11-13 2010-05-20 Biotronik Vi Patent Ag Increasing the efficiency of pharmaceutical active ingredient-releasing medical devices by combination with an inhibitor of the transport protein P-glycoprotein
US20100125325A1 (en) 2008-11-20 2010-05-20 Medtronic Vascular, Inc. Stent With Cathodic Protection and Stent Delivery System
DE102008043970A1 (en) 2008-11-21 2010-05-27 Biotronik Vi Patent Ag A method for producing a corrosion-inhibiting coating on an implant of a biocorrodible magnesium alloy and implant produced by the method
US9283304B2 (en) 2008-11-25 2016-03-15 CARDINAL HEALTH SWITZERLAND 515 GmbH Absorbable stent having a coating for controlling degradation of the stent and maintaining pH neutrality
US20100217370A1 (en) 2009-02-20 2010-08-26 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
WO2012049919A1 (en) 2010-10-15 2012-04-19 Jsr株式会社 Method for forming resist pattern and radiation-sensitive resin composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923912A2 (en) * 1997-12-18 1999-06-23 Schneider (Usa) Inc. Stent-graft with bioabsorbable structural support

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERKLAND C, PACK DW, KIM KK.: "Controlling surface nano-structure using flow-limited field-injection electrostatic spraying (FFESS) of poly(D,L-lactide-co-glycolide)." BIOMATERIALS, vol. 25, no. 25, 20 February 2004 (2004-02-20), pages 5649-5658, XP002451388 cited in the application *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103768655A (en) * 2014-02-17 2014-05-07 苏州大学 Preparation method of porous tantalum skeleton
CN105664259A (en) * 2016-01-18 2016-06-15 铜仁学院 Method for constructing slow release system for medicament on surface of medical titanium alloy implant
CN107137788A (en) * 2017-04-28 2017-09-08 淮阴工学院 A kind of method for preparing chitosan/test tube of hepari graphene oxide composite multilayer membrane in medical magnesium alloy surface

Also Published As

Publication number Publication date
US20070244569A1 (en) 2007-10-18
US8048150B2 (en) 2011-11-01
WO2007121323A3 (en) 2007-12-13
EP2010099A2 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
US8048150B2 (en) Endoprosthesis having a fiber meshwork disposed thereon
JP5026970B2 (en) Medical device and method of making the same
JP5139060B2 (en) Medical device having multiple layers
EP2214738B1 (en) Degradable endoprosthesis
EP2897661B1 (en) Drug-eluting rotational spun coatings and methods of use
US7955382B2 (en) Endoprosthesis with adjustable surface features
JP4684991B2 (en) Local drug delivery using drug-loaded nanocapsules
EP1812092B1 (en) Medical devices comprising polyoxometalates
EP2182996B1 (en) Medical devices comprising porous inorganic fibers for the release of therapeutic agents
US20080071353A1 (en) Endoprosthesis containing magnetic induction particles
US20090043276A1 (en) Drug delivery device, compositions and methods relating thereto
CN101808677A (en) Goods with ceramic coated surfaces

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07760597

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007760597

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007760597

Country of ref document: EP